Document:

Collaboration Agreement

 Exhibit 10.204 
  
 Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. 
  
 COLLABORATION AGREEMENT 
  
 THIS COLLABORATION AGREEMENT
(the “Agreement”) is entered into and made effective as of November 19, 2003 (the “Effective Date”) by and between SYRRX, INC., a Delaware corporation having its principal place of
business at 10410 Science Center Drive, San Diego, CA 92121 (“Syrrx”), and DEVELOPMENT PARTNERS, LLC, a Delaware limited liability company having its principal place of business at 3151 South 17th
Street, Wilmington, NC 28412 (“PPD”), a wholly owned subsidiary of PHARMACEUTICAL PRODUCT DEVELOPMENT, INC., a North Carolina corporation having its principal place of
business at 3151 South 17th Street, Wilmington, NC 28412 (“PPD, Inc.”). Syrrx and PPD are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” PPD, Inc. is a party to this Agreement
solely for purposes of Sections 17.18 and 17.19. 
  
 RECITALS 
  
 WHEREAS, Syrrx possesses proprietary design expertise and know-how related to the discovery and identification of small molecules for drug development in a variety of disease areas; and 
  
 WHEREAS, PPD is a provider of drug discovery and
development services for pharmaceutical, biotechnology and medical device companies, with expertise and capability in preclinical studies and clinical trials; and 
  
 WHEREAS, PPD and Syrrx desire to collaborate on the discovery, development, and further preclinical
investigation of serine protease dipeptidyl IV inhibitors with the intent of developing or commercializing one or more such inhibitors as human drug products in the Field under the terms of this Agreement. 
  
 NOW, THEREFORE, the Parties agree as
follows: 
  

	1.	DEFINITIONS 

  
 The following terms shall have the following meanings as used in this Agreement: 
  
 1.1 “Accepted Disease” means, with respect to a particular IND Ready Candidate, the Nominated Disease that
corresponded with such IND Ready Candidate when it was accepted as such. 
  
 1.2 “Affiliate” means, (a) with respect to Syrrx, a particular person, corporation, partnership, or other entity that controls, is controlled by or is under common control with Syrrx; and (b) with
respect to PPD, (i) PPD, Inc. or (ii) a particular person, corporation, partnership, or other entity that controls, is controlled by or is under common control with PPD or PPD, Inc. For the purposes of the definition in this Section 1.2, the word
“control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct the
management and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 

 1.3 “Allowable Expenses” means those expenses incurred after the first commercial launch
of a Collaboration Product, PPD Terminated Product or Syrrx Terminated Product, which are generally consistent with the Commercialization Plan and Commercialization Budget (or the equivalent for a PPD Terminated Product or Syrrx Terminated Product)
and are specifically attributable to such Collaboration Product, PPD Terminated Product or Syrrx Terminated Product, and shall consist of (a) Cost of Goods Sold, (b) Commercialization Costs, (c) Distribution Expenses, (d) Post-Launch Product R&D
Expenses, (e) Allocated Administration Expenses, (f) Patent Expenses, (g) Currency Gains or Losses, and (h) Regulatory Expenses (as such terms are defined in this Article 1 or in Exhibit A). Allowable Expenses shall exclude Pre-Commercialization
Costs and Development Costs, even if incurred after the first commercial launch of a Collaboration Product, PPD Terminated Product or Syrrx Terminated Product. 
  

1.4 “Change of Control” means the occurrence of any of the following: (a) any consolidation or merger of a Party with or into any
Third Party, or any other corporate reorganization involving a Third Party, in which those persons or entities that are stockholders of such Party immediately prior to such consolidation, merger or reorganization own less than fifty percent (50%) of
the surviving entity’s voting power immediately after such consolidation, merger or reorganization; (b) a change in the legal or beneficial ownership of fifty percent (50%) or more of the voting securities of any Party (whether in a single
transaction or series of related transactions) where, immediately after giving effect to such change, the legal or beneficial owner of more than fifty percent (50%) of the voting securities of such Party is a Third Party; or (c) the sale, transfer,
lease, license or other disposition of all or substantially all of a Party’s assets in one or a series of related transactions to a Third Party. Notwithstanding Section 17.19, this Section 1.4 shall not apply to any Affiliate of Syrrx that is
(i) a subsidiary of Syrrx, (ii) has not performed any work under the Collaboration, and (iii) does not have any rights with respect to DP4 IP, this Agreement or Syrrx Technology. 
  
 1.5 “Clinical Development” means those Development activities that take place after a Lead Candidate,
Potential IND Ready Candidate or Reserved IND Ready Candidate is accepted as an IND Ready Candidate, including the design and manufacturing of CTM and Finished Product incorporating the IND Ready Candidate or a prodrug, metabolite, ionized form
(e.g., salt), solvate (e.g., hydrate), stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof. 
  
 1.6 “Collaboration” means all activities performed by or on behalf of Syrrx or PPD in the course of performing the activities described
in, or fulfilling of their obligations pursuant to, this Agreement. 
  
 1.7 “Collaboration Product” means a human therapeutic product that (a) comprises, consists of, or incorporates an IND Ready Candidate (or a prodrug, metabolite, ionized form (e.g., salt), solvate (e.g., hydrate),
stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof) together with any formulation ingredients, regardless of the formulation or mode of administration of such product, and (b) is not a Partnered
Product, PPD Terminated Product, Syrrx Terminated Product or Other Product. 
  

 -2- 

 1.8 “Commence”, when used to describe a Phase I Trial, Phase II Trial, Phase IIIa Trial,
Phase IIIb Trial, or Phase IV Trial, shall mean the first dosing of the first patient for such trial. 
  
 1.9 “Commercialization” shall mean all activities that are undertaken during and/or after Completion of a Phase IIIa Trial for a
particular Collaboration Product and that relate to the commercial manufacture, marketing and sale of such Collaboration Product including Pre-Commercialization, advertising, education, planning, marketing, promotion, distribution, market and
product support studies, Phase IIIb Trials (except for those Phase IIIb Trials designated by the Parties as being part of Development) and Phase IV Trials. 
  
 1.10 “Complete”, when used to describe a Phase I Trial, Phase II Trial, Phase IIIa Trial, Phase IIIb Trial, or Phase IV Trial, shall mean
the date when all data and results of such trial have been collected and analyzed and the final study report has been approved by the JOC. 
  
 1.11 “Compound Screening” means the activities described in Section 3.4(a). 
  
 1.12 “Confidential Information” shall have the meaning assigned to it in Section 12.1. 
  
 1.13 “Control” means, with respect to an item of
Information, compound, material or intellectual property right, that a Party owns or has a license to such item, a Patent claiming such compound, or right and has the ability to disclose and grant a license or sublicense as provided for in this
Agreement under such item, Patent, or right without violating the terms of any agreement or other arrangement with any Third Party. 
  
 1.14 “CTM” means a Collaboration Product that is in a finished pharmaceutical dosage form that is (a) suitable for administration and
dosing to humans in clinical trials, but (b) not suitable for commercial sale (for example, without limitation, not in packaged form such as blister packs or other containers and not including external packaging and package inserts). 
  
 1.15 “Development” means all activities relating to
identifying and characterizing Target Inhibitors, submitting for and conducting Phase I Trials, Phase II Trials, and Phase IIIa Trials (and where approved by the Parties pursuant to Section 3.2(e), certain Phase IIIb Trials) upon Collaboration
Products, PPD Terminated Products or Syrrx Terminated Products, obtaining Regulatory Approval of a Collaboration Product, and all activities relating to developing the ability to manufacture Drug Substance, CTM and Finished Product. This includes,
but is not limited to: (a) compound screening and optimization, medicinal chemistry, and SAR structure design, (b) preclinical testing, toxicology, formulation, clinical studies, regulatory affairs and outside counsel regulatory legal services and
(c) manufacturing process development for bulk and final forms of Target Inhibitors, Drug Substance, CTM and Finished Product, validation documentation, all documentation generated in connection with the manufacturing and/or processing activities
and manufacturing and quality assurance technical support activities with respect to CTM or Finished Product, provided that they occur prior to the first commercial sale of a Collaboration Product. Development shall not include a Party’s costs
incurred in connection with the construction of a manufacturing facility. 
  
 1.16 “Development Budget” shall have the meaning set forth in Section 3.3(a). 
  

 -3- 

 1.17 “Development Costs” means the direct expenses incurred by a Party through
its internal efforts or the efforts of a Third Party on account of such Party, provided such costs are incurred after the Effective Date and consistent with the Development Plan and Development Budget (or the equivalent for a PPD Terminated Product
or Syrrx Terminated Product) and are specifically attributable to the Compound Screening or Preclinical Development of Target Inhibitors, the Clinical Development of Collaboration Products under Development Plans and Development Budgets, or the
Clinical Development of PPD Terminated Products or Syrrx Terminated Products under the equivalent of a Development Plan and Development Budget, including, without limitation: 
  
 (a) costs of conducting Compound Screening efforts; 
  
 (b) costs of conducting Preclinical Development to accept or reject a Lead Candidate as an IND Ready Candidate; 

 
 (c) costs of GMP manufacturing of Drug Substance; 
  
 (d) costs of designing and manufacturing of CTM for Phase I Trials, Phase II
Trials and Phase IIIa Trials (and where approved by the Parties pursuant to Section 3.2(e), certain Phase IIIb Trials); 
  
 (e) costs of conducting Clinical Development of an IND Ready Candidate; 
  
 (f) costs of preparing, submitting, reviewing or developing data or information for IND or NDA submission, or equivalent
regulatory filings outside of the United States; 
  
 (g) fees,
including FDA user fees, associated with U.S. and foreign regulatory filings or other U.S. and foreign governmental requirements related to Collaboration Products; 
  
 (h) manufacturing process development and scale-up of CTM for Phase IIIa Trials (and Phase IIIb Trials to the extent such is
treated as being included under Development as opposed to Commercialization) in bulk and finished form; and 
  
 (i) such other costs directly related to Development that are later identified and mutually agreed upon by the JOC. 
  
 Each of the foregoing may include PPD’s costs arising from its employee’s direct
performance of the stated Development activities, provided that such costs shall be [*] of the normal and customary rates that PPD charges Third Parties at such time, in arm’s length transactions, for equivalent services.

  
 Except as provided in the Initial Development Plan, each of the foregoing may
also include Syrrx’s costs arising from its employee’s direct performance of the stated Development activities, provided that such costs shall be [*] of the normal and customary rates that Syrrx charges Third Parties at such
time, in arm’s length transactions, for equivalent services. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -4- 

 Notwithstanding the foregoing, Development Costs shall exclude (X) a Party’s overhead expenses (to the extent not
included in Section 1.17(i) or in rates to be charged by PPD or Syrrx for its employees as provided in the two preceding paragraphs above), Phase IIIb Costs for Phase IIIb Trials not treated as Development, and Phase IV Costs, (Y) costs associated
with each Party’s preparation for and participation in meetings of the JOC, PT, JFC, JCC, JIPC or any other committee formed pursuant to this Agreement, and (Z) costs associated with each Party’s (i) record-keeping regarding expenses
incurred or revenues received pursuant to this Agreement and (ii) preparation of financial reporting and reconciliation documents called for under this Agreement. 
  
 1.18 “Development Plan” shall have the meaning set forth in Section 3.2(a). 
  
 1.19 “Diligent Efforts” means the carrying out of
obligations or tasks in a sustained manner consistent with the efforts a Party devotes to a research, development or marketing project for a pharmaceutical product or products of similar market potential, profit potential or strategic value
resulting from its own research efforts, based on conditions then prevailing. Diligent Efforts requires that a Party use commercially reasonable efforts to carry out its obligations in accordance with timelines set forth in a Development Plan,
Commercialization Plan or Launch Plan by: (a) promptly assigning responsibility for such obligations to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis, (b) setting and consistently seeking
to achieve specific and meaningful objectives for carrying out such obligations, and (c) consistently making and implementing decisions and allocating resources designed to advance progress with respect to such objectives. The Parties understand and
agree that development timelines are subject to delays outside of the control of each Party and that lack of adherence to development timelines attributable as a direct result of the occurrence of one or more of these delays, despite reasonable
efforts to avoid such, shall not be considered failure to use Diligent Efforts. Delays may be caused by Third Party vendor non-performance, needed JOC or subcommittee action or approvals, FDA requirements or inaction, patient enrollment problems,
investigator performance failure, potential adverse safety findings and Investigational Research Board (IRB) inaction. 
  
 1.20 “Direct Commercialization” shall have the meaning assigned in Section 5.1(b). 
  
 1.21 “DP4 IP” means any and all inventions, developments,
results, know-how and other Information (including physical, chemical or biological materials), and all Patents relating thereto, made, conceived or reduced to practice by a Party or its Affiliate [*].  
  
 1.22 “Drug Substance” means a Lead Candidate (or a prodrug,
metabolite, ionized form (e.g., salt), solvate (e.g., hydrate), stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof) together with any formulation ingredients, that is suitable for administration and
dosing to animals. 
  
 1.23 “Early Stage Development
Costs” means all Development Costs other than (a) Phase IIIa Development Costs and (b) Phase IIIb Costs (in instances where the Parties agreed, pursuant to Section 3.2(e), to classify the Phase IIIb Trial as part of Development).

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -5- 

 1.24 “Exercise Period” means, with respect to a particular Rejected Inhibitor, a period,
prior to the expiration (pursuant to Section 3.7(d)) of the option set forth in Section 3.7(a) for such Rejected Inhibitor, that (a) starts with Syrrx’s written notification to PPD that it has Completed the first Phase I Trial or Phase II Trial
for such Rejected Inhibitor and (b) ends [*] later after receipt by PPD of the final study report for such Phase I Trial or Phase II Trial. 
  
 1.25 “FDA” means the United States Food and Drug Administration, or a successor federal agency thereto. 
  
 1.26 “Field” means the treatment of humans for one or more
of the following diseases: [*] and type-2 diabetes, and [*]. 
  
 1.27 “Finished Product” means a Collaboration Product in a finished pharmaceutical dosage form that is suitable for commercial sale (for example, without limitation, in packaged form such as blister
packs or other containers and including external packaging and package inserts). 
  
 1.28 “Good Cause” means, at the time that PPD issues a PPD Notice pursuant to Section 4.3, Syrrx does not have the financial ability to satisfy or otherwise remove any then existing liens or
obligations which contractually preclude Syrrx from granting, pledging, assigning and/or conveying to PPD liens and security interests in all of Syrrx’s property and assets (other than the Excluded Assets) as required under Section 4.4(h).

  
 1.29 “Good Clinical Practices” or “GCP”
shall mean current Good Clinical Practices as specified in the United States Code of Federal Regulations, at the time of testing, and all FDA and ICH guidelines, including the ICH Consolidated Guidelines on Good Clinical Practices. 

 
 1.30 “Good Laboratory Practices” or “GLP” shall
mean current Good Laboratory Practices as specified in the United States Code of Federal Regulations at 21 CFR §58 at the time of testing and all applicable ICH guidelines. 
  
 1.31 “Good Manufacturing Practices” or “GMP” shall mean current Good Manufacturing Practices and
standards as provided for (and as amended from time to time) in European Community Directive 91/356/EEC (Principles and Guidelines of Good Manufacturing Practice for Medicinal Products) and in the Current Good Manufacturing Practice Regulations of
the United States Code of Federal Regulations Title 21 (21 CFR §§210-211) in relation to the production of pharmaceutical intermediates and active pharmaceutical ingredients, as interpreted by ICH Harmonized Tripartite Guideline, Good
Manufacturing Practice Guide for Active Pharmaceutical Ingredients, and subject to any arrangements, additions or clarifications agreed from time to time between the Parties. 
  
 1.32 “IND” means an Investigational New Drug Application filed with the FDA necessary to commence
human clinical trials in conformance with applicable laws and regulations. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -6- 

 1.33 “IND Ready Candidate” means (a) a former Lead Candidate that the JOC decided meets
Nomination Criteria and was accepted in accordance with Section 3.6(d)(i) or (b) a former Reserved IND Ready Candidate that was accepted by the JOC in accordance with Section 3.6(d)(ii). IND Ready Candidates are incorporated into Collaboration
Products that undergo Clinical Development under the Collaboration. 
  
 1.34 “Independent Profit” means the profits or losses resulting from the Commercialization of a particular Syrrx Terminated Product or PPD Terminated Product and shall be equal to Net Sales for such Product less Allowable
Expenses for such Product. 
  
 1.35 “Information”
means information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge,
know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal
information or descriptions. 
  
 1.36 “Inhibitor of
Target” means [*]. 
  
 1.37
“Initial Development Budget” means the Development Budget that the Parties have agreed upon in writing as of the Effective Date. 
  
 1.38 “Initial Lead Candidates” means Syrrx compounds: SYR110085, SYR110322 and [*]. 
  
 1.39 “Initial Development Plan” means the Development Plan
that the Parties have agreed upon in writing as of the Effective Date. 
  
 1.40 “Initial Target Inhibitors” means the Target Inhibitors disclosed by Syrrx to PPD in writing as of the Effective Date. 
  
 1.41 “Joint Commercialization Committee” or “JCC” means the committee described in Section 2.4. 
  
 1.42 “Joint Finance Committee” or “JFC”
means the committee described in Section 2.5. 
  
 1.43
“Joint IP” means any and all inventions, developments, results, know-how and other Information (including physical, chemical or biological materials), and all Patents relating thereto, that is (a) made, conceived or reduced to practice
jointly by employee(s) or agent(s) of both Parties in the performance of the Collaboration and (b) is not DP4 IP, PPD Information or Syrrx Information. 
  
 1.44 “Joint Intellectual Property Committee” or “JIPC” means the committee described in Section 2.6. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -7- 

 1.45 “Joint Operating Committee” or “JOC” means the committee described
in Section 2.2. 
  
 1.46 “Launch Budget” shall
have the meaning assigned in Section 5.4(a). 
  
 1.47
“Launch Plan” shall have the meaning assigned in Section 5.4(a). 
  
 1.48 “Lead Candidate” means a Target Inhibitor that the JOC decided meets the Lead Candidate Selection Criteria and that has been selected by the JOC pursuant to Section 3.6(c). 
  
 1.49 “Lead Candidate Screening” means activities performed
to determine whether a particular Target Inhibitor satisfies the Lead Candidate Selection Criteria. 
  
 1.50 “Lead Candidate Selection Criteria” means the criteria approved by the JOC that each Target Inhibitor must fulfill before the JOC
can select it for Preclinical Development pursuant to Section 3.6(c), as a Lead Candidate for such disease. Lead Candidate Selection Criteria shall at least include [*]. 
  
 1.51 “Lead Marketing Party” shall have the meaning assigned in Section 5.5. 
  
 1.52 “Licensing Revenues” means any and all forms of
consideration that the Parties receive from a Third Party Partner in connection with a Partnering Agreement, which may include upfront license fees, annual license or maintenance payments, milestone payments, royalties, imputed income on
interest-free loans received from such Third Party and other similar payments; provided, however, that Licensing Revenues shall exclude any amounts received by a Party or its Affiliate by way of (a) an equity investment by such Third Party
(but solely to the extent that such investment is at a price equal to or less than [*] of the fair market value of such Party’s or its Affiliate’s stock sold in such investment), (b) a loan at then current market rates and
terms, (c) research and development support (at a reasonable FTE value), (d) reimbursement of patent prosecution, maintenance, enforcement or defense expenses, or (e) payments directly attributable to supplying goods (at no more than [*]
of actual manufacturing cost) and/or services to such Third Party to enable their Clinical Development or commercialization of such Partnered Product.  
  
 1.53 [*]. 
  
 1.54 “NDA” means a New Drug Application submitted and filed with the FDA necessary for approval of a drug in conformance with
applicable laws and regulations. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -8- 

 1.55 “Net Sales” means the total amount billed or invoiced in United States dollars (or
converted thereto in accordance with the Agreement) by a Party or its licensee, or sublicensees (to the extent licensing and sublicensing is permitted under this Agreement) for sales of Collaboration Products, PPD Terminated Products or Syrrx
Terminated Products to a Third Party less, to the extent included within the amount invoiced to and paid by the customer, deductions for: (a) transportation charges, and other charges, such as insurance, relating thereto, (b) sales and excise taxes,
customs and any other governmental charges, all to the extent imposed upon the sale of the Collaboration Products and paid by the selling party, (c) distributors fees, rebates or allowances actually granted or allowed, including government and
managed care rebates, (d) quantity discounts, cash discounts or chargebacks actually granted, allowed or incurred in the ordinary course of business in connection with the sale of the Collaboration Products, and (e) allowances or credits to
customers, not in excess of the selling price of the Collaboration Products, on account of governmental requirements, rejection, outdating recalls or return of the Collaboration Products. 
  
 1.56 “New Target Inhibitor” shall have the meaning set forth in Section 3.6(a)(ii). 
  
 1.57 “Nominated Disease” means, with respect to a
particular Lead Candidate, the disease within the Field for which such Lead Candidate was selected for Preclinical Development. 
  
 1.58 “Nomination Criteria” means, with respect to each disease in the Field, the criteria proposed by the PT and approved by the JOC that
the JOC must reasonably consider before accepting or rejecting each Lead Candidate, pursuant to Section 3.6(d), as an IND Ready Candidate for such disease. The Parties anticipate such criteria to be equivalent to the data needed to support an IND
filing for such disease. Nomination Criteria shall at least include [*]. 
  
 1.59 “Other Product” means a human therapeutic pharmaceutical product that (a) comprises, consists of, or incorporates (i) a Target Inhibitor listed in the Target Inhibitor Catalog, Lead Candidate,
Potential IND Ready Candidate, or Reserved IND Ready Candidate, or (ii) a prodrug, metabolite, ionized form (e.g., salt), solvate (e.g., hydrate), stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof,
regardless of the formulation or mode of administration of such product and (b) is not a Collaboration Product, Partnered Product, Syrrx Terminated Product or PPD Terminated Product.  
  
 1.60 “Partnered Commercialization” shall have the meaning
assigned in Section 5.1. 
  
 1.61 “Partnered
Product” means, with respect to particular territories and diseases, (a) a former Collaboration Product, PPD Terminated Product or Syrrx Terminated Product that is the subject of a Partnering Agreement; and (b) all other human therapeutic
products that (i) contain the same IND Ready Candidate (or a prodrug, metabolite, ionized form (e.g., salt), solvate (e.g., hydrate), stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof) as such
former Collaboration Product, PPD Terminated Product or Syrrx Terminated Product and (ii) are the subject of the same Partnering Agreement. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -9- 

 1.62 “Partnering Agreement” means an executed and in-force written agreement between one
or both Parties and a Third Party, wherein such Third Party is granted the right to develop (if applicable) and commercialize, alone or in collaboration with Syrrx and/or PPD, a human therapeutic product that comprises, consists of, or incorporates
an IND Ready Candidate (or a prodrug, metabolite, ionized form (e.g., salt), solvate (e.g., hydrate), stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof). PPD and Syrrx shall both be parties to each
Partnering Agreement for a former Collaboration Product. PPD (but not Syrrx) shall be a party to each Partnering Agreement for a former Syrrx Terminated Product. Syrrx (but not PPD) shall be a party to each Partnering Agreement for a former PPD
Terminated Product. For clarity, an agreement in which a Party engages a Third Party to perform, on behalf of such Party, certain obligations of such Party under the Development Plan or Commercialization Plan is not a Partnering Agreement.

  
 1.63 “Partnering Costs” means, with respect
to a particular Partnered Product or its predecessor Collaboration Product, PPD Terminated Product or Syrrx Terminated Product, (a) the costs and expenses incurred by the Parties and approved by the JOC in connection with identifying and negotiating
with potential Third Party Partners and preparing, negotiating and executing a Partnering Agreement for such Partnered Product, and (b) the costs and expenses incurred by the Parties in the performance of such Partnering Agreement, solely to the
extent that such costs and expenses are not reimbursed by the Third Party Partner. 
  
 1.64 “Partnering Profit” means, on a quarter-by-quarter basis with respect to a particular Partnered Product, (a) the sum of the Parties’ Licensing Revenues for such Partnered Product for such
quarter, minus (b) the sum of the Parties’ Partnering Costs for such Partnered Product for such quarter. 
  
 1.65 “Passive Marketing Party” shall have the meaning assigned in Section 5.5. 
  
 1.66 “Patent” means (a) an unexpired letters patent
(including inventor’s certificates) which has not been held invalid or unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been taken within the required time period, including without limitation any
substitution, extension, registration, confirmation, reissue, re-examination, renewal or any like filing thereof, or (b) a pending application for letters patent, including without limitation any continuation, division or continuation-in-part
thereof and any provisional applications. 
  
 1.67
“Permitted Disease” means, with respect to a particular Rejected Inhibitor, any disease that is: (a) the Rejected Disease, provided that such disease is not a Pursued Disease at the time of the rejection of such Rejected
Inhibitor and does not subsequently become a Pursued Disease prior to Syrrx’s initiation of GLP toxicology studies for such Rejected Inhibitor; (b) a disease within the Field that is not within the scope of [*] and that is not a
Pursued Disease at the time of the rejection of such Rejected Inhibitor and does not subsequently become a Pursued Disease prior to Syrrx’s initiation of GLP toxicology studies for such Rejected Inhibitor; (c) a disease outside of the Field;
and (d) a Pursued Disease for which at least thirty (30) months have passed since the most recent filing by the Parties of an IND for a Collaboration Product that is directed to such Pursued Disease. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -10- 

 1.68 “Phase I Trial” means that portion of the clinical development program that
generally provides for the first introduction into humans of a Collaboration Product with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of the CTM in healthy patients, and generally
consistent with 21 CFR §312.21(a). 
  
 1.69 “Phase II
Trial” means a clinical trial of a Collaboration Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Product is safe for its
intended use and to obtain sufficient information about such Collaboration Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b). 
  
 1.70 “Phase III Loan” means a line of credit provided by PPD
to Syrrx pursuant to Article 4 for the financing of some or all of Syrrx’s portion of Shared Phase IIIa Development Costs (and Phase IIIb Costs, if applicable). 
  
 1.71 “Phase IIIa Development Costs” means all Development Costs incurred by either Party for (a) direct
support of the performance of a Phase IIIa Trial for a Collaboration Product, PPD Terminated Product or Syrrx Terminated Product or (b) process development for a Collaboration Product, PPD Terminated Product or Syrrx Terminated Product in a Phase
IIIa Trial. For clarity, Phase IIIa Development Costs include (i) costs to formulate and manufacture Phase IIIa Trial CTM and (ii) excludes Phase IIIb Costs, unless the Parties mutually agree to treat a Phase IIIb Trial within the scope of
Development as provided under Section 3.2(e), in which case Phase IIIa Development Costs shall include Phase IIIb Costs. 
  
 1.72 “Phase IIIa Trial” means that portion of the clinical development program that provides for the pivotal human clinical trials of a
Collaboration Product, which trial(s) is/are designed to (a) establish that such Collaboration Product is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the Collaboration
Product in the dosage range to be prescribed; (c) be a pivotal study for submission of a NDA, and (d) be generally consistent with 21 CFR §312.21(c), but excluding a Phase IIIb Trial. 
  
 1.73 “Phase IIIb Costs” means, with respect to a Phase IIIb
Trial for a Collaboration Product, (a) if the Parties agree pursuant to Section 3.2(e) that such trial will be considered part of Development, then, all Development Costs incurred by either Party for direct support of the performance of such trial,
or (b) if the Parties do not agree pursuant to Section 3.2(e) that such trial will be considered part of Development, then all costs incurred by either Party for direct support of the performance of such trial if any only if such costs would have
been Development Costs if such trial had been considered part of Development. 
  
 1.74 “Phase IIIb Trial” means product support clinical trials of a Collaboration Product (i.e., a clinical trial which is not required for receipt of Regulatory Approval but which may be useful in
providing additional drug profile data) commenced before receipt of Regulatory Approval. 
  

 -11- 

 1.75 “Phase IV Trial” means any clinical trial of a Collaboration Product that is
commenced in a particular country after receipt of Regulatory Approval in such country. 
  
 1.76 “Phase IV Costs” means all expenses incurred by either Party or for its account which are generally consistent with the Commercialization Plan and specifically attributable to: (a) direct support
of the performance of a Phase IV Trial for a Collaboration Product or (b) process development for a Collaboration Product in a Phase IV Trial. All Phase IV Costs shall be treated as Post-Launch Product R&D Expenses in accordance with Exhibits A
and B. 
  
 1.77 “Potential IND Ready Candidate”
means (a) a former Lead Candidate that was not accepted as an IND Ready Candidate pursuant to Section 3.6(d)(ii) or (b) a former Reserved IND Ready Candidate that was redesignated as a Potential IND Ready Candidate in accordance with Section
3.6(d)(ii). 
  
 1.78 “PPD Existing Patent Rights”
means all Patents Controlled by PPD or its Affiliate as of the Effective Date. 
  
 1.79 “PPD Generic Third Party Agreement” means, with respect to a particular PPD Terminated Product, an agreement between PPD and a Third Party that relates to such PPD Terminated Product and to other
products as well. 
  
 1.80 “PPD Information”
means all Information (other than DP4 IP) produced by PPD or its Affiliate (solely or together with Syrrx) in the course of performing the Development Plan or the Commercialization Plan. For clarity, PPD Information includes all Information
generated by PPD or its Affiliate during the course of the Collaboration that is related to Regulatory Filings or Regulatory Documentation other than DP4 IP. 
  
 1.81 “PPD Specific Third Party Agreement” means, with respect to a particular PPD Terminated Product, an agreement between PPD and a
Third Party that relates solely to such PPD Terminated Product. 
  
 1.82 “PPD Technology” means (a) PPD Information, (b) all data contained in Regulatory Documentation (other than DP4 IP, PPD Information and Syrrx Information), and (c) all Information and Patents that (i)are
Controlled by PPD or its Affiliate during the Term as a result of PPD’s or its Affiliate’s entry into a license agreement with a Third Party and (ii) that (1) relate to the composition of matter, manufacture or use of a Target Inhibitor or
(2) are incorporated into any Product or necessary for the discovery, identification, manufacture, development, and commercial use or sale of any Product. 
  
 1.83 “PPD Terminated Product” means 
  
 (a) a former Collaboration Product for which PPD terminated its rights and obligations pursuant to Section 13.2(c); and 
  
 (b) all other human therapeutic products that contain the same IND
Ready Candidate (or a prodrug, metabolite specific to such former Collaboration Product, ionized form (e.g., salt), solvate (e.g., hydrate), stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof) as
such former Collaboration Product. 
  

 -12- 

 1.84 “Preclinical Development” means, with respect to a particular Target Inhibitor, all
Development activities performed after its selection as a Lead Candidate and prior to the time that it is accepted as an IND Ready Candidate. In particular, Preclinical Development shall include those studies set forth as Nomination Criteria by the
JOC. 
  
 1.85 “Pre-Commercialization” means all
Commercialization activities undertaken prior to or less than one (1) year after the launch date in accordance with the Launch Plan of a Collaboration Product. Pre-Commercialization shall include advertising, education, product-related public
relations, health care economic studies, governmental affairs activities for reimbursement and formulary acceptance, sales force training, trademark selection, filing, prosecution and enforcement, and other activities included within the Launch
Plan. 
  
 1.86 “Pre-Commercialization Costs”
means the expenses, excluding Development Costs, incurred prior to or less than one (1) year after the launch date in accordance with the Launch Plan of a Collaboration Product, by a Party or for its account which are specifically attributable to
the Pre-Commercialization of such Collaboration Product and generally consistent with the Launch Budget. Pre-Commercialization Costs shall exclude administrative expenses that are not attributable to sales force procurement, training, retention and
compensation. 
  
 1.87 “Product” means a
Collaboration Product, Other Product, Partnered Product, PPD Terminated Product or Syrrx Terminated Product. 
  
 1.88 “Product Profit” means the profits or losses resulting from the Commercialization of Collaboration Products and shall be equal to
Net Sales of Collaboration Products less Allowable Expenses for Collaboration Products. 
  
 1.89 “Project Team” or “PT” means the committee described in Section 2.3. 
  
 1.90 “Pursued Diseases” means (a) all diseases in the Field for which, at the time in question, a Lead Candidate, IND Ready Candidate,
Collaboration Product or Partnered Product is being developed under the Collaboration, (b) all diseases in the Field for which, at the time in question, a Syrrx Terminated Product is being developed outside of the Collaboration, [*]. 
  
 1.91 “Regulatory Agent” means that Party designated by an
appropriate authorization to the FDA to be the primary contact with, and recipient of correspondence from, the FDA in connection with any FDA matter or filing relating to a Collaboration Product. 
  
 1.92 “Regulatory Approval” means any and all approvals
(including supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national (e.g., the European Commission or the Council of the European Union),
regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the manufacture, distribution, use or sale of a Collaboration Product in a regulatory jurisdiction. 

 
 1.93 “Regulatory Documentation” means, with respect to a
Collaboration Product, all regulatory filings and supporting documents created, submitted to the FDA or any equivalent agency or government authority outside of the United States (including any supra-national 
  

 [*] Confidential treatment
requested; certain information omitted and filed separately with the SEC. 
  

 -13- 

 agency such as in the European Union) relating to such Product, and all data contained therein (other than DP4 IP, PPD
Information and Syrrx Information), including, without limitation, the contents of any IND(s), NDA(s), BLA(s), Drug Master File (“DMF”), correspondence to and from the FDA or any equivalent agency or governmental authority outside of the
United States, minutes from meetings (whether in person or by audioconference or videoconference) with regulatory authorities, registrations and licenses, regulatory drug lists, advertising and promotion documents shared with regulatory authorities,
adverse event files, complaint files and manufacturing records.  
  
 1.94 “Regulatory Filing” means the new drug application (“NDA”) or biologic license application (“BLA”) or investigational new drug application (“IND”) or any foreign counterparts thereof and
any other filings required by Regulatory authorities relating to the study, manufacture or commercialization of any Collaboration Product. 
  
 1.95 “Rejected Disease” means, with respect to a particular Rejected Inhibitor, the Nominated Disease that corresponded with such
Rejected Inhibitor when it was a Lead Candidate. 
  
 1.96
“Rejected Inhibitor” means (a) a former Potential IND Ready Candidate that Syrrx selects in accordance with Section 3.6(d)(ii) and that has not been redesignated a Potential IND Ready Candidate in accordance with Section 3.6(e); (b) a
former Lead Candidate for which PPD notifies Syrrx in writing pursuant to Section 3.4(c) of its decision to terminate Preclinical Development activities; and (c) a Target Inhibitor upon which Syrrx has performed some Compound Screening activities
and for which PPD subsequently notifies Syrrx in writing pursuant to Section 3.4(a) of its decision to terminate Compound Screening activities. For clarity, a Target Inhibitor shall cease to be listed in the Target Inhibitor Catalog at such time as
it becomes a Rejected Inhibitor. 
  
 1.97 “Reserved IND
Ready Candidate” means a former Potential IND Ready Candidate that is designated as such in accordance with Section 3.6(d)(ii) and has not been redesignated, pursuant to Section 3.6(d)(ii), as a Potential IND Ready Candidate. 
  
 1.98 “Shared Phase IIIa Development Costs” means all Phase
IIIa Development Costs incurred by either Party with respect to a Collaboration Product for which the Parties have entered into a Phase III Loan or Syrrx is paying half of Phase IIIa Development Costs out of its own resources. 
  
 1.99 “Sole IP” means any and all inventions, developments,
results, know-how and other Information (including physical, chemical or biological materials), and all intellectual property relating thereto, that is (a) made, conceived or reduced to practice solely by employee(s) or agent(s) of a Party in the
performance of its duties to the Collaboration and (b) is not DP4 IP, PPD Information or Syrrx Information. 
  
 1.100 “Syrrx Existing IP” means all rights to all Patents Controlled by Syrrx or its Affiliate as of the Effective Date. 
  

 -14- 

 1.101 “Syrrx Generic Third Party Agreement” means, with respect to a particular Syrrx
Terminated Product, an agreement between Syrrx and a Third Party that relates to such Syrrx Terminated Product and to other products as well. 
  
 1.102 “Syrrx Information” means all Information (other than DP4 IP) produced solely by Syrrx or its Affiliate in the course of performing
the Development Plan or the Commercialization Plan. For clarity, Syrrx Information includes Information generated solely by Syrrx or its Affiliate during the course of the Collaboration that is related to Regulatory Filings or Regulatory
Documentation. 
  
 1.103 “Syrrx Specific Third Party
Agreement” means, with respect to a particular Syrrx Terminated Product, an agreement between Syrrx and a Third Party that relates solely to such Syrrx Terminated Product. 
  
 1.104 “Syrrx Technology” means (a) DP4 IP, (b) Syrrx Information, and (c) all Information and
Patents (i) that are Controlled by Syrrx or its Affiliate during the Term as a result of Syrrx’s or its Affiliate’s entry into a license agreement with a Third Party and (ii) that (1) relate to the composition of matter, manufacture or use
of a Target Inhibitor or (2) are incorporated into any Product or necessary for the discovery, identification, manufacture, development, and commercial use or sale of any Products. 
  
 1.105 “Syrrx Terminated Product” means 
  
 (a) a former Collaboration Product for which: 
  
 (i) Syrrx terminated its rights and obligations pursuant to Section 13.2(c); or 
  
 (ii) pursuant to Section 4.3(e), Syrrx elects without Good Cause to decline
the offer of a Phase III Loan and does not commit to pay for its half of the Phase IIIa Development Costs for the corresponding Collaboration Product and PPD Commences a Phase IIIa Trial for such Product; and 
  
 (b) all other human therapeutic products that contain the same IND Ready
Candidate (or a prodrug, metabolite specific to such former Collaboration Product, ionized form (e.g., salt), solvate (e.g., hydrate), stereoisomer (e.g., enantiomer, diastereomer, mixture of isomers), resonant form, or tautomer thereof) as such
former Collaboration Product. 
  
 1.106 “Target”
means human serine protease dipeptidyl peptidase IV (DP4). 
  
 1.107 “Target Inhibitor” means [*]. 
  
 1.108 “Term” shall have the meaning assigned to it in Section 13.1. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -15- 

 1.109 “Third Party” means any individual, corporation, partnership, limited liability
company or other entity other than (i) Syrrx, (ii) PPD or (iii) an Affiliate of either of them. 
  
 1.110 “Third Party Partner” means a Third Party that has entered into a Partnering Agreement. 
  
 2. MANAGEMENT OF THE
COLLABORATION 
  
 2.1 Overall Management
Structure. The overall management of the Collaboration shall be vested in the Joint Operating Committee (the “JOC”), with responsibility, as further discussed in Section 2.2, for establishing the strategic direction of the
Collaboration and for managing and directing the research, development and commercialization efforts of the Parties under the Collaboration. The JOC shall establish a Project Team (the “PT”) that reports to the JOC and assists with the
day-to-day management of Preclinical Development, Clinical Development and launch of Target Inhibitors, IND Ready Candidates, and Collaboration Products, as the case may be. The JOC may establish one or more other committees that report to the JOC
and assist the JOC in managing and directing the Collaboration. The committees formed by the JOC and PT are intended to facilitate management of the various Collaboration activities of the Parties; they shall provide information to the JOC upon
which the JOC may base its decisions. Each Party agrees to use good faith, cooperative efforts to facilitate and assist the efforts of the JOC, PT and all such additional committees established by the JOC. The JOC may also establish a Joint
Commercialization Committee (the “JCC”) to oversee the commercialization activities of the Parties with respect to Products. The JOC may also establish a Joint Finance Committee (“JFC”), to develop and submit to the JOC for
approval, annual budgets of expenses to be incurred by the Parties for the development of Target Inhibitors, IND Ready Candidates, and Collaboration Products. In addition, the JOC may also establish a Joint Intellectual Property Committee (the
“JIPC”) which shall be responsible for making recommendations to the JOC regarding intellectual property prosecution, Third Party licensing, infringement and patent enforcement issues relating to DP4 IP, Sole IP and Joint IP. Each
committee may further establish one or more subcommittees as it deems appropriate and delegate one or more of its responsibilities to such subcommittee, provided that the subcommittee’s actions will be subject to review and approval by the
committee. 
  
 2.2 Joint Operating Committee. 

 
 (a) Membership. The Joint Operating Committee (the
“JOC”) shall be composed of at least six members, three members appointed by each Party. Each Party shall designate its initial JOC representatives within thirty (30) days after the Effective Date. Each Party may replace its JOC
representatives at any time upon written notice to the other Party. PPD will designate one of its initial JOC representatives as the initial Chairperson of the JOC. 
  
 The Chairperson shall alternate between the Parties every twelve (12) months. The Chairperson shall be responsible for scheduling meetings,
preparing and circulating an agenda in advance of each meeting, and preparing and issuing minutes of each meeting within 30 days thereafter. 
  
 (b) Responsibilities. During the term of this Agreement, the JOC shall meet at least on a quarterly basis as provided in Section 2.7. The JOC will
make its decisions by 
  

 -16- 

 unanimous vote, with each Party’s representatives collectively having one vote. It shall determine the overall
strategy for the Collaboration and shall oversee the PT, JCC, JFC and JIPC and any other committees formed by it. In addition to the other duties specifically attributed to the JOC in this Agreement, the JOC shall (i) maintain the Target Inhibitor
Catalog, (ii) evaluate the progress of the Development Plan and Commercialization Plan, (iii) determine the circumstances and terms under which a Party can engage a Third Party to perform certain obligations of such Party under the Development Plan
or Commercialization Plan, (iv) monitor compliance with the diligence provisions set forth in Sections 3.5 and 5.9, (v) serve as the initial forum to resolve any disputes that arise in the PT, JCC, JFC or JIPC, (vi) approve all modifications and
addenda to the Development Plan and Commercialization Plan, and (vii) approve all budgets including the Development Budgets, Commercialization Budgets and Launch Budgets, and any amendments to any budgets. 
  
 2.3 Project Team. 
  
 (a) Membership. The Parties shall establish a Project Team
(“PT”) composed of as many members from each Party as deemed necessary to perform obligations set forth in a Development Plan. One representative from each Party on the PT shall be the individual at the Party with primary responsibility
for the day-to-day management and execution of the Development Plan. The PT shall report directly to the JOC and shall take its direction from the JOC. Each Party may replace its appointed PT representatives at any time. PPD and Syrrx shall each
designate one of its representatives as a co-Project Team Leader. The co-Project Team Leaders shall be responsible for scheduling meetings, preparing and circulating an agenda in advance of each meeting, and preparing and issuing minutes of each
meeting within thirty (30) days thereafter. 
  
 (b)
Responsibilities. During the Term, the PT shall meet at least monthly and as further needed as provided in Section 2.7. The PT serves an advisory role to the JOC and shall at all times defer to the authority of the JOC. The PT shall inform
the JOC regarding matters relating to the advancement of Target Inhibitors to Lead Candidates, Preclinical Development of a Lead Candidate, Clinical Development of an IND Ready Candidate for use in the Accepted Disease or in any additional diseases
approved pursuant to Section 3.8, in order to obtain Regulatory Approvals as set forth in Article 3, including the following activities: (i) preparation of proposed Development Plans and Development Budgets, and modifications thereto as needed; (ii)
oversight of implementation of Development Plans and Development Budgets, (iii) oversight of outsourced work; and (iv) management of the flow of Information with respect to Preclinical Development being conducted for each Lead Candidate and Clinical
Development being conducted for each IND Ready Candidate. At its meetings, the PT shall review the progress of the Development Plan and consider modifications to such Development Plan. The PT shall summarize for the JOC the progress of the
Development Plan since the last JOC meeting, bring to the attention of the JOC any overarching issues or significant changes in a proposed modification or amendment to a Development Plan, and address any issues raised by the JOC at its previous
meeting. The PT shall also propose Lead Candidate Selection Criteria or Nomination Criteria for different diseases within the Field and submit them to the JOC for approval. The PT shall prepare and timely submit to the JOC objective reports
regarding Target Inhibitors or Lead Candidates that one or both Parties believe fulfill either the Lead Candidate Selection Criteria or the Nomination Criteria, as the case may be, for acceptance by the JOC as a Lead Candidate or an IND Ready
Candidate pursuant to Section 3.6(b) or 3.6(d), as the case may be. 
  

 -17- 

 2.4 Joint Commercialization Committee. 
  
 (a) Membership. The JOC may establish a Joint Commercialization
Committee (the “JCC”) that would be composed of four (4) members, with two (2) members appointed by each Party. It is anticipated that within thirty (30) days after the later of such establishment and the first IND Ready Candidate begins
Clinical Development, each Party would appoint two representatives to the JCC. Each Party could replace its JCC representatives at any time upon written notice to the other Party. PPD would designate one of its representatives as the initial
Chairperson of the JCC. The Chairperson would alternate between the Parties every twelve (12) months. The Chairperson would be responsible for scheduling meetings, preparing and circulating an agenda in advance of each meeting, and preparing and
issuing minutes of each meeting within thirty (30) days thereafter. 
  
 (b) Responsibilities. Starting with its formation pursuant to Section 2.4(a) and continuing throughout the Term, it is anticipated that the JCC would meet at least quarterly as provided in Section 2.7. The JCC would operate by
unanimous vote, with each Party’s representatives collectively having one vote. As the Development of Collaboration Products advances, the JCC would also evaluate, and make recommendations to the JOC regarding, potential arrangements for the
manufacturing, marketing and sales, and/or licensing of a Collaboration Product to Third Parties. As set forth in greater detail in Article 5, the JCC would be responsible for overseeing the pre-launch and post-launch commercialization of
Collaboration Products under the Collaboration. At its meetings, the JCC would review the progress of the Commercialization Plan and consider proposing to the JOC modifications to such Commercialization Plan. The JCC would also summarize for the JOC
the progress of the Commercialization Plan since the last JOC meeting, bring to the attention of the JOC any overarching issues or significant changes in a proposed modified Commercialization Plan, and address any issues raised by the JOC at its
previous meeting.  
  
 2.5 Joint Finance Committee.

  
 (a) Membership. The JOC may also establish a Joint
Finance Committee (the “JFC”) that would be composed of four (4) members, with two (2) members appointed by each Party. Each Party would be able to replace its JFC representatives at any time upon written notice to the other Party. Syrrx
would designate one of its representatives as the initial Chairperson of the JFC. The Chairperson would alternate between the Parties every twelve (12) months. The Chairperson would be responsible for scheduling meetings, preparing and circulating
an agenda in advance of each meeting, and preparing and issuing minutes of each meeting within thirty (30) days thereafter. 
  
 (b) Responsibilities. It is anticipated that the JFC, if formed, would meet at least quarterly during the Term, as provided in Section 2.7. The JFC
would operate by unanimous vote, with each Party’s representatives collectively having one vote. The JFC would develop and submit to the JOC for approval Development Budgets, Launch Budgets, Commercialization Budgets and any other budgets
required under this Agreement. In particular, the JFC would be responsible for providing the Parties with an estimated budget for Phase IIIa Development Costs (and, if applicable, Phase IIIb Costs) in order to establish the maximum amount of the
Phase III Loan. 
  

 -18- 

 2.6 Joint Intellectual Property Committee. The JOC may also establish a Joint Intellectual
Property Committee (the “JIPC”) that would devise a strategy for the protection of intellectual property arising from the Collaboration. It is anticipated that the committee would consist of one member from each Party’s senior
management team or the Party’s designated alternate. The Syrrx representative would serve as the initial Chairperson of the JIPC. The Chairperson would alternate between the Parties every twelve (12) months. 
  
 2.7 Meetings. The Parties shall endeavor to schedule meetings of the
JOC, PT, and all other committees that are formed, at least sixty (60) days in advance. Committee meetings held in person will alternate between sites designated by each Party or as otherwise agreed upon by the Parties. When possible, the meetings
of a given committee should occur at the same location as the JOC meetings, with the JOC meeting occurring after the meetings of the other committees. With the consent of the representatives of each Party serving on a particular committee, other
representatives of each Party may attend meetings of that committee as nonvoting observers. A meeting of a committee may be held by audio or video teleconference with the consent of both Parties. Meetings of a committee shall be effective only if at
least one representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses of participating in the committee meetings. 
  
 2.8 Obligations of Parties. Syrrx and PPD shall provide the JOC, PT, and all other committees that are formed, and
their authorized representatives with reasonable access during regular business hours to all records, documents, and Information relating to the Collaboration which any such committee may reasonably require in order to perform its obligations
hereunder, provided that if such records, documents or Information are under a bona fide obligation of confidentiality to a Third Party, then Syrrx or PPD, as the case may be, may withhold access thereto to the extent necessary to satisfy such
obligation. 
  
 3. DEVELOPMENT 
  
 3.1 Overview. 
  
 (a) Goals. The general goals and intent of the Collaboration are to
discover Target Inhibitors, to perform sufficient screening work on certain Target Inhibitors for them to satisfy Lead Candidate Selection Criteria to become Lead Candidates, to perform sufficient preclinical work on certain Lead Candidates for them
to satisfy the Nomination Criteria to become IND Ready Candidates, and to clinically develop and commercialize, either alone or together with a Third Party Partner, Collaboration Products. 
  
 (b) General. In all matters related to the Collaboration, the Parties
shall be guided by standards of reasonableness in economic terms and fairness to each of the Parties, striving to balance the legitimate interests and concerns of the Parties, to further each Development Plan and Commercialization Plan and to
realize the economic potential of Collaboration Products.  
  

 -19- 

 (c) Independence. Subject to the terms of this Agreement, the activities and resources of each
Party shall be managed by such Party, acting independently and in its individual capacity. The relationship between Syrrx and PPD is that of independent contractors and neither Party shall have the power to bind or obligate the other Party in any
manner, or be or become or be deemed to be or to become, liable or responsible for the debts, liabilities or obligations of the other Party.  
  
 3.2 Development Plans. 
  
 (a) Definition. The Preclinical Development of Target Inhibitors and Lead Candidates and the Clinical Development of IND Ready Candidates shall be
governed by a Development Plan that describes the proposed overall program to achieve regulatory agency registration of a Collaboration Product, including, but not limited to, description of Drug Substance, CTM, preclinical, clinical and regulatory
activities, with estimated budgets and timelines necessary to achieve such approval related to an Accepted Disease (the “Development Plan”).  
  

(b) Initial Development Plan. As of the Effective Date, the Parties have agreed upon and approved an Initial Development Plan that sets forth
the Preclinical Development and Clinical Development studies for the Initial Lead Candidates. If the Initial Lead Candidates are terminated and the Parties later initiate Preclinical Development for type II diabetes upon one or more additional Lead
Candidates, the Parties shall perform upon such Lead Candidates the types of Preclinical Development and Clinical Development studies described in the Initial Development Plan, or as further modified by the JOC. 
  
 (c) Development Plan Addenda. In addition to the Initial Development
Plan, the Collaboration shall include one or more Development Plans that shall be approved by the JOC and made part of this Agreement by the JOC and attached hereto as Development Plan Addenda.  
  
 (d) Updates. The PT shall prepare and submit for the JOC’s
consideration, by September 1 of each calendar year, an updated Development Plan that includes a detailed description of all Development anticipated to be performed during the following calendar year. The JOC shall provide comments on each such
updated Development Plan within thirty (30) days following its submission to them. Within thirty (30) days following such original submission, the JOC shall either approve the original Development Plan or a modified version thereof that is
consistent with the objectives for the Collaboration Products and the aims of the Collaboration. The Development Plan shall also be revised in accordance with Sections 3.4(d)(i) and 3.8. 
  
 (e) Phase IIIb Trials. For some diseases, the Parties may, but shall not be obligated to, choose to treat a selected
Phase IIIb Trial as falling within the scope of Development, such as when such Phase IIIb Trial is typically performed in the industry in order to support a NDA or to expand the product label. By way of example, a Phase IIIb Trial for non-insulin
dependent type II diabetes with more advanced disease is an example of a Phase IIIb Trial that is highly supportive of an NDA for type II diabetes. For clarity, if the Parties are unable to agree whether to include a Phase IIIb Trial within the
scope of Development, the dispute will not be subject to arbitration under Article 16 and the Phase IIIb Costs will be deemed to be part of Commercialization.  
  

 -20- 

 (f) Third Party Development Contracts. To the extent a Party is performing any task under a
Development Plan or Commercialization Plan that needs to be performed by a Third Party, such Party shall be responsible for entering into contracts with such Third Party. Prior to entry into a given Third Party contract, such contract shall be
approved by the JOC pursuant to Section 2.2(b)(iii).  
  
 3.3 Development Budget. 
  
 (a)
Definition. The expenses incurred by the Parties in the course of performing the Development Plan shall be governed by a development budget (“Development Budget”). Except as permitted by Sections 3.3(e)(ii) and 3.3(f)(ii), the
Development Budget shall constitute the maximum Development Costs to be incurred thereunder in each calendar year, unless such budget is modified by the JOC. 
  
 (b) Initial Development Budget. As of the Effective Date, the Parties have agreed upon and approved an Initial
Development Budget that sets forth the Parties’ financial projections for the Initial Development Plan. 
  
 (c) Development Budgets. A Development Budget shall be included with each Development Plan submitted to the JOC and attached hereto as a
Development Plan Addendum or an updated Development Plan. 
  
 (d)
Modifications. The JOC (or the JFC, if formed) shall prepare and submit to the Parties, by September 1 of each calendar year, an updated Development Budget that includes a detailed description of all Development costs authorized to be
incurred during the following calendar year. The Parties shall provide comments on each such updated Development Budget within thirty (30) days following its submission to them. Within thirty (30) days following such original submission, the JOC
shall either approve the original Development Budget or a modified version thereof that is consistent with the objectives for the development of Collaboration Products and the aims of the Collaboration.  
  
 (e) Early Stage Development Costs. 
  
 (i) Syrrx shall be solely responsible for [*] of Early Stage
Development Costs for the Initial Lead Candidates. PPD shall bear the remainder of all Early Stage Development Costs for the Initial Lead Candidates after [*] is depleted. The Parties will strive to develop an IND Ready Candidate from
among the Initial Lead Candidates and the Early Stage Development Costs for the Initial Lead Candidates leading to the first IND Ready Candidate will not exceed [*]. For clarity, the first [*] may be used for GMP
manufacturing or GLP manufacturing if authorized by the JOC for Preclinical Development for the Initial Lead Candidates. The first [*] will not be used for costs associated with Compound Screening of Target Inhibitors other than the
Initial Lead Candidates. In the event that the JOC decides to 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -21- 

 terminate development of all of the Initial Lead Candidates or otherwise decides that the development of additional
Target Inhibitors is warranted and the Early Stage Development Costs incurred with respect to the Initial Lead Candidates are less than [*], then the remaining portion of the [*] may be used for payment of Compound
Screening costs and other Early Stage Development Costs for Preclinical Development of additional Target Inhibitors as approved by the JOC. Such costs shall be subject to approval by the JOC based upon a Development Plan for such additional Target
Inhibitors. The JOC shall also determine whether any additional Preclinical Development work will be performed on any additional Target Inhibitors other than the Initial Lead Candidates in excess of the [*] referenced above. Such
additional Preclinical Development work and the costs associated therewith shall be set forth in a Development Plan and Development Budget and approved by the JOC. If Syrrx desires to perform Preclinical Development work on Target Inhibitors beyond
that which is authorized by the JOC, Syrrx may perform such additional Preclinical Development pursuant to this Agreement, provided however, that any costs that Syrrx incurs in performing such additional Preclinical Development shall not be treated
as Early Stage Development Costs and shall be paid solely by Syrrx. If Syrrx elects to perform such additional Preclinical Development, it shall keep the JOC informed of the progress of such work and the costs associated therewith. If PPD later
votes to accept a given Target Inhibitor that Syrrx develops without JOC approval as an IND Ready Candidate, any reasonable costs that Syrrx incurs in performing such additional Preclinical Development for that Target Inhibitor shall retroactively
be deemed an Early Stage Development Cost. 
  
 (ii) Each Party
shall maintain accurate books and records of all costs and expenses allowable as Early Stage Development Costs, within the Development Budget. Within 30 days after the end of each calendar quarter, each Party shall submit to the JOC a summary of all
Early Stage Development Costs incurred during that quarter, including reasonable detail demonstrating the specific basis for the costs and expenses included in the summary. The JOC shall review all such expenses to determine if they fall within the
Development Budget. Any amounts exceeding [*] of the Development Budget shall be borne by the Party making such expenditure, unless approved by JOC and if so approved shall be Early Stage Development Costs. 
  
 (iii) As long as Syrrx’s cumulative expenditures (both directly and
through reimbursement of PPD) upon Early Stage Development Costs between the Effective Date and the end of the quarter for which the report provided pursuant to Section 3.3(e)(ii) pertains are less than a total of [*], the JOC shall
send Syrrx an invoice to reimburse PPD an amount equal to the smaller of (1) its Early Stage Development Costs for such quarter or (2) that portion of its Early Stage Development Costs for such quarter, that once paid by Syrrx, would bring
Syrrx’s cumulative expenditures (both directly and through reimbursement of PPD) upon Early Stage Development Costs since the Effective Date up to a total of [*]. Syrrx shall reimburse PPD for the amount stated on such invoice
within thirty (30) days of receiving such invoice. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -22- 

 (iv) Once Syrrx’s cumulative expenditures (both directly and through reimbursement of PPD) upon
Early Stage Development Costs equals [*], PPD will thereafter be solely responsible for all future Early Stage Development Costs. PPD shall reimburse Syrrx for any Early Stage Development Costs that it incurs after such time within
thirty (30) days of receiving an invoice from Syrrx therefore. 
  
 (v) Either Party may audit, in accordance with the procedures set forth in Section 10.7, the accuracy of the other Party’s submissions pursuant to this Section 3.3(e).  
  
 (f) Shared Phase IIIa Development Costs. 
  
 (i) Except as set forth in Section 3.3(f)(ii), all Shared Phase IIIa
Development Costs shall be shared equally by the Parties. 
  
 (ii) Each Party shall maintain accurate books and records of all costs and expenses allowable as Shared Phase IIIa Development Costs, within the Development Budget. Within thirty (30) days after the end of each calendar quarter, each
Party shall submit to the JOC a summary of all Shared Phase IIIa Development Costs incurred during that quarter, including reasonable detail demonstrating the specific basis for the costs and expenses included in the summary. The JOC shall review
all such expenses to determine if they fall within the Development Budget. Any amounts exceeding [*] of the Development Budget shall be borne by the Party making such expenditure, unless approved by JOC and if so approved shall be
Shared Phase IIIa Development Costs. The JOC shall submit to the Party that bore less than half of such Shared Phase IIIa Development Costs for that quarter (the “Invoiced Party”) an invoice for the amount that Party must remit to the
other Party (the “Non-Invoiced Party) to bring the Invoiced Party’s share of the Shared Phase IIIa Development Costs up to one-half for the previous quarter. The Invoiced Party shall remit the amount on the invoice to the Non-Invoiced
Party within 30 days of receiving such invoice. In the event that Syrrx is the Invoiced Party, it may remit such invoiced amount from its Phase III Loan and it may reimburse itself by drawing upon such Phase III Loan, for all other Shared Phase IIIa
Development Costs it incurred during that quarter. In the event that Syrrx is the Non-Invoiced Party, it may reimburse itself by drawing upon its Phase III Loan for all Shared Phase IIIa Development Costs it incurred during that quarter that were
not reimbursed by PPD pursuant to this Section 3.3(f)(ii). Either Party may audit, in accordance with the procedures set forth in Section 10.7, the accuracy of the other Party’s submissions pursuant to this Section 3.3(f).  

 
 (g) Phase IIIb Costs and Phase IV Costs. All Phase IIIb Costs and
Phase IV Costs shall be Post-Launch Product R&D Expenses, which are taken into account in the calculation of Product Profit, except for those Phase IIIb Costs incurred with respect to a Phase IIIb Trial that the Parties mutually agree to include
within the scope of Development pursuant to Section 3.2(e). If a Phase IIIb Trial is included within the scope of Development pursuant to Section 3.2(e), then such Phase IIIb Costs shall be classified as Development Costs and shall be subject to the
procedures set forth in Section 3.3(f) if the Parties have entered into a Phase III Loan which covers such Phase IIIb Trial or if Syrrx pays its half of such costs. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -23- 

 3.4 Development Plan Responsibilities 
  
 Compound Screening. Syrrx shall be solely responsible for carrying out, in accordance
with a Development Plan, compound screening activities to discover Target Inhibitors, performing SAR structure design, medicinal chemistry, and activities described in Section 1.50 to identify Target Inhibitors that satisfy Lead Candidate Selection
Criteria to become Lead Candidates. Syrrx shall perform the medicinal chemistry work specified in a Development Plan where Syrrx is reimbursed for all approved Development Costs. If the JOC determines that the Collaboration will benefit from
Syrrx’s performance of medicinal chemistry work over and above the work specified in a Development Plan, then the JOC may further authorize Syrrx to perform such additional work and Syrrx may seek reimbursement for all approved Development
Costs including the cost of Syrrx employees to perform such work. At any point during Compound Screening activities, PPD shall have the right, at its sole discretion, to terminate such activities for a given Target Inhibitor. PPD shall inform Syrrx
in writing of such termination. In the event of such termination, PPD shall have no further obligation to pay Early Development Costs for such Target Inhibitor and the Target Inhibitor shall become a Rejected Inhibitor and be denoted as such in the
Target Inhibitor Catalog. 
  
 (a) GMP Manufacturing. Syrrx
shall be solely responsible for carrying out, in accordance with a Development Plan, GMP manufacturing of Drug Substances consisting of those Target Inhibitors selected for animal testing. PPD agrees to carry out such GMP manufacturing tasks as are
reasonably requested by Syrrx, accepted by PPD and agreed by the JOC. 
  
 (b) Preclinical Development. PPD shall be solely responsible for carrying out Preclinical Development activities on Lead Candidates as set forth in a Development Plan to fulfill Nomination Criteria to enable
the JOC to select an IND Ready Candidate, and, except as set forth in Section 3.3(e), shall be solely responsible for all costs associated therewith. It is anticipated that the Development Plan will allocate to PPD responsibility for performing GLP
toxicity and pharmacokinetic studies on such Lead Candidates. At any point during Preclinical Development activities, PPD shall have the right, at its sole discretion, to terminate such activities for a given Lead Candidate. PPD shall inform the
Syrrx in writing of such termination. In the event of such termination, PPD shall have no further obligation to pay Early Development Costs for such Lead Candidate and the Lead Candidate shall become a Rejected Inhibitor and be denoted as such in
the Target Inhibitor Catalog. Syrrx agrees to carry out such Preclinical Development tasks as are reasonably requested by PPD, accepted by Syrrx and agreed by the JOC. 
  
 (c) Clinical Development. 
  
 (i) Promptly following the selection of any IND Ready Candidate by the JOC, the PT shall prepare a proposed revision to the Development Plan to prepare
an IND filing for at least one Collaboration Product corresponding to such IND Ready Candidate and to generate all data, Information and Regulatory Documentation required to obtain Regulatory Approval for such Collaboration Product. In addition, the
JOC shall give reasonable consideration to suggestions from the PT when it revises the Development Plan for the purposes described above and the Development Budget to include the costs associated with Clinical Development of such Collaboration
Product. 
  

 -24- 

 (ii) PPD shall be solely responsible for carrying out all Clinical Development activities pursuant to
the Development Plan, provided that the JOC shall discuss and agree how manufacture and supply responsibilities for CTM employed in Phase I Trials, Phase II Trials and Phase III Trials will be allocated between the Parties. Syrrx agrees to carry out
such Clinical Development tasks as are reasonably requested by PPD, accepted by Syrrx and agreed by the JOC. 
  
 (d) Development Records and Reports.  
  
 (i) Reports. At each meeting of the PT, each Party shall report to the PT the work it has performed during Target Inhibitor screening and under
the Development Plan since the previous meeting. 
  
 (ii)
Records. Each Party shall maintain complete and accurate records of all work conducted under the Collaboration and all results, data and developments made pursuant to its efforts under the Collaboration. Such records shall be complete and
accurate and shall fully and properly reflect all work done and results achieved in the performance of the Collaboration in sufficient detail and in good scientific manner appropriate for patent and regulatory drug development and approval purposes.
Each Party shall have the right to review and copy such records of the other Party at reasonable times to the extent necessary for such Party to conduct its obligations under the Agreement. 
  
 (e) Regulatory Affairs. 
  
 (i) Consistent with the Development Plan but subject to the remainder of
this Section 3.4(f), PPD shall be responsible for developing Regulatory Documentation and preparing and submitting Regulatory Filings, seeking Regulatory Approvals, and maintaining Regulatory Approvals for Collaboration Products, including preparing
all reports necessary as part of an IND, NDA, DMF, BLA or other necessary filing required for Regulatory Approval. All such Regulatory Documentation, Regulatory Filings and Regulatory Approvals shall be owned solely by and filed solely in the name
of PPD, and PPD shall be fully responsible for all regulatory activities and requirements and maintaining Regulatory Approvals. 
  
 (ii) Concurrent with each filing of a Regulatory Filing for a Collaboration Product and each receipt of a Regulatory Approval for a Collaboration
Product, PPD shall file with the FDA or the applicable equivalent foreign entity, all documents necessary to grant Syrrx a right of reference to such Regulatory Filing or Regulatory Approval for all purposes, subject in each case to the requirements
and restrictions of the FDA or the applicable foreign entity. For clarity, PPD shall not be in breach of this Section 3.4(f)(ii) if the FDA refuses to accept or acknowledge any such documents for any reason, provided PPD makes reasonable efforts to
revise such documents to meet the FDA’s requirements for acceptance or acknowledgement. 
  
 (iii) Syrrx hereby covenants that it will not file with the FDA or the applicable equivalent foreign entity any documents in which Syrrx invokes the right of reference 
  

 -25- 

 set forth in Section 3.4(f)(ii) except as necessary or useful to permit Syrrx to exercise its rights under this Agreement
with respect to PPD Terminated Products. Subject to approval by the JOC, Syrrx may invoke its right of reference to perform its obligations under the Development Plan, Commercialization Plan or Partnering Agreements. For the sake of clarity, the
foregoing covenant shall preclude Syrrx from filing with the FDA or the applicable equivalent foreign entity any documents in which Syrrx invokes the right of reference outside of the Field for any Inhibitor of the Target that is not a PPD
Terminated Product. 
  
 (iv) The negative covenant set forth in
Section 3.4(f)(iii) shall terminate, on a Collaboration Product-by-Collaboration Product basis, at such time as PPD fails to perform any of its material obligations under this Agreement with respect to such Collaboration Product and fails to cure
such breach within thirty (30) days after Syrrx’s notice thereof. 
  
 (v) PPD hereby covenants that during the Term it will not revoke the right of reference set forth in Section 3.4(f)(ii) with respect to a given Collaboration Product unless Syrrx fails to perform any of its material obligations under this
Agreement with respect to that Collaboration Product being referenced and fails to cure such breach within thirty (30) days after PPD’s notice thereof. 
  
 (vi) PPD shall keep Syrrx and the JOC informed on an ongoing basis regarding the schedule and process for Regulatory Documentation and Regulatory Filings
and give Syrrx the ability to comment on and participate in the preparation of Regulatory Documentation and Regulatory Filings and shall provide Syrrx with reasonable advance notice of any meeting or substantive telephone conference call with any
regulatory agency relating to any Regulatory Documents and Regulatory Filing. Syrrx shall have the right to participate with PPD in any such meeting or conference call. PPD shall promptly furnish Syrrx with copies of all Regulatory Documentation and
Regulatory Filings (in both paper and electronic form), correspondence that PPD receives from any regulatory agency relating to any such Regulatory Filings, and contact reports it receives concerning substantive conversations or substantive meetings
with any regulatory agency relating to any such Regulatory Filings. PPD shall prepare all responses to correspondence that are received from any regulatory agency relating to any Regulatory Documents and any Regulatory Filing. Syrrx shall be
provided with advance notice of any such responses and shall be given an opportunity to comment. 
  
 (f) Standard of Practice. In conducting any Development activities hereunder, each Party shall (i) ensure that its employees, agents, clinical
institutions and clinical investigators comply with all FDA statutory and regulatory requirements with respect to Collaboration Products, including but not limited to: the Federal Food, Drug and Cosmetic Act, as amended (FFDCA); the Public Health
Service Act (PHSA); regulatory provisions regarding protection of human subjects, financial disclosure by clinical investigators, Institutional Review Boards (IRB), Good Clinical Practices, Good Laboratory Practices, IND regulations, and any
conditions imposed by a reviewing IRB or the FDA; and (ii) not utilize, in conducting studies on Collaboration Products any person or entities that at such time are debarred by FDA, or that, at such time, are under investigation by FDA for debarment
action pursuant to the provisions of the Generic Drug Enforcement Act of 1992 (21 U.S.C. Section 335). 
  

 -26- 

 3.5 Development Diligence. 
  
 (a) The Parties shall use Diligent Efforts to conduct their respective tasks, as assigned under the Development Plan,
throughout the Collaboration and shall conduct the Collaboration in good scientific manner, and in compliance in all material respects with the requirements of applicable laws, rules and regulations, including without limitation then-current Good
Laboratory Practices, Good Clinical Practices, and Good Manufacturing Practices, to attempt to achieve their objectives efficiently and expeditiously. 
  
 (b) If a Party fails to use Diligent Efforts to perform a task assigned to it under the Development Plan and does not cure such failure within
[*] after the other Party’s written notice thereof, such Party shall not be in material breach of this Agreement, but shall be deemed to have voluntarily terminated its rights, pursuant to Section 13.2(c), with respect to the
affected Target Inhibitor or Collaboration Product. 
  
 3.6
Target Inhibitor Advancement Activities. 
  
 (a) Target
Inhibitor Catalog. The JOC will be solely responsible for maintaining the Target Inhibitor Catalog, which shall specifically identify each Target Inhibitor, related data and its date of entry, as follows: 
  
 (i) Within thirty (30) days of the Effective Date, the JOC will prepare a
Target Inhibitor Catalog consisting of the Initial Target Inhibitors (along with relevant information relating thereto including at least in vitro activity data and minimum selectivity panel data), specifically identifying each Initial Target
Inhibitor and its designation as such. Given the highly confidential nature of the chemical identity (including chemical structure) of Target Inhibitors, the Target Inhibitor Catalog shall not include the chemical identity of any Target Inhibitor.
PPD may at any time request the identity of a given Target Inhibitor and Syrrx shall provide promptly the chemical identity of such Target Inhibitor to PPD. Such chemical identities shall be deemed the Confidential Information of both Parties, and
each Party shall, in addition to its regular obligations with respect to Confidential Information of the other Party, limit disclosure of such information to those employees that require such information to carry out the tasks assigned to such Party
in a Development Plan or Commercialization Plan. 
  
 (ii) Target
Inhibitors identified after the Effective Date (each a “New Target Inhibitor”) shall be reported by Syrrx to the JOC, which will enter each New Target Inhibitor (along with relevant information relating thereto) into the Target Inhibitor
Catalog, designate each New Target Inhibitor as such, and record the entry date as the “Date of Entry” for such New Target Inhibitor. 
  
 (iii) The JOC will note, and thereafter update, the status of each Target Inhibitor and its associated products on the Target Inhibitor Catalog (e.g.,
Lead Candidate, IND Ready Candidate, Reserved IND Ready Candidate, Potential IND Ready Candidate, PPD Terminated Product, or Syrrx Terminated Product). 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -27- 

 (iv) The JOC will provide an updated Target Inhibitor Catalog to the PT following each JOC meeting.

  
 Lead Candidate Screening. Within thirty (30) days of the Effective Date
with respect to Initial Target Inhibitors and otherwise within thirty (30) days of the entry of a given New Target Inhibitor into the Target Inhibitor Catalog, the PT shall propose (i) the Lead Candidate Selection Criteria to be used for the disease
in the Field for which such Target Inhibitor is directed (to the extent such criteria have not already been established for such disease), and (ii) a related timeline and budget for Lead Candidate Screening. The PT shall report the Target Inhibitor
and its associated Lead Candidate Selection Criteria for such disease to the JOC. Within thirty (30) days of the JOC’s receipt of the above PT report, the JOC shall decide whether to authorize such Target Inhibitor to enter Lead Candidate
Screening studies. Upon authorization, the JOC shall record, in the Target Inhibitor Catalog, the Target Inhibitor’s entry for implementation of Lead Candidate Screening for such disease. Syrrx shall perform such Lead Candidate Screening and
report its results to the PT. The PT shall then provide to the JOC a report (1) providing scientific justification why such Target Inhibitor fulfills or does not fulfill the Lead Candidate Selection Criteria for such disease and (2) the Nomination
Criteria for the relevant disease in the Field (“Lead Candidate Report”). 
  
 (b) Lead Candidate Selection for Diseases Within the Field. 
  
 (i) Within ninety (90) days of the JOC’s receipt of the Lead Candidate Report, the JOC shall decide if such Target Inhibitor shall become a Lead
Candidate. The JOC shall not be obligated to authorize the performance of Preclinical Development of more than [*] Lead Candidates during any Calendar Year. Notwithstanding the foregoing, the Parties anticipate that [*]
Target Inhibitors may enter Lead Candidate selection during or following Preclinical Development of the Initial Lead Candidates. In this case, the JOC may decide to authorize the performance of Preclinical Development on more than [*]
of such Target Inhibitors. The JOC’s authorization of Preclinical Development of more than [*] of such Target Inhibitors shall count towards the following Calendar Year’s Preclinical Development requirement. All Lead
Candidates will enter Preclinical Development using the Nomination Criteria. If PPD elects to terminate Preclinical Development activities of a Lead Candidate under Section 3.4(c), the Lead Candidate shall become a Rejected Inhibitor.
Notwithstanding the foregoing, the JOC may request additional Lead Selection Criteria information or modify the recommended Nomination Criteria. The JOC shall record a Target Inhibitor’s selection as a Lead Candidate for such disease in the
Target Inhibitor Catalog. PPD shall perform Preclinical Development upon such Lead Candidate and report its results to the PT. For the purposes of this Section 3.6(c)(i), “Calendar Year” shall mean any year beginning January 1st and ending December 31st, provided that the period from the Effective Date to December 31, 2003 shall be included in the 2004 Calendar Year. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -28- 

 (ii) The PT shall provide to the JOC a report providing scientific justification why a particular Lead
Candidate fulfills the Nomination Criteria for a Nominated Disease (the “Preclinical Report”). If the JOC requests further information regarding whether a particular Lead Candidate fulfills the Nomination Criteria for its Nominated
Disease, the PT will promptly provide such information to the JOC. 
  
 (c) Acceptance of IND Ready Candidates for Diseases Within the Field Within ninety (90) days of the JOC’s receipt of the Preclinical Report, the JOC shall either accept or reject such Lead Candidate. Each Lead Candidate accepted
by the JOC shall be designated thereafter an IND Ready Candidate, the disease shall be its Accepted Disease, and the Lead Candidate shall be listed as such in the Target Inhibitor Catalog. Subject to Sections 3.4(f)(iii), 3.4(f)(iv) and 9.3, neither
Party shall prepare or file an IND for any disease in the Field for any Collaboration Product containing or comprising a Target Inhibitor that is not accepted by the JOC as an IND Ready Candidate. 
  
 (i) Each Lead Candidate that is rejected or otherwise not accepted by the
JOC as an IND Ready Candidate within ninety (90) days of receipt of the associated Preclinical Report shall be designated thereafter a Potential IND Ready Candidate. The JOC may designate in writing a maximum of [*] Potential IND Ready
Candidates as Reserved IND Ready Candidates. Reserved IND Ready Candidates may be accepted by the JOC as IND Ready Candidates at any time. Reserved IND Ready Candidates are ineligible for redesignation by Syrrx as Rejected Inhibitors. The JOC may
subsequently designate additional or different Potential IND Ready Candidates as Reserved IND Ready Candidates, provided there is never more than a total of [*] Reserved IND Ready Candidates at any one time. The JOC may redesignate one
or more Reserved IND Ready Candidates as Potential IND Ready Candidates in order to be able to designate different Potential IND Ready Candidates as Reserved IND Ready Candidates without exceeding the maximum limit of [*] Reserved IND
Ready Candidates at any time. A Reserved IND Ready Candidate shall automatically be redesignated a Potential IND Ready Candidate after [*] as a Reserved IND Ready Candidate. 
  
 (d) Rejected Inhibitors. With respect to any Lead Candidate that became a Potential IND Ready Candidate solely as a
result of the vote of PPD’s representatives on the JOC to reject or not accept such Lead Candidate as an IND Ready Candidate, Syrrx may, at its sole discretion, select such Potential IND Ready Candidate as a Rejected Inhibitor, and thereafter
develop such Rejected Inhibitor(s) pursuant to the terms and conditions of this Agreement. If Syrrx fails to file an IND or enter into a collaboration or a license agreement with a Third Party with respect to a particular Rejected Inhibitor within
[*] after the date of its selection as a Rejected Inhibitor, then such Rejected Inhibitor shall return to the Collaboration and be re-listed in the Target Inhibitor Catalog as a Potential IND Ready Candidate that may then be subject to
designation as a Reserved IND Candidate pursuant to Section 3.6(d)(ii). Syrrx may grant licenses or sublicenses under the DP4 IP, PPD Information and Syrrx Information, with respect to Rejected Inhibitors. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -29- 

 Other Inhibitor Nominations. At any meeting of the PT, Syrrx may give notice to PPD of its interest in developing
a particular Target Inhibitor outside of the Collaboration for a disease outside the Field. In combination with such notice, Syrrx shall present a report summarizing any Preclinical Development data that has been collected to date by Syrrx regarding
such Target Inhibitor. Within [*] of Syrrx’s notice, PPD may request that the Parties instead develop such Target Inhibitor within the Collaboration for a disease within the Field. Absent such a timely request, Syrrx shall be free
to develop such Target Inhibitor outside the Collaboration for any and all diseases outside the Field. Should PPD request that the Target Inhibitor be pursued against a disease within the Field, the Parties will work diligently, in accordance with
the Development Plan, to establish whether such Target Inhibitor satisfies the Nomination Criteria for such disease and the JOC will have a period of [*] after such request in which to accept such Target Inhibitor as an IND Ready
Candidate. If such Target Inhibitor is not accepted within such period, it shall become a Potential IND Ready Candidate that Syrrx may thereafter designate as a Rejected Inhibitor pursuant to Section 3.6(e). 
  
 3.7 Rejected Inhibitor Option. 
  
 (a) Grant. For each Rejected Inhibitor, Syrrx hereby grants PPD the
option to negotiate with Syrrx, during the applicable Exercise Period, to reach agreement on the terms under which the Parties would collaborate with respect to the further development of such Rejected Inhibitor for its Permitted Diseases within the
Field and the commercialization of such Rejected Inhibitor. At PPD’s request, Syrrx shall provide PPD with such Information that PPD may reasonably need in order to make an informed decision whether to exercise such option. 
  
 (b) Exercise. PPD may exercise an option set forth in Section 3.7(a)
with respect to a particular Rejected Inhibitor by providing written notice thereof to Syrrx during an Exercise Period for such Rejected Inhibitor. 
  
 (c) Negotiation. During the remainder of the Exercise Period following PPD’s notice pursuant to Section 3.7(b), the Parties shall (i)
negotiate in good faith to reach agreement on the terms under which the Parties would collaborate with respect to the further development of such Rejected Inhibitor for its Permitted Diseases within the Field and the commercialization of such
Rejected Inhibitor and (ii) if agreement is reached on all terms, execute a collaboration agreement or legally binding heads of agreement that sets forth the agreed upon terms (each, a “Rejected Inhibitor Agreement”). Such time period for
entering a Rejected Inhibitor Agreement shall be extended if the Parties agree in writing that they are negotiating in good faith to reach such an agreement, and have made significant progress in so doing, but cannot conclude such negotiations
and/or execute a definitive agreement within such Exercise Period. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -30- 

 (d) Expiration. Each option set forth in Section 3.7(a) shall expire on the earliest of: (i) the
Parties’ execution of a Rejected Inhibitor Agreement with respect to such Rejected Inhibitor, (ii) the expiration (without extension) of all Exercise Periods for such Rejected Inhibitor without the execution of a Rejected Inhibitor Agreement
with respect to such Rejected Inhibitor, and (iii) Syrrx’s grant of a license to a Third Party or collaboration with a Third Party to (1) develop the applicable Rejected Inhibitor or products containing or comprising such Rejected Inhibitor for
one or more of its Permitted Diseases or (2) commercialize such Rejected Inhibitor or products containing or comprising such Rejected Inhibitor, provided that Syrrx shall not grant such a license during an Exercise Period for such Rejected
Inhibitor. 
  
 (e) Effect of Expiration. After the
expiration of the option for a particular Rejected Inhibitor, (i) Syrrx shall not have any obligation, to notify PPD of Syrrx’s completion of its analysis of the full data set from the first Phase I Trial, Phase II Trial or Phase IIIa Trial for
such Rejected Inhibitor, and (ii) Syrrx shall not have any other obligations to PPD under this Agreement with respect to such Rejected Inhibitor. 
  
 3.8 Clinical Development of a Collaboration Product in Multiple Diseases Within the Field. Upon Completion of a Phase I Trial for a given
Collaboration Product, either Party may request that such Collaboration Product be approved for Clinical Development in diseases within the Field other than the Accepted Disease for the corresponding IND Ready Candidate. If the PT recommends
approval of such Collaboration Product for Clinical Development in such disease within the Field, and if the JOC concurs with the PT’s recommendation, the PT shall revise the Development Plan and the Development Budget to reflect the Clinical
Development work to be performed upon such Collaboration Product for such disease. 
  
 3.9 Target Inhibitors Other Than IND Ready Candidates. Except as set forth in Section 3.6(d) above, Syrrx shall retain all development rights to any Target Inhibitor that (i) does not fulfill the Lead Candidate
Selection Criteria or Nomination Criteria or (ii) is not accepted by the JOC as an IND Ready Candidate or a Reserved IND Ready Candidate, and such Target Inhibitors shall not be subject to any terms of this Agreement other than those set forth in
Sections 3.6(f), 3.7, 9.2, and 9.3.  
  
 3.10 Syrrx
Change of Control. In the event of any Change of Control of Syrrx, or its successors or permitted assigns, at the effective time of such Change of Control, PPD shall have [*]. The foregoing shall not be interpreted as applying to
any dispute concerning the rights or obligations of the Parties pursuant to this Agreement or any alleged breach of such an obligation. Such disputes shall be resolved in accordance with Article 16 regardless of whether Syrrx has undergone a Change
of Control. 
  
 3.11 PPD Change of Control. In the event of
any Change of Control of PPD, or its successors or permitted assigns, at the effective time of such Change of Control, Syrrx shall have [*]. The foregoing shall not be interpreted as applying to any dispute concerning the rights or
obligations of the Parties pursuant to this Agreement or any alleged breach of such an obligation. Such disputes shall be resolved in accordance with Article 16 regardless of whether PPD has undergone a Change of Control. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -31- 

 4. LINE OF CREDIT 
  
 4.1 Overview. PPD will consider making available to Syrrx a line of
credit that Syrrx may utilize to fund fifty percent (50%) of the Phase IIIa Development Costs for one Collaboration Product (the “Phase III Loan”) and will do so for each Collaboration Product to reach a Phase IIIa Trial until a Phase III
Loan is made. For each Collaboration Product that reaches a Phase IIIa Trial after the Parties have entered into a Phase III Loan, PPD shall have no obligation to consider offering a Phase III Loan to Syrrx and Syrrx shall have no obligation to
entertain an offer. In the process of considering whether to offer a Phase III Loan to Syrrx, PPD may conduct due diligence and PPD may decide whether to offer a Phase III Loan in its sole and absolute discretion. This Article 4 sets forth the
manner in which the Parties will negotiate the terms of, and decide whether to enter into the applicable agreements for such Phase III Loan. Once the Parties have entered into the agreements for a given Phase III Loan, such agreements shall
supercede the terms set forth in this Article 4, and PPD shall have no further obligations to make additional lines of credit available to Syrrx pursuant to this Agreement. 
  
 4.2 Negotiation of Additional Terms. The maximum aggregate amount that Syrrx could borrow from PPD under the Phase
III Loan would be one-half of the Phase IIIa Development Costs (and Phase IIIb Costs, if applicable) set forth in such Development Budget for such trial(s) or any subsequent amendment of such Development Budget that is approved by the JOC (the
“Maximum Amount”). All money that Syrrx receives pursuant to a Phase III Loan shall be used solely to pay for Syrrx’s half of Phase IIIa Development Costs (and Phase IIIb Costs, if applicable) for the applicable Collaboration Product.
Additional terms of such a Phase III Loan are those terms set forth in this Article 4 and, to the extent not otherwise specified therein, such additional terms that the Parties negotiate in good faith that are customarily contained in loan documents
required by commercial lenders for comparable loans. 
  
 4.3
Entry into Phase III Loan; Alternatives. Within [*] after the JOC has agreed upon the Development Budget for a Phase IIIa Trial (and Phase IIIb Trial, if applicable) for a Collaboration Product (the “Due Diligence
Period”), PPD shall conduct its due diligence upon Syrrx, Syrrx’s financial condition, the Collateral (as defined in Section 4.4(h)) and other matters. PPD’s willingness to enter into the Phase III Loan Documents is subject to its
receipt and satisfactory review of such due diligence documents, reports, affidavits and certificates as it may require, including, without limitation, financial statements, budgets, forecasts, asset summaries, legal opinions, appraisals,
environmental audits, surveys, flood certifications, title insurance, UCC searches, subordination agreements, evidence of hazard insurance, evidence of Syrrx’s compliance with laws, and other documents and assurances. The scope of PPD’s
due diligence requests upon Syrrx shall be commercially reasonable. Prior to the expiration of the Due Diligence Period, PPD shall inform Syrrx in writing if, in PPD’s sole and absolute discretion, it has determined that it is willing, subject
to negotiation and execution of the Phase III Loan Documents, to extend a Phase III Loan to Syrrx for such Collaboration Product (the “PPD Notice”). Failure by PPD to deliver the PPD Notice to Syrrx prior to the expiration of the Due
Diligence Period shall be deemed an election by PPD not to extend the Phase III Loan pursuant to Section 4.3(b). Within [*] of receipt by Syrrx of the PPD Notice (the “Response Period”), Syrrx shall inform PPD in writing
whether (i) Syrrx is willing, subject to negotiation and 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -32- 

 execution of the Phase III Loan Documents, to enter into a Phase III Loan for such Phase IIIa Trial (and Phase IIIb
Trial, if applicable); (ii) Syrrx is unable to accept the offer pursuant to Section 4.3(c) for Good Cause; or (iii) Syrrx is unable to accept the offer pursuant to Section 4.3(e) without Good Cause (the “Syrrx Notice”). Failure by Syrrx to
deliver the Syrrx Notice to PPD prior to the expiration of the Response Period shall be deemed an election by Syrrx to decline the offer of the Phase III Loan without Good Cause pursuant to Section 4.3(e). Within [*] of the receipt by
PPD of the Syrrx Notice (the “Document Period”), the Parties shall negotiate in good faith and attempt to agree upon the Phase III Loan Documents. 
  
 (a) Phase III Loan or Self Funding by Syrrx. If the Parties agree upon and execute the Phase III Loan
Documents, then they shall share the Phase IIIa Development Costs and the Product Profit arising from such Collaboration Product as set forth in Section 5.16(a). The same terms shall apply if Syrrx declines an offer for a Phase III Loan from PPD and
pays for its half of the Phase IIIa Development Costs from an alternative source of funding. 
  
 (b) No Offer of Phase III Loan. If PPD elects not to extend the Phase III Loan to Syrrx for a Collaboration Product that is ready to begin a Phase IIIa Trial, then, at PPD’s election, either (1) PPD will
pay [*] of the Phase IIIa Development Costs for such Collaboration Product (in which case Section 5.16(b) shall apply) or (2) the Parties will enter into a Partnering Agreement for such Collaboration Product prior to incurring any
Phase IIIa Development Costs (in which case Section 6.1 shall apply). The failure by PPD to deliver the PPD Notice to Syrrx prior to the expiration of the Due Diligence Period shall be deemed an election by PPD not to extend the Phase III Loan.
 
  
 (c) Syrrx Declines Offer of Phase III Loan for Good
Cause. If Syrrx elects to decline the offer of the Phase III Loan with Good Cause, then, at PPD’s election, either (1) PPD will pay all of the Phase IIIa Development Costs for such Collaboration Product (in which case Section 5.16(b) shall
apply) or (2) the Parties will enter into a Partnering Agreement for such Collaboration Product prior to incurring any Phase IIIa Development Costs (in which case Section 6.1 shall apply). 
  
 (d) Parties Fail to Agree upon Phase III Loan Documents. If the
Parties fail to agree upon and execute the Phase III Loan Documents during the Document Period, then, at PPD’s election, either (1) PPD will pay [*] of the Phase IIIa Development Costs for such Collaboration Product (in which case
Section 5.16(b) shall apply) or (2) the Parties will enter into a Partnering Agreement for such Collaboration Product prior to incurring any Phase IIIa Development Costs (in which case Section 6.1 shall apply). 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -33- 

 (e) Syrrx Declines Offer of Phase III Loan without Good Cause and Fails to Self Fund. If Syrrx
elects without Good Cause to decline the offer of a Phase III Loan for a Collaboration Product that is ready to begin a Phase IIIa Trial and does not offer in writing to pay for its half of the Phase IIIa Development Costs from an alternative source
of funding, then such Collaboration Product shall be deemed to be a Syrrx Terminated Product upon PPD’s Commencement of a Phase IIIa Trial for such Product, and PPD shall have no further obligation to make a Phase III Loan to Syrrx under this
Agreement. If PPD does not Commence a Phase IIIa Trial with respect to such Collaboration Product, the Parties will enter into a Partnering Agreement for such Collaboration Product prior to incurring any Phase IIIa Development Costs (in which case
Section 6.1 shall apply). 
  
 (f) Self Funding by Syrrx and PPD
Refusal to Conduct Phase III. If PPD elects not to extend the Phase III Loan to Syrrx pursuant to Section 4.3(b), and Syrrx within [*] offers in writing to pay for its half of the Phase IIIa Development Costs from an alternative
source of funding, PPD shall commit in writing within [*] to Commence the Phase IIIa Trial and pay for its half of the Phase IIIa Development Costs. 
  
 (g) Option to Terminate Collaboration Product. At any point in time, regardless of the presence or
absence of a Phase III Loan, either Party may notify the other Party, pursuant to Section 13.2(c), that it no longer wishes to participate in the Development or Commercialization of a Collaboration Product and as a result the Collaboration Product
shall become a Syrrx Terminated Product or PPD Terminated Product based on which Party provides such notice. 
  
 4.4 Terms and Conditions of Phase III Loan. It is recognized by the Parties that this Article does not constitute a formal loan agreement and as
such this Article does not set forth all the terms and conditions of the Phase III Loan. Rather, this Article is intended only as an outline, in summary format, of the major points of understanding which shall be the basis of the final Phase III
Loan documentation, which shall include, without limitation, a Phase III Loan agreement, promissory note(s), security agreements, UCC financing statements, deeds of trust, mortgages and other instruments and documents (all if applicable) to evidence
the Phase III Loan and the security thereof (hereinafter collectively referred to as the “Phase III Loan Documents”) and which shall be in a form mutually acceptable to PPD and Syrrx. The Phase III Loan Documents may have terms and
conditions not set forth herein, including but not limited to conditions precedent, representations and warranties, affirmative covenants, negative covenants, events of default, definition of terms, and other commercially reasonable terms customary
to financings of the type contemplated by this Article. In addition to satisfactory due diligence, PPD’s willingness to extend a Phase III Loan to Syrrx in accordance with the terms of this Agreement is subject, without limitation, to the
agreement upon, and the execution and delivery of, the definitive Phase III Loan Documents. The date on which the last of the Phase III Loan Documents is executed is hereinafter referred to as the “Phase III Loan Closing” or “Phase
III Loan Closing Date”. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -34- 

 (a) Interest Rate. Interest on any unpaid principal of the Phase III Loan shall be calculated and
compounded daily, based on the actual days elapsed over a three hundred sixty (360) day banking year, at [*] and agreed upon by PPD and Syrrx. 
  
 (i) Late Fee. If any payment is not made within ten days after the date such payment is due, Syrrx shall pay PPD a late fee equal to the lesser of
(1) [*] of the amount of such unpaid amount or (2) the maximum amount permitted to be charged under applicable law. 
  
 (ii) Computation. In the event the Prime Rate changes from time to time hereafter, the applicable rate of interest hereunder shall be increased or
decreased, effective as of the day the Prime Rate is changed, by an amount equal to such change in the Prime Rate. All interest chargeable under the Phase III Loan Documents shall be computed on the basis of a 360 day year for the actual number of
days elapsed. 
  
 (iii) Default Rate. In the event of a
default by Syrrx under the Phase III Loan Documents, interest on the unpaid principal balance shall accrue at a default rate to be agreed upon by the Parties in the Phase III Loan Documents. 
  
 (b) Fees and Expenses. Neither Party shall be obligated to pay
the other Party any fee in consideration for entering into the Phase III Loan. Each Party shall separately cover any expenses, including attorney fees, that their Party incurs in association with preparing the Phase III Loan and entering into the
Phase III Loan and performing the Party’s respective obligations under the Phase III Loan. 
  
 (c) Use of Proceeds. Syrrx shall use all money it receives pursuant to a Phase III Loan solely to pay its half of Phase IIIa Development Costs (and
Phase IIIb Costs, if applicable) for the applicable Collaboration Product. 
  
 (d) Advances. The JOC shall meet periodically to review and approve Phase IIIa Development Costs (and Phase IIIb Costs, if applicable). PPD’s commitment to make advances under the Phase III Loan shall
apply to any Phase IIIa Development Costs (and Phase IIIb Costs, if applicable) approved by the JOC. If not terminated sooner in accordance with the terms of the Phase III Loan Documents, PPD’s obligation to make advances under the Phase III
Loan shall terminate when the total aggregate amount of advances made by it to Syrrx under the Phase III Loan equals the Maximum Amount. PPD’s commitment to make advances under the Phase III Loan, however, shall be subject to Syrrx’s
satisfaction and continued compliance with, all of the positive and negative covenants and conditions set forth herein and in the Phase III Loan Documents. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -35- 

 (e) Conditions for Terminating Phase III Loan Advances. PPD’s obligation to make advances
under the Phase III Loan shall terminate upon the earliest to occur of the following events (the “Termination Date”): (i) occurrence of an event of default under the Phase III Loan Documents or the Agreement that is not cured by Syrrx
within any applicable cure period stated therein, unless such event of default is waived by PPD in writing in its sole and absolute discretion, (ii) termination of this Agreement by either Party for any reason, (iii) the effective date on which the
Collaboration Product involved in the Phase IIIa Trial (or Phase IIIb Trial, if applicable) becomes a PPD Terminated Product or a Syrrx Terminated Product, (iv) six (6) months after the last approval by the JOC of Phase IIIa Development Costs (and
Phase IIIb Development Costs, if applicable) following the declared Completion of the Phase IIIa Trial (or Phase IIIb Trial, if applicable), or (v) such other events as may be set forth in the Phase III Loan Documents. Upon the Termination Date, PPD
shall have no further obligation to make Phase III Loan advances to Syrrx.  
  
 (f) Repayment of Phase III Loan (Interest). Accrued interest on the principal balance of the Phase III Loan outstanding from time to time shall be payable monthly in arrears on the first day of each calendar
month (commencing on the first day of the first calendar month following the Closing Date and continuing each month thereafter until such time as all accrued and unpaid principal and interest due and owing under the Phase III Loan Documents is paid
in full). 
  
 (g) Repayment of Phase III Loan (Principal).
Repayment of the principal of the Phase III Loan shall be as follows: 
  
 (i) Repayment. Commencing [*] after the Completion of the Phase IIIa Trial (the “Commencement Date”), Syrrx shall make [*] payments of principal to PPD in an amount equal
to [*] of the outstanding principal amount of the Phase III Loan as of the Commencement (the “Monthly Principal Payments”). Syrrx shall pay in full all outstanding principal and accrued and accrued interest to PPD on the
first day of the [*] following the Commencement Date. For clarity, in the event that any one of subsections (ii)-(vi) should apply, repayment shall then be governed by the applicable other subsection rather than this subsection.

  
 (ii) Repayment of Principal Upon Partnered
Commercialization. If the Parties choose to pursue Partnered Commercialization of the Collaboration Product pursuant to Article 6 before or after the Commencement Date, then the Monthly Principal Payments shall cease as of the date of the
Partnering Agreement, and repayment of the principal of the Phase III Loan shall resume on the first day of the first calendar month following the [*] anniversary of the date of the Partnering Agreement (the “Partnered Commercialization
Commencement Date”). Commencing on the Partnered Commercialization Commencement Date, Syrrx shall make [*] payments of principal to PPD in an amount equal to [*] of the outstanding principal amount of the Phase III
Loan as of the Partnered Commercialization Commencement Date (the “Partnered Commercialization Monthly Principal Payments”). Syrrx shall pay in full all outstanding principal and accrued interest to PPD on the first day of the
[*] month following the Partnered Commercialization Commencement Date (the “Partnered Commercialization Maturity Date”). To the extent that any consideration is realized 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -36- 

 by Syrrx under the Partnering Agreement prior to the Partnered Commercialization Maturity Date, Syrrx shall apply
[*] of such consideration to prepay the immediately upcoming Partnered Commercialization Monthly Principal Payments. Interest payments will be adjusted to reflect such prepayment. To the extent that the amount of prepayments made by
Syrrx from the consideration realized from the Partnering Agreement is not sufficient to prepay the entire outstanding principal of the Phase III Loan, then Syrrx shall continue to repay the remaining Partnered Commercialization Monthly Principal
Payments of the Phase III Loan upon their originally scheduled due dates. 
  
 (iii) Repayment of Principal Upon Direct Commercialization. Subsequent to the Commencement Date, if the Parties choose to pursue Direct Commercialization of the Collaboration Product pursuant to Article 5 and
have not previously chosen Partnered Commercialization, then the Monthly Principal Payments shall cease as of the approval date of the NDA for the Collaboration Product (the “NDA Approval Date”), and repayment of the principal of the Phase
III Loan shall resume at such time that the Parties realize Product Profits from the commercialization of the Collaboration Product. Once Product Profits are realized from the commercialization of the Collaboration Product, Syrrx shall make monthly
payments of principal to PPD equal to [*] of the Product Profits realized by Syrrx in a given quarter for that Collaboration Product, until such time as Syrrx has repaid all of the principal amount of the Phase III Loan plus all
accumulated interest thereon. If the principal of the Phase III Loan is not repaid in full from Product Profits within [*] months of the NDA Approval Date (the “Direct Commercialization Maturity Date”), then Syrrx shall pay
in full all outstanding principal and accrued interest to PPD on the Direct Commercialization Maturity Date. 
  
 (iv) Repayment of Principal Following Discontinued Phase III Development of a Collaboration Product. In the event that the Parties mutually agree
to discontinue pursuing any further development of a Collaboration Product, repayment of the principal of the Phase III Loan shall commence on the first day of the first calendar month following the [*] anniversary of the last
administration under the Phase IIIa Trial (or Phase IIIb Trial, if applicable) (the “Discontinued Development Commencement Date”) and continue on the same date of each month thereafter. Syrrx shall make [*] payments of
principal to PPD in an amount equal to [*] of the outstanding principal amount of the Phase III Loan as of the Discontinued Development Commencement Date. Syrrx shall pay in full all outstanding principal and accrued interest to
PPD on the first day of the [*] month following the Discontinued Development Commencement Date. 
  
 (v) Repayment of Principal Following Designation of a Collaboration Product as a Syrrx Terminated Product. Repayment of the principal of the Phase
III Loan shall commence on the [*] anniversary of the first day of the first calendar month that Syrrx gives written notice of its election to discontinue pursuing any further development of a Collaboration Product under a Phase IIIa
Trial by designating the Collaboration Product a Syrrx Terminated Product (the “Syrrx Terminated Product Commencement Date”), and shall continue on the same date of each month thereafter. Syrrx shall make [*] payments of
principal to PPD in an amount equal to [*] of the outstanding principal amount of the Phase III Loan as of the Syrrx Terminated Product Commencement Date. Syrrx shall pay in full all outstanding principal and accrued interest to PPD on
the first day of the [*] month following the Syrrx Terminated Product Commencement Date. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -37- 

 (vi) Repayment of Principal Following Designation of a Collaboration Product as a PPD Terminated
Product. Repayment of the principal of the Phase III Loan shall commence on the [*] anniversary of the first day of the first calendar month that PPD gives written notice of its election to discontinue pursuing any further
development of a Collaboration Product under a Phase III Trial by designating the Collaboration Product a PPD Terminated Product (the “PPD Terminated Product Commencement Date”), and shall continue on the same date of each month
thereafter. Syrrx shall make [*] payments of principal to PPD in an amount equal to [*] of the outstanding principal amount of the Phase III Loan as of the PPD Terminated Product Commencement Date. Syrrx shall pay in full
all outstanding principal and accrued interest to PPD on the first day of the [*] month following the PPD Terminated Product Commencement Date. 
  
 (vii) Voluntary Prepayment. The principal of the Phase III Loan may be prepaid in whole or in part by Syrrx at any time without premium or
penalty. Interest payments will be adjusted to reflect such prepayment. 
  
 (viii) Prepayment Upon Change of Control. If Syrrx undergoes a Change of Control, Syrrx shall pay to PPD in full all outstanding principal and accrued interest on the Phase III Loan on the first day of the
first calendar month following the date of the closing of the transaction that resulted in the Change of Control. 
  
 (h) Collateral. At the time of the Phase III Loan Closing and in order to secure payment of the Phase III Loan, Syrrx shall grant, pledge, assign
and/or convey to PPD first priority liens and security interests in all of its property and assets (other than the Excluded Assets), including, without limitation, the following (collectively, the “Collateral”): 
  

	 	1.	A first priority security interest in all existing and after-acquired property and assets of Syrrx, including, without limitation, in Syrrx’s Accounts (including all health
care-insurance receivables), Inventory, Equipment, Goods, Fixtures, Documents, Instruments, Chattel Paper, Investment Property, Deposit Accounts, Letter-of-Credit Rights, Supporting Obligations, Commercial Tort Claims, As-Extracted Collateral,
Money, Software, Vehicles and General Intangibles (as said terms are defined in the Uniform Commercial Code of the State of North Carolina). 

  

	 	2.	A first priority deed of trust lien on all real property and improvements then or thereafter owned by Syrrx, together with an assignment of leases and rents covering all such
property. 

  

	 	3.	A first priority leasehold deed of trust lien on or assignment of all of Syrrx’s interest in any lease to which Syrrx is then or thereafter a party.

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -38- 

 As used herein, “Excluded Assets” means and refers to property which Syrrx is prohibited from pledging or
assigning to PPD by law or binding contract and whose exclusion from the Collateral granted to PPD is acceptable to PPD in its sole discretion. “Excluded Assets” shall also refer to any property that PPD gives Syrrx written consent to
exclude as Collateral prior to creation of the Phase III Loan or during the term of the Phase III Loan. The Excluded Assets shall be specifically identified in the Phase III Loan Documents. 
  
 Any security interest granted to PPD shall reserve to Syrrx the right to grant non-exclusive
and exclusive licenses to the Collateral as Syrrx deems appropriate in its sole business judgment in conjunction with any collaboration agreements, or partnering arrangements (“Collaboration Agreements”) or license agreements
(“License Agreements”) that Syrrx chooses to enter into with Third Parties as it deems appropriate in its sole business judgment. PPD’s prior written consent shall not be required in order for Syrrx to enter into such Collaboration
Agreements or License Agreements (but PPD’s liens and security interests granted under the Phase III Loan Documents shall not be released, subordinated, or otherwise disturbed without PPD’s prior written consent). 
  
 To the extent that Syrrx desires to enter into a Collaboration Agreement or a Licensing
Agreement with a Third Party (“Collaboration Transferee” or “License Transferee”) who requires that certain Collateral subject to the Collaboration Agreement or Licensing Agreement not be subject to PPD’s security interest,
PPD will execute and deliver such releases and other instruments as may be reasonably necessary to establish that the rights and interests of the Collaboration Transferee or License Transferee are free of the security interest created by the Phase
III Loan Documents provided that (1) Syrrx is not then in default under the terms of this Agreement or the Phase III Loan Documents, (2) the Collaboration Agreement or License Agreement, as applicable, provides Syrrx with rights and interests which
are reasonably equivalent in value to the Collateral to be released by PPD, and (3) Syrrx executes and delivers to PPD the Replacement Security Documents (defined below). 
  
 If Syrrx does grant non-exclusive or exclusive license(s) to the Collateral pursuant to a Collaboration Agreement or a License Agreement for
which PPD released its security interest with respect to certain such Collateral, then PPD shall retain its security interest in Syrrx’s remaining interest in the Collateral and proceeds thereof, and PPD’s security interests and liens
shall attach to the entirety of Syrrx’s rights, title and interest in the Collaboration Agreement or License Agreement, as applicable and all proceeds thereof (the “Replacement Collateral”). As used herein, “Replacement Security
Documents” means and refers to all security agreements, financing statements, assignments, consents, filings and other documents, instruments and agreements that may be required, in PPD’s reasonable discretion, to provide PPD with
perfected first priority liens and security interests in and to the Replacement Collateral. 
  
 (i) Representations and Warranties. The Phase III Loan Document shall contain such warranties and representations as are customarily contained in loan documents required by commercial lenders for comparable
loans as of the Closing Date.  
  
 (j) Negative
Covenants. The Phase III Loan Agreement shall include the following negative covenants, which, if Syrrx were to violate and fail to cure (within any applicable cure period set forth in the Phase III Loan Documents) on or after the Phase III Loan
Closing Date, would serve as a basis for PPD, in its sole and absolute discretion, to discontinue its obligation to make any advances under the Phase III Loan. 
  

 -39- 

	 	1.	Debt. On and subsequent to the Phase III Loan Closing Date, Syrrx shall not create, incur, assume, owe or suffer to exist any debt in excess of [*], except debt
to PPD, debt outstanding on the Closing Date acceptable to PPD (and which shall be fully subordinated in payment to the Phase III Loan on terms and conditions acceptable to PPD), and accounts payable to trade creditors incurred in the ordinary
course of business. 

  

	 	2.	Liens. Subsequent to the Phase III Loan Closing Date, and except for liens of a type and size to be mutually agreed upon based on exceptions customarily contained in loan
documents required by commercial lenders for comparable loans as of the Closing Date, Syrrx shall not create, incur, assume, be subject to or suffer to exist any mortgage, security interest, pledge, charge, assignment, attachment or other lien upon
or with respect to any property or asset of Syrrx (including the Collateral), whether now owned or hereafter acquired, except liens and security interests to PPD and liens acceptable to PPD in its sole and absolute discretion.

  

	 	3.	Additional Negative Covenants. Such other negative covenants as are customarily contained in loan documents required by commercial lenders for comparable loans as of the
Closing Date. 

  
 (k) Affirmative Covenants.
The Phase III Loan Agreement shall include the following affirmative covenants, which, if Syrrx were to violate and fail to cure (within any applicable cure period set forth in the Phase III Loan Documents) on or after the Phase III Loan Closing
Date, would serve as a basis for PPD, in its sole and absolute discretion, to discontinue its obligation to make any advances under the Phase III Loan. 
  

	 	1.	Annual Financials. Syrrx shall provide to PPD its fiscal year-end financial statement as soon as available and in any event no later than one hundred twenty (120) days of
Syrrx’s fiscal year-end, such statement to include a consolidated balance sheet of Syrrx and its subsidiaries, if any, as of the end of such fiscal year and the related, consolidated statements of income, stockholders’ equity and cash
flows for the fiscal year then ended, each audited by an independent accounting firm reasonably acceptable to PPD and prepared in accordance with generally accepted accounting principles. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -40- 

	 	2.	Quarterly Financials. Within forty five (45) days after end of each calendar quarter in each calendar year (other than the last calendar quarter in each calendar year), Syrrx
shall provide to PPD, in form and content reasonably acceptable to PPD, a consolidated balance sheet of Syrrx and its subsidiaries, if any, and the related consolidated statements of income, stockholders’ equity and cash flows, unaudited and
internally prepared in accordance with generally accepted accounting principles (other than accompanying notes), such consolidated balance sheet to be as of the end of such calendar quarter and such consolidated statements of income,
stockholders’ equity and cash flows to be for such calendar quarter and for the period from the beginning of the calendar year to the end of such calendar quarter, in each case with comparative statements for the prior calendar year. At the
time of delivery of each quarterly statement, Syrrx also shall deliver a management narrative report explaining all significant variances from forecasts, and all significant developments in its business, the development and commercialization of its
intellectual property, collaboration agreements, financings, marketing, sales and operations. 

  

	 	3.	Monthly Financials. Within thirty (30) days after the end of each month in each calendar year (other than the last month in each calendar year), Syrrx shall provide to PPD,
in form and content reasonably acceptable to PPD, a consolidated balance sheet of Syrrx and its subsidiaries, if any, and the related consolidated statements of income, stockholders’ equity and cash flows, unaudited and internally prepared in
accordance with generally accepted accounting principles (other than accompanying notes), such consolidated balance sheet to be as of the end of such month and such consolidated statements of income, stockholders’ equity and cash flows to be
for such month and for the period from the beginning of the calendar year to the end of such month, in each case with comparative statements for the prior calendar year. 

  

	 	4.	Tax Returns. Syrrx shall provide to PPD its U.S. income tax returns and all state income tax returns each year within 30 days of filing. 

  

	 	5.	Inspection Rights. PPD will have the right, on a monthly basis and with at least five days advance written notice to Syrrx, to inspect and audit Syrrx’s records during
normal business hours for the purpose of determining Syrrx’s compliance with the covenants herein and in the Phase III Loan Documents. 

  

	 	6.	Claims. Promptly after the commencement thereof, Syrrx shall provide to PPD notice of all claims, demands, actions, suits, claims, proceedings, investigations and/or
inquiries commenced or threatened that could materially adversely affect Syrrx or its subsidiaries (if any) or Syrrx’s business. 

  

	 	7.	Insurance; Etc. Syrrx shall maintain adequate liability and hazard insurance on all of its properties and assets (including the Collateral); and comply with all local, state
and federal laws, ordinances, rules and government regulations to which it, its assets and business are subject. 

  

 -41- 

	 	8.	Certain Phase III Loans. Stockholders, officers, directors, members and managers of Syrrx shall subordinate their loans to Syrrx, if any, to the Phase III Loan pursuant to a
reasonable subordination agreement. 

  

	 	9.	Taxes. Syrrx shall pay or discharge as they become due all taxes, assessments and governmental charges levied upon Syrrx, its business and its properties and assets.

  

	 	10.	Additional Affirmative Covenants. Such other affirmative covenants as are customarily contained in loan documents required by commercial lenders for comparable loans as of
the Closing Date. 

  
 (l) Complete Disclosure
Prior to Entry into Phase III Loan. Syrrx agrees that all material facts relating to the business, operations, financial condition, prospects, properties, assets, liabilities or capitalization of Syrrx will be disclosed to PPD by Syrrx prior to
entry into a formal Phase III Loan Agreement. 
  
 (m) Governing
Law. Notwithstanding anything to the contrary in this Agreement, the Phase III Loan Documents shall be governed by the laws of the State of North Carolina. 
  

(n) Jurisdiction; Venue. Notwithstanding anything to the contrary in this Agreement, any legal action or proceeding arising out of or relating
to the Phase III Loan or the Phase III Loan Documents shall be instituted in the United States District Court for the Eastern District of North Carolina. If for any reason such legal action or proceeding cannot be instituted or maintained in such
court, then such legal action or proceeding shall be instituted in the Superior Court in New Hanover County, North Carolina. Syrrx consents to the jurisdiction of such courts and waives any objection to the maintenance of any legal action or
proceeding in courts of the State of North Carolina on the basis of improper venue or inconvenient forum. Article 16 of this Agreement shall not apply to any default, dispute, collection action, controversy or claim arising out of or relating to the
Phase III Loan or the Phase III Loan Documents. 
  
 4.5
Termination of Commitment. 
  
 (a) PPD’s commitment to
enter into a Phase III Loan Agreement with Syrrx, as well as PPD’s obligation to make any advances under the Phase III Loan from and after the Closing Date, shall be terminated, at the option of PPD upon written notice to Syrrx, upon the
occurrence of any of the following events from and after the date hereof. If Syrrx is then not able to fund the associated Phase IIIa Trial in the absence of the Phase III Loan, then, at PPD’s election, either (1) PPD will pay all of the Phase
IIIa Development Costs for such Collaboration Product (in which case Section 5.16(b) shall apply) or (2) the Parties will enter into a Partnering Agreement for such Collaboration Product prior to incurring any Phase IIIa Development Costs (in which
case Section 6.1 shall apply). 
  

	 	1.	A material adverse change in Syrrx’s business, operations, financial condition, prospects, properties, assets, liabilities or capitalization, or disposal by Syrrx of a material
portion of its assets. 

  

 -42- 

	 	2.	Syrrx is or becomes insolvent (as evidenced under a commercially reasonable standard); Syrrx is unable to pay its debts as they become due in the ordinary course; or a proceeding is
commenced by or against Syrrx under any bankruptcy or insolvency law. 

  

	 	3.	A default by Syrrx in the repayment of any indebtedness for borrowed money (excluding indebtedness to trade creditors), unless Syrrx contests the same in good faith and provides a
surety bond reasonably acceptable to PPD as security for the same. 

  

	 	4.	Any material violation, breach or default by Syrrx of the terms of the Phase III Loan Documents or this Agreement (and subsequent failure to cure same within any applicable cure
period). 

  

	 	5.	Upon the effective date that the Parties mutually agree to terminate this Agreement. 

  

	 	6.	Should Syrrx or PPD fail to receive any necessary Third Party approvals or consents required in connection with the consummation of the transactions contemplated herein.

  

	 	7.	Should any suit or proceeding (whether at law or in equity or before or by any federal, state, municipal or governmental authority, agency, board or bureau) be filed against or
involve Syrrx which, if adversely determined, would have a material adverse effect upon the business, operation, financial condition, assets, liabilities or capitalization of Syrrx, unless Syrrx contests the same in good faith and provides a surety
bond reasonably acceptable to PPD as security for same. 

  
 5.
DIRECT COMMERCIALIZATION 
  
 5.1 Commercialization Decision.  
  
 (a)
At its meetings, the JOC (or a subcommittee thereof) shall discuss, with respect to each Collaboration Product then in Clinical Development, whether and how to pursue commercialization of such Collaboration Product, whether directly or indirectly
(including, without limitation, through out-licensing or partnering arrangements with one or more Third Parties), whereby such Third Parties would assume responsibility for further Clinical Development (if applicable) and commercialization of such
Collaboration Product. 
  
 (b) No earlier than the acceptance of a
Lead Candidate as an IND Ready Candidate and no later than [*] after the Completion of a Phase IIIa Trial for a particular Collaboration Product, the JOC shall decide whether and to what extent the Parties will commercialize such
Collaboration Product directly (“Direct Commercialization”) or with the assistance of a Third Party licensee or collaborator (other than a Third Party manufacturer or supplier of marketing or promotion services) with a financial interest
in the success of the Collaboration Product (“Partnered Commercialization”). Both Parties recognize that a given 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -43- 

 Collaboration Product may be commercialized in some territories and in some diseases via Direct Commercialization and in
other territories and in other diseases via Partnered Commercialization. Accordingly, multiple commercialization decisions may be needed for a given Collaboration Product.  
  
 5.2 Responsibilities of the JOC During Commercialization. The purpose of the JOC shall also be to (a) oversee the
Commercialization of Collaboration Products, including the planning, annual budgeting, commercial manufacturing, marketing, sales and distribution and sub-licensing of Collaboration Products, (b) monitor, review and comment on costs incurred by the
Parties in the commercial manufacture, marketing, sale and distribution of Collaboration Products, (c) prepare and approve the Commercialization Plans and Launch Plans, any budgets related thereto, and the selection of trademarks for Collaboration
Products, (d) receive and provide to the Parties all sales, pricing, and financial reports pertaining to Pre-Commercialization and Commercialization of Collaboration Products, (e) determine the price for Collaboration Products pursuant to Section
5.13, (f) oversee Collaboration Product manufacturing pursuant to Section 5.18 and (g) facilitate the flow of Information with respect to the Commercialization of each Collaboration Product. If the JOC fails to reach consensus as to any matter
involving Commercialization, the matter will be referred for dispute resolution in accordance with Article 16. 
  
 5.3 Commercialization Plan and Commercialization Budget.  
  
 (a) If the JOC decides, pursuant to Section 5.1, to pursue Direct Commercialization of a Collaboration Product in one or
more territories for one or more diseases, the JOC shall develop and approve a comprehensive written plan for the direct development and commercialization of such Collaboration Product in such territories and diseases (a “Commercialization
Plan”). The Commercialization Plan will set forth in detail the marketing, sale and distribution activities to be undertaken with respect to such Collaboration Product (including advertising, education, planning, marketing, sales force training
and distribution), as well as the activities required for the manufacture of such Collaboration Product following commercial launch, and in each case whether such activities are undertaken before or after Regulatory Approval. The Commercialization
Plan shall include but not be limited to (a) demographics, market dynamics and market strategies, estimated country launch dates, a sales and expense forecast (including [*] of estimated sales and expenses), manufacturing plans and
expected product profile based upon the Development Plan, and (b) a market plan (including pricing strategies pertaining to discounts, and samples); it being understood that such market plans will evolve over time. 
  
 (b) In addition, the JOC shall develop and approve the commercialization
budget to be included as part of the Commercialization Plan (the “Commercialization Budget”). The Commercialization Budget shall include a budget of the expenses expected to be incurred in connection with performing the Commercialization
Plan, including Pre-Commercialization Costs and Allowable Expenses, and shall set forth the maximum Allowable Expenses to be incurred in each calendar year, unless such budget is modified by mutual agreement of the Parties. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -44- 

 (c) By September 1 of each subsequent year, the JOC, after taking into consideration the Parties’
comments, will prepare and approve a more complete Commercialization Plan. The Commercialization Budget shall be approved by the JOC no later than December 1 of each year. It is understood that each Commercialization Plan and Commercialization
Budget will become more comprehensive as the project evolves. 
  
 5.4 Launch Plan. 
  
 (a) Each Commercialization
Plan shall be updated, in advance of the launch of the applicable Collaboration Product to include a launch plan (the “Launch Plan”) and launch budget (the “Launch Budget”) for such launch and the [*] following the
launch date. Each such Launch Plan and Launch Budget shall be developed and approved by the JOC, after taking into consideration the Parties’ comments. 
  
 (b) It is understood that determining a date for Regulatory Approval and thus launch date is difficult. The failure to accurately estimate the launch date
shall not constitute a breach hereunder. As a result of this uncertainty, the JOC shall estimate for each country a realistic date for Regulatory Approval, and the JOC will use this estimated date to prepare its Launch Plan at least [*]
prior to the estimated Regulatory Approval. By September 1 of each calendar year thereafter, if not yet executed, each Launch Plan and Launch Budget for each Collaboration Product shall be updated by the JOC or the JFC, if formed and approved by
the JOC.  
  
 (c) Each Launch Plan shall include (i)
updated market and sales forecasts in units and estimated revenues of Collaboration Product for [*] following the first commercial launch of a Collaboration Product, (ii) estimated resource requirements, and (iii) such other matters
deemed appropriate by the JOC. 
  
 (d) Each Launch Budget shall
include a breakdown of individual Allowable Expense items expected to be incurred in connection with performing the applicable Launch Plan, and shall include all related Pre-Commercialization Costs. 
  
 5.5 Lead Marketing Party. 
  
 (a) The JOC will designate one of the Parties to be the Lead Marketing Party
with respect to the Commercialization of each Collaboration Product (the “Lead Marketing Party”). The Lead Marketing Party shall be obligated and responsible for carrying out Commercialization of such Collaboration Product pursuant to its
Commercialization Plan. The Party that is not the Lead Marketing Party (the “Passive Marketing Party”) agrees to carry out the Commercialization tasks relating to Commercialization of Collaboration Products referred to in Section 5.7(c),
and such other Commercialization tasks as are reasonably requested by the Lead Marketing Party and accepted by the Passive Marketing Party. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -45- 

 (b) The Lead Marketing Party must comply with all regulations and guidance documents issued by the FDA
and other regulatory authorities for all promotional and advertising activities and that all Parties will have the opportunity to review for compliance. 
  
 (c) The Parties intend that neither Party shall benefit or be disadvantaged financially with respect to which Party is designated as the Lead Marketing
Party. If the Parties discover that any terms of this Agreement are inconsistent with this goal, then the Parties shall discuss in good faith amending this Agreement to accomplish this goal. 
  
 (d) The Lead Marketing Party for a particular Collaboration Product shall
initially bear all Commercialization Costs (as defined in Exhibit A) for such Collaboration Product other than those initially borne by the Passive Marketing Party pursuant to Section 5.7. Such costs shall be taken into account when the Parties
allocate the Product Profits for such Collaboration Product in accordance with Sections 5.16 and 5.17. 
  
 5.6 Option to Co-Promote. The Lead Marketing Party with respect to a particular Collaboration Product shall give the Passive Marketing Party
[*] written notice of the anticipated date of commercial launch of such Collaboration Product. The Passive Marketing Party shall have the right, but not the obligation, to co-promote such Collaboration Product on a country-by-country
basis, commencing at any time from the date of commercial launch of such Collaboration Product in the first country, by providing [*] advance written notice to the Lead Marketing Party. 
  
 5.7 Responsibilities of the Parties. 
  
 (a) If the Passive Marketing Party exercises its right to co-promote a
particular Collaboration Product, the Passive Marketing Party shall contribute, at its election, [*] of the sales efforts required for the Commercialization of such Collaboration Product, under such reasonable terms and arrangements as
to which the Parties shall agree and set forth in a separate co-promotion agreement, with the Passive Marketing Party remaining responsible for its share of the Pre-Commercialization Costs as set forth in Section 5.11. The Passive Marketing
Party’s co-promotion efforts shall be coordinated with the Lead Marketing Party’s promotion efforts through the JOC consistent with the Commercialization Plan. The Parties agree to facilitate communication and cooperation between their
respective operating entities with the objective of maximizing sales for the co-promoted Products on a country by country basis.  
  
 (b) If the Passive Marketing Party does not exercise its Co-Promotion Option for a particular Collaboration Product, the Lead Marketing Party will provide
[*] of the sales efforts required for such Collaboration Product, and the Passive Marketing Party’s participation in the Commercialization of such Collaboration Product shall be limited to the activities provided in Section
5.7(c), with the Passive Marketing Party remaining responsible for its share of the Pre-Commercialization Costs as set forth in Section 5.11. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -46- 

 (c) It is recognized that the Parties bring particular strengths to the ongoing Commercialization of
Collaboration Products. It is expected that while the Lead Marketing Party will provide most of the marketing and selling efforts for Collaboration Products, and that the Passive Marketing Party will provide members for the Lead Marketing Party
product teams, participating in the development of all strategies and performing activities relating to the following marketing functions as part of the Commercialization Plan and Launch Plans: 
  
 ·    [*] 
  
 ·    [*] 
  
 ·    [*] 
  
 ·    [*] 
  
 ·    [*] 
  
 Prior to the launch of a Collaboration Product, the JOC shall establish the Passive Marketing Party headcount necessary to perform such activities. The
Passive Marketing Party activities will be performed in accordance with each approved Commercialization Plan and Commercialization Budget and each approved Launch Plan and Launch Budget. All other marketing activities that have not been assigned to
the Passive Marketing Party will be the responsibility of the Lead Marketing Party unless determined otherwise by the JOC. 
  
 (d) The Lead Marketing Party shall book all sales for the relevant Collaboration Product, invoice Third Parties that purchase such Collaboration Product,
and collect payment for all such Collaboration Products sold. 
  
 5.8 Right to Engage Third Parties. If the Lead Marketing Party determines that it needs promotion support (such as co-marketing or co-promotion) and the Passive Marketing Party does not want to provide it or is not capable of
providing it, then the Lead Marketing Party may contract for additional promotion support from a Third Party. In such event, the JOC will review the terms of the engagement of such Third Party, and such engagement shall be subject to the prior
written approval of the Passive Marketing Party. The approved costs of engaging such Third Party will be a Commercialization Cost. 
  
 5.9 Commercialization Efforts. Each Party shall use Diligent Efforts to carry out its obligations under the Commercialization Plans and Launch
Plans within the Commercialization Budgets and Launch Budgets and to cooperate with each other in carrying out the Commercialization Plans and Launch Plans.  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -47- 

 5.10 Advertising and Education. The JOC will assign to the Parties or any Third Party the
preparation of advertising and education materials for Collaboration Products. All promotional platforms and campaigns shall be subject to review and approval by the JOC. Each Party shall have the right to set the guidelines for the use of its
trademarks, and all promotional materials containing such trademarks shall comply in all material respects with such guidelines. Any materials containing a Party’s trademarks or referring to a Party shall be subject to prior review and approval
by such Party.  
  
 (a) If any written and visual
promotion or educational materials refer to or identify both Parties, the Parties shall be presented and described with equal prominence. All product labeling (including patient dosing materials such as tablets, capsules and ampules), documentary
information, promotional material and oral presentations (where practical) regarding the detailing and promoting of Collaboration Products shall display the names and logos of the Passive Marketing Party and the Lead Marketing Party with equal
prominence.  
  
 (b) Notwithstanding the foregoing,
subsections (a) and (b) are subject to the requirements of applicable laws and regulations of each country in which such materials are presented or in which Collaboration Products are Commercialized. 
  
 5.11 Pre-Commercialization Costs. The Parties shall [*]
all Pre-Commercialization Costs incurred pursuant to each Launch Budget approved by the JOC for each Collaboration Product. Each Party shall maintain accurate books and records of all costs and expenses allowable as Pre-Commercialization Costs,
within the applicable Launch Budget. Within [*] after the end of each calendar quarter, each Party shall submit to the JOC (or the JFC, if formed) a summary of all Pre-Commercialization Costs incurred during that quarter, including
reasonable detail demonstrating the specific basis for the costs and expenses included in the summary. The JOC shall review all such expenses to determine if they fall within the applicable Launch Budget. Any amounts expended outside a Launch Budget
shall be borne by the Party making such expenditure, unless approved by the JOC, and if so approved shall be Pre-Commercialization Costs. With respect to the expenses within [*] of a Launch Budget, the JOC shall submit to the Party
that bore less than [*] (or any other percentage agreed upon by the Parties) such Pre-Commercialization Costs for that quarter an invoice for the amount that Party must remit to the other Party to bring that Party’s share of the
Pre-Commercialization Costs up to [*] (or any other percentage agreed upon by the Parties) for the previous quarter. Such Party shall remit the amount on the invoice to the other Party within [*] of receiving such
invoice. Either Party may audit, in accordance with the procedures set forth in Section 10.7, the accuracy of the other Party’s submissions pursuant to this Section 5.11. 
  
 5.12 Training Program. The Lead Marketing Party will develop adequate training programs for personnel involved in the
sales and promotion of Collaboration Products. 
  
 The Parties agree to utilize
such training programs on an ongoing basis to assure a consistent, focused promotional strategy. Training shall be carried out at a time which is acceptable to the JOC, and which is prior to but reasonably near the date on which Regulatory Approval
is expected. The preparation of materials shall be considered Pre-Commercialization Costs or Commercialization Costs, as the case may be. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -48- 

 5.13 Pricing, Pricing Approvals and Product Distribution. The JOC shall determine the
overall pricing strategy for a particular Collaboration Product at least ninety (90) days prior to commercial launch of such product. The Lead Marketing Party shall obtain such Collaboration Products pricing approvals as may be required and arrange
for distribution of each Collaboration Product in each applicable country. The JOC shall have the ability to extend the 90-day period if necessary. 
  
 5.14 Product Recalls. In the event that any regulatory agency schedules an inspection, threatens or initiates any action to remove a Collaboration
Product from the market, the Lead Marketing Party shall notify the Passive Marketing Party of such communication within one business day of receipt by the Lead Marketing Party. If the Lead Marketing Party commences an internal product quality
investigation, it shall promptly notify and consult with the Passive Marketing Party regarding such investigation. Further, if either Party believes that a recall of a Collaboration Product is necessary, such Party shall notify and consult with the
other Party within two (2) working days of its determination and both Parties shall cooperate to allow such recall to occur under the direction of the JOC. In the event of a dispute about whether to recall a Collaboration Product, such recall shall
occur. The expenses of a product recall shall be an Allowable Expense shared by the Parties, except to the extent one Party is responsible for such expense pursuant to Section 15.1. For the purposes of this Section 5.14, “Recall” shall
mean any action by either Party to recover title to or possession of a Collaboration Product sold or shipped to Third Parties. The term “Recall” also includes the failure by either Party to sell or ship a Collaboration Product to Third
Parties which would have been subject to recall if it had been sold or shipped.  
  
 5.15 Tax Consideration. Either Party may take advantage of tax considerations which benefit it and not the other Party. In the event that a Party takes advantage of a tax consideration which benefits it and not
the other Party, no compensation to the other Party is required unless such affects the other Party’s Product Profit negatively, in which case compensation shall be provided to the other Party to make it whole. 
  
 5.16 Allocation of Product Profits. 
  
 (a) If PPD and Syrrx share equally Phase IIIa Development Costs for a
particular Collaboration Product, then PPD and Syrrx shall share equally in the Product Profits hereunder with respect to such Collaboration Product until such Collaboration Product is permanently withdrawn from and is no longer being sold anywhere.

  
 (b) To the extent that PPD and Syrrx do not share equally
Phase IIIa Development Costs for a particular Collaboration Product, then PPD shall be entitled to retain [*]. 
  
 (c) The following examples demonstrate how the Parties intend to implement Section 5.16(b): 
  

	 	(i)	[*]. 

  

	 	(ii)	[*]. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -49- 

 5.17 Remittance of Each Party’s Share of Product Profits. 
  
 (a) Subject to Section 5.17(b), within [*] of the end of each
calendar quarter following the launch of each Collaboration Product, or such shorter period as agreed by the JOC, each Party shall report to the JOC as outlined in Exhibit B its revenues and individual Allowable Expenses (with appropriate supporting
information) involved in the computation of Product Profit and accrued during such quarter with respect to such Collaboration Product. The Parties shall determine and report Commercialization Costs for their respective full-time equivalent sales
force personnel using the same mutually acceptable mechanism. Under the circumstances set forth in Section 5.16(b), Syrrx need not provide such a report and PPD’s report shall specify the amounts of any Phase IIIa Development Costs with respect
to such Collaboration Product (with appropriate supporting information) that it wishes to deduct from the Product Profit prior to its allocation between the Parties pursuant to Section 5.16(b). 
  
 (b) Within [*] after receipt of such report, the JOC shall
determine whether either Party needs to make a payment to the other Party to achieve the allocation of Product Profits set forth in Section 5.16(a) or 5.16(b), as applicable, and shall send the first Party an invoice for such amount. The first Party
shall pay the other Party the amount of such invoice within [*] of the date of such invoice. 
  
 (c) Either Party may audit, in accordance with the procedures set forth in Section 10.7, the accuracy of the other Party’s submissions pursuant to
this Section 5.17. 
  
 5.18 Manufacture and Supply. The JOC
will discuss and agree upon how product manufacturing and supply responsibilities for Finished Product shall be allocated between the Parties. 
  
 6. PARTNERED COMMERCIALIZATION 
  
 6.1 Partnered Commercialization Prior to Phase IIIa Trial or Where All Phase IIIa Development Costs Are Shared by the Parties. 
  
 (a) Applicability. This Section 6.1 shall apply in each circumstance
in which: 
  
 (i) the JOC decides, pursuant to Section 5.1, to
pursue Partnered Commercialization of a Collaboration Product in one or more territories for one or more diseases either (1) prior to its first Commencement of a Phase IIIa Trial, or (2) after its first Commencement of a Phase IIIa Trial but at such
time as all Phase IIIa Development Costs have been shared equally by the Parties; or 
  
 (ii) PPD decides, as applicable pursuant to Article 4, that the Parties will pursue Partnered Commercialization of a Collaboration Product in one or more territories for one or more diseases either (1) prior to its
first Commencement of a Phase IIIa Trial, or (2) after its first Commencement of a Phase IIIa Trial but at such time as all Phase IIIa Development Costs have been shared equally by the Parties. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -50- 

 (b) Partnering Agreement. The JOC shall (i) allocate responsibility for identifying potential
partners, (ii) designate one or more potential partners to engage in negotiations, and (iii) assign one or both Parties with the responsibility of taking the lead in such negotiations. The Party taking the lead shall keep the other Party informed
regarding such negotiations, and any Partnering Agreement must be approved and entered into by both Parties. If the Parties do not enter into a Partnering Agreement within [*] of PPD’s decision, pursuant to Section 6.1(a)(ii), to
pursue Partnered Commercialization, [*]. The Parties recognize that a Partnering Agreement with a Third Party for the Commercialization of a Collaboration Product may involve the Parties incurring Partnering Costs, for example by
co-participation with the partner, and such costs shall be approved by the JOC. The Parties shall strive to use internal resources of the Parties as much as practical to minimize Partnering Costs. 
  
 (c) Economics. The Parties will share [*] realized, with
respect to such Partnered Product. 
  
 (d) Reporting and
Reconciliation. 
  
 (i) Within [*] in which
there is a Collaboration Product for which one or both Parties are attempting to negotiate a Partnering Agreement pursuant to this Section 6.1, each Party shall report to the JOC or (JFC, if formed) the total of all Partnering Costs it incurred in
such quarter with respect to such Collaboration Product. If one Party incurred more such Partnering Costs during such quarter, then the JOC shall promptly send the other Party an invoice for [*]. The other Party shall pay the amount of
such invoice to the first Party within [*] of the date of such invoice. 
  
 (ii) Within [*] following the execution of a Partnering Agreement entered into pursuant to this Section 6.1, each Party shall report to the JOC or (JFC, if formed) the Partnering Costs it incurred during
such quarter with respect to such Partnering Agreement and the Licensing Revenues it received during such quarter with respect to such Partnering Agreement. Within [*] after receipt of such reports, the JOC shall calculate the amount
of any payment due from one Party to another to achieve the allocation of Partnering Costs and Licensing Revenue set forth in Section 6.1(c) and shall send such Party an invoice for such amount. The invoiced Party shall pay the amount of such
invoice to the other Party within [*] of the date of such invoice. 
  
 (iii) Either Party may audit, in accordance with the procedures set forth in Section 10.7, the accuracy of the other Party’s reports pursuant to this Section 6.1(d). 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -51- 

 6.2 Partnered Commercialization After At Least a Portion of Phase IIIa Development Costs Are Not
Shared by The Parties. 
  
 (a) Applicability. This
Section 6.2 shall apply in instances when PPD decides that the Parties will pursue Partnered Commercialization of a Collaboration Product in one or more territories for one or more diseases after one of the following circumstances: 
  
 (i) PPD and Syrrx did not enter into a Phase III Loan for such
Collaboration Product pursuant to Section 4.3(b), 4.3(c) or 4.3(d), Syrrx did not commit to pay for [*] of the Phase IIIa Development Costs for such Collaboration Product, and PPD subsequently paid for all of the Phase IIIa Development
Costs incurred for such Collaboration Product for the entire Phase IIIa Trial or a portion of such Trial; and 
  
 (ii) PPD and Syrrx entered into a Phase III Loan, and pursuant to Section 4.6(a), PPD terminated its commitment to continue making advances under the
Phase III Loan and subsequently paid for [*] of the Phase IIIa Development Costs incurred for such Collaboration Product for the remainder of such Phase IIIa Trial or a portion of such remainder. 
  
 (b) Partnering Agreement. In the event of any of the circumstances
described in Section 6.2(a), the JOC shall (i) allocate responsibility for identifying potential partners, (ii) designate one or more potential partners to engage in negotiations, and (iii) assign one or both Parties with the responsibility of
taking the lead in such negotiations. The Party taking the lead shall keep the other Party informed regarding such negotiations, and any Partnering Agreement must be approved and entered into by both Parties. If the Parties do not enter into a
Partnering Agreement within [*] of PPD’s decision to pursue Partnered Commercialization, [*]. The Parties recognize that a Partnering Agreement with a Third Party for the Commercialization of a Collaboration Product may involve
the Parties incurring Partnering Costs, for example by co-participation with the partner, and such costs shall be approved by the JOC. The Parties shall strive to use internal resources of the Parties as much as practical to minimize Partnering
Costs. 
  
 (c) Economics. To the extent that PPD and Syrrx
do not share equally Phase IIIa Development Costs for a particular Collaboration Product that becomes a Partnered Product, then PPD [*]. 
  
 (d) Reporting and Reconciliation. 
  
 (i) Within [*] in which there is a Collaboration Product for which one or both Parties are attempting to negotiate a Partnering Agreement pursuant to
this Section 6.2, each Party shall report to the JOC or (JFC, if formed) the total of all Partnering Costs it incurred in such quarter with respect to such Collaboration Product. If one Party incurred more such Partnering Costs during such quarter,
then the JOC shall promptly send the other Party an invoice for [*]. The other Party shall pay the amount of such invoice to the first Party within [*] of the date of such invoice. 
  
 (ii) Within [*] following the execution of a Partnering
Agreement entered into pursuant to this Section 6.2, each Party shall report to the JOC (or JFC, if formed) the Partnering Costs it incurred during such quarter with respect to such Partnering Agreement and the Licensing Revenues it received during
such quarter with respect to such Partnering Agreement. Within [*] after receipt of such reports, the JOC shall calculate the amount of any payment due from one Party to another to achieve the allocation of Partnering Profit set forth
in Section 6.2(c) and shall send such Party an invoice for such amount. The invoiced Party shall pay the amount of such invoice to the other Party within [*] of the date of such invoice. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -52- 

 (iii) Either Party may audit, in accordance with the procedures set forth in Section 10.7, the accuracy
of the other Party’s reports pursuant to this Section 6.2(d). 
  
 6.3 Partnered Commercialization for Syrrx Terminated Products 
  
 (a) Applicability. This Section 6.3 shall apply in each circumstance in which PPD decides to pursue Partnered Commercialization of a Syrrx Terminated Product in one or more territories for one or more diseases.

  
 (b) Partnering Agreement. PPD shall be responsible for
identifying potential partners and engaging in negotiations with them. PPD shall keep Syrrx informed regarding such negotiations. PPD may not obligate Syrrx through any Partnering Agreement involving a Syrrx Terminated Product unless PPD discloses
the terms of the Partnering Agreement to Syrrx and obtains Syrrx’s prior written consent. The Parties also agree that the Partnering Agreement shall in no way alter the economics for Syrrx Terminated Products specified in Section 6.3(c).

  
 (c) Economics. 
  
 (i) With respect to any such Partnered Product for which Syrrx terminated
its interest, pursuant to Section 13.2(c), prior to the [*].  
  
 (ii) With respect to any such Partnered Product for which Syrrx terminated its interest, pursuant to Section 13.2(c), after the [*]. 
  
 (d) Reporting and Reconciliation. 
  
 (i) Within [*] in which there is a Syrrx Terminated Product for which PPD is attempting to negotiate a
Partnering Agreement pursuant to this Section 6.3, [*] shall report to the JOC or (JFC, if formed) the total of all Partnering Costs it incurred in such quarter with respect to such Collaboration Product. The JOC or (JFC, if formed)
shall keep such information for calculating payments pursuant to Section 6.3(d)(ii). 
  
 (ii) Within [*] following the execution of a Partnering Agreement entered into pursuant to this Section 6.3, each Party shall report to the JOC or (JFC, if formed) the Partnering Costs it incurred during
such quarter with respect to such Partnering Agreement and the Licensing Revenues it received during such quarter with respect to such Partnering Agreement. Within [*] after receipt of such reports, the JOC or (JFC, if formed) shall
calculate the amount of any payment due from one Party to another to achieve the allocation of Partnering Profit set forth in Section 6.3(c)(i) or 6.3(c)(ii), as applicable, and shall send such Party an invoice for such amount. The invoiced Party
shall pay the amount of such invoice to the other Party within [*] of the date of such invoice. 
  
 (iii) Either Party may audit, in accordance with the procedures set forth in Section 10.7, the accuracy of the other Party’s reports pursuant to
this Section 6.3(d). 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -53- 

 6.4 Partnered Commercialization for PPD Terminated Products. 
  
 (a) Applicability. This Section 6.4 shall apply in each circumstance
in which Syrrx decides to pursue Partnered Commercialization of a PPD Terminated Product in one or more territories for one or more diseases. 
  
 (b) Partnering Agreement. Syrrx shall be responsible for identifying potential partners and engaging in negotiations with them. Syrrx shall keep
PPD informed regarding such negotiations. Syrrx may not obligate PPD through any Partnering Agreement involving a PPD Terminated Product unless Syrrx discloses the terms of the Partnering Agreement to PPD and obtains PPD’s prior written
consent. The Parties also agree that the Partnering Agreement shall in no way alter the economics for PPD Terminated Products specified in Section 6.4(c). 
  
 (c) Economics. 
  
 (i) With respect to any such Partnered Product for which PPD terminated its interest, pursuant to Section 13.2(c), prior to the [*].

  
 (ii) With respect to any such Partnered Product for which PPD
terminated its interest, pursuant to Section 13.2(c), after the [*]. 
  
 (d) Reporting and Reconciliation. 
  
 (i) Within [*] in which there is a PPD Terminated Product for which Syrrx is attempting to negotiate a Partnering Agreement pursuant to this Section 6.4, Syrrx shall report to the JOC or (JFC, if formed)
the total of all Partnering Costs it incurred in such quarter with respect to such Collaboration Product. The JOC or (JFC, if formed) shall keep such information for calculating payments pursuant to Section 6.4(d)(ii). 
  
 (ii) Within [*] following the execution of a Partnering
Agreement entered into pursuant to this Section 6.4, each Party shall report to the JOC or (JFC, if formed) the Partnering Costs it incurred during such quarter with respect to such Partnering Agreement and the Licensing Revenues it received during
such quarter with respect to such Partnering Agreement. Within [*] after receipt of such reports, the JOC shall calculate the amount of any payment due from one Party to another to achieve the allocation of Partnering Profit set forth
in Section 6.4(c)(i) or 6.4(c)(ii), as applicable, and shall send such Party an invoice for such amount. The invoiced Party shall pay the amount of such invoice to the other Party within [*] of the date of such invoice. 
  
 (iii) Either Party may audit, in accordance with the procedures set forth in
Section 10.7, the accuracy of the other Party’s reports pursuant to this Section 6.4(d). 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -54- 

 7. INDEPENDENT DEVELOPMENT AND COMMERCIALIZATION

  
 7.1 Syrrx Terminated Products. 
  
 (a) Control. PPD shall solely control and bear [*]
associated with the Development and Commercialization of Syrrx Terminated Products. PPD shall report to the JOC at least once a year concerning the status of each Syrrx Terminated Product. 
  
 (b) Allocation of Independent Profits. 
  
 (i) Termination Prior to [*]. With respect to any Syrrx
Terminated Product for which Syrrx terminated its interest, pursuant to Section 13.2(c), prior to the [*], PPD shall be entitled [*] of all Independent Profit realized [*]. Once PPD is no longer entitled
[*] of all Independent Profit pursuant to this Section 7.1(b)(i), PPD will [*] and Syrrx will [*] of all Independent Profit with respect to such Syrrx Terminated Product. 
  
 (ii) Termination After [*]. With respect to any Syrrx
Terminated Product for which Syrrx terminated its interest, pursuant to Section 13.2(c), after the [*], PPD shall be entitled [*] of all Independent Profit realized [*]. Once PPD is no longer entitled
[*] of all Independent Profit pursuant to Section 7.1(b)(ii), the Parties will [*] all Independent Profit with respect to such Syrrx Terminated Product. 
  
 (c) Development Cost Reporting. Within [*] prior to the launch of each Syrrx Terminated Product, PPD
shall report to the JOC its [*] for such Syrrx Terminated Product for such quarter (with appropriate supporting information) and its Phase IIIa Trial development budget for such Syrrx Terminated Product. 
  
 (d) Remittance of Independent Profit. Within [*]
following the launch of each Syrrx Terminated Product, PPD shall report to the JOC in a mutually agreed format (i) its revenues and individual Allowable Expenses (with appropriate supporting information) for such quarter and with respect to such
Syrrx Terminated Product, (ii) its computation of Independent Profit for such quarter with respect to such Syrrx Terminated Product, and (iii) the amounts of any [*] with respect to such Syrrx Terminated Product that it wishes to
[*] pursuant to Section 7.1(b)(i) or 7.1(b)(ii). Within [*] after receipt of such report, the JOC shall determine whether PPD needs to make a payment to Syrrx to achieve the allocation of Independent Profits set forth in
Section 7.1(b)(i) or 7.1(b)(ii) (as applicable) and shall send PPD an invoice for such amount. PPD shall pay Syrrx the amount of such invoice within thirty (30) days of the date of such invoice. 
  
 (e) Audit. Syrrx may audit, in accordance with the procedures set
forth in Section 10.7, the accuracy of PPD’s submissions pursuant to this Section 7.1. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -55- 

 7.2 PPD Terminated Products. 
  
 (a) Control. Syrrx shall solely control and bear all costs associated with the Development and Commercialization of
PPD Terminated Products. Syrrx shall report to the JOC at least once a year concerning the status of each PPD Terminated Product. 
  
 (b) Allocation of Independent Profits. 
  
 (i) Termination Prior to [*]. With respect to any PPD Terminated Product for which PPD terminated its interest, pursuant to Section
13.2(c), prior to the [*], Syrrx shall be entitled [*]. Once Syrrx is no longer entitled [*] pursuant to this Section 7.2(b)(i), Syrrx will [*] and PPD will [*] of all Independent
Profit with respect to such PPD Terminated Product. 
  
 (ii)
Termination After [*]. With respect to any PPD Terminated Product for which PPD terminated its interest, pursuant to Section 13.2(c), after the [*], Syrrx shall be entitled [*]. Once Syrrx is no longer
entitled [*] pursuant to Section 7.2(b)(ii), the Parties will [*] with respect to such PPD Terminated Product. 
  
 (c) Development Cost Reporting. Within [*] prior to the launch of each PPD Terminated Product, Syrrx shall report to the JOC its
[*] for such PPD Terminated Product for such quarter (with appropriate supporting information) and its Phase IIIa Trial development budget for such PPD Terminated Product. 
  
 (d) Remittance of Independent Profit. Within [*] following the launch of each PPD Terminated Product,
Syrrx shall report to the JOC in a mutually agreed format (i) its revenues and individual Allowable Expenses (with appropriate supporting information) for such quarter and with respect to such PPD Terminated Product, (ii) its computation of
Independent Profit for such quarter with respect to such PPD Terminated Product, and (iii) the amounts of any [*] with respect to such PPD Terminated Product that it wishes [*] pursuant to Section 7.2(b)(i) or 7.2(b)(ii).
Within thirty (30) days after receipt of such report, the JOC shall determine whether Syrrx needs to make a payment to PPD to achieve the allocation of Independent Profits set forth in Section 7.2(b)(i) or 7.2(b)(ii) (as applicable) and shall send
Syrrx an invoice for such amount. Syrrx shall pay PPD the amount of such invoice within [*] of the date of such invoice. 
  
 (e) Audit. PPD may audit, in accordance with the procedures set forth in Section 10.7, the accuracy of Syrrx’s submissions pursuant to this
Section 7.2. 
  
 8. LICENSES AND
RELATED RIGHTS 
  
 8.1
License to PPD. Subject to the terms of this Agreement, Syrrx hereby grants to PPD: 
  
 (a) a worldwide, exclusive license, with the right to grant sublicenses, under the Syrrx Technology, 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -56- 

 (i) to make, have made, use, import, sell, and offer for sale, solely for use in the Field,
Collaboration Products and Partnered Products; 
  
 (ii) to make,
have made, and import, solely for use in accordance with Section 8.1(a)(iii), Target Inhibitors listed in the Target Inhibitor Catalog, Lead Candidates, IND Ready Candidates, Potential IND Ready Candidates, and Reserved IND Ready Candidates;

  
 (iii) to use, solely in the Field, Target Inhibitors listed
in the Target Inhibitor Catalog, Lead Candidates, IND Ready Candidates, Potential IND Ready Candidates, and Reserved IND Ready Candidates; and 
  
 (iv) to make, have made, use, import, offer for sale, and sell, solely in the Field, Other Products; 
  
 (b) a worldwide, exclusive license, with the right to grant sublicenses,
under the Syrrx Technology, to use, make, have made, import, sell, have sold and offer for sale, for all purposes in the Field, Syrrx Terminated Products; and 
  

(c) a worldwide, nonexclusive, fully paid license, with the right to grant sublicenses, under the DP4 IP that PPD Controlled before the Effective Date,
to practice such DP4 IP for all purposes outside the Field. 
  
 8.2 License Limitations. 
  
 (a) The license set
forth in Section 8.1(a) is subject to Syrrx’s right to (i) practice the Syrrx Technology as necessary or useful for Syrrx to perform its responsibilities under a Development Plan and a Commercialization Plan, (ii) with approval from the JOC,
grant licenses under the Syrrx Technology to Third Parties solely for such Third Parties to perform such responsibilities on behalf of Syrrx, and (iii) grant non-exclusive or exclusive licenses under the Syrrx Technology with respect to one or more
Partnered Products to each Third Party with which Syrrx or the Parties enter into a Partnering Agreement in accordance with Section 6.1, 6.2 or 6.4. 
  
 (b) PPD hereby covenants that it will not practice any Syrrx Technology for any purpose other than that expressly permitted in Section 8.1. 

  
 8.3 Licenses to Syrrx. Subject to the terms of this
Agreement, PPD hereby grants to Syrrx: 
  
 (a) a worldwide,
exclusive license, with the right to grant sublicenses, under the PPD Technology, 
  
 (i) to make, have made, use, import, sell, and offer for sale, solely for use in the Field, Collaboration Products and Partnered Products; 
  
 (ii) to make, have made, and import, solely for use in accordance with Section 8.3(a)(iii), Target Inhibitors listed in the
Target Inhibitor Catalog, Lead Candidates, IND Ready Candidates, Potential IND Ready Candidates, and Reserved IND Ready Candidates; 
  

 -57- 

 (iii) to use, solely in the Field, Target Inhibitors listed in the Target Inhibitor Catalog, Lead
Candidates, IND Ready Candidates, Potential IND Ready Candidates, and Reserved IND Ready Candidates; and 
  
 (iv) to make, have made, use, import, offer for sale, and sell, solely in the Field, Other Products; 
  
 (b) a worldwide, exclusive, fully paid, irrevocable license, with the right
to grant sublicenses, under the PPD Technology, to use, make, have made, import, sell, have sold and offer for sale, for all purposes, Rejected Inhibitors and products containing or comprising Rejected Inhibitors; and 
  
 (c) a worldwide, exclusive license, with the right to grant sublicenses,
under the PPD Technology, to use, make, have made, import, sell, have sold and offer for sale, for all purposes, PPD Terminated Products. 
  
 8.4 License Limitations. 
  
 (a) The license set forth in Section 8.3(a) is subject to PPD’s right to (i) practice the PPD Technology as necessary or useful for PPD to perform
its responsibilities under the Development Plan and the Commercialization Plan, (ii) with approval from the JOC, grant licenses under the PPD Technology to Third Parties solely for such Third Parties to perform such responsibilities on behalf of
PPD, and (iii) grant non-exclusive or exclusive licenses under the PPD Technology with respect to one or more Partnered Products to each Third Party with which PPD or the Parties enter into a Partnering Agreement in accordance with Section 6.1, 6.2
or 6.3. 
  
 (b) Syrrx hereby covenants that it will not practice
any PPD Technology for any purpose other than that expressly permitted in Section 8.3. 
  
 8.5 Third Party License Obligations. The JOC (or the JIPC, if formed) shall be responsible for evaluating whether and when a Party or Parties will enter into licensing agreements with Third Parties.
Decisions regarding entering into licensing agreement with Third Parties shall be formally made by the JOC. [*]. 
  
 8.6 Obligations Under [*]. 
  
 8.7 Sharing of Data. 
  
 (a) During the Term, both Parties shall have the right to access all PPD Information and Syrrx Information as it is generated. 
  
 (b) Notwithstanding Section 8.7(a), if PPD terminates a given Collaboration
Product pursuant to Section 13.2(c), then Syrrx shall cease to have any obligation to provide PPD with access to any Syrrx Information with respect to such PPD Terminated Product. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -58- 

 (c) Notwithstanding Section 8.7(a), if Syrrx terminates a given Collaboration Product pursuant to Section
13.2(c), then PPD shall cease to have any obligation to provide Syrrx with access to any PPD Information with respect to such Syrrx Terminated Product. 
  

9. EXCLUSIVITY 
  
 9.1 PPD. 
  
 (a) Subject to Section 9.1(b), PPD shall not, except pursuant to the Collaboration for use in the Field, (i) discover, develop, or commercialize any
Inhibitor of the Target or any products containing or derived from such Inhibitors, (ii) acquire from any Third Party the right to discover, develop, or commercialize one or more Inhibitors of the Target outside the Collaboration, (iii) enter into
any agreement in which any Third Party pursuant to such agreement discovers, develops, or commercializes one or more Inhibitors of the Target, or (iv) invest in any Third Party that, at the time such investment is made, is engaged or intends to
engage in the discovery, development or commercialization of one or more Inhibitors of the Target. 
  
 (b) Notwithstanding Section 9.1(a), PPD may provide services to Third Parties in connection with the preclinical and clinical development of one or more
Inhibitors of the Target and products containing or comprising such inhibitors, provided that: 
  
 (i) such services are limited to those that are usual and customary for clinical research organizations in general and PPD in particular; 
  
 (ii) those PPD employees who perform formulation work pursuant to this
Agreement (1) shall not perform for any Third Party any formulation work upon any Inhibitor of the Target and (2) shall not advise, or disclose any formulation related Information generated in the course of the Collaboration to, any PPD employee
performing for any Third Party any formulation work upon any Inhibitor of the Target; and 
  
 (iii) PPD shall not retain (1) any right, title, interest or license in any such Inhibitor; or (2) any right to receive (directly or indirectly) any consideration in connection with the subsequent development,
regulatory filings, regulatory approval, promotion or sales of such Inhibitors or products (other than normal and customary fees and expenses charged by PPD for any such services).  
  
 9.2 Syrrx. Subject to Sections 3.6(e), 3.9 and 9.3, Syrrx shall not,
outside the Collaboration, (a) discover, develop, or commercialize one or more Inhibitors of the Target or products containing or comprising Inhibitors of the Target; (b) grant (by assignment, license or otherwise) to any Third Party the right to
discover, develop, or commercialize one or more Inhibitors of the Target or products containing or comprising Inhibitors of the Target; (c) enter into any agreement in which any Third Party pursuant to such agreement discovers, develops, or
commercializes one or more Inhibitors of the Target or products containing or comprising Inhibitors of the Target or products containing or comprising Inhibitors of the Target; or (d) invest in any Third Party that is engaged in the discovery,
development or commercialization of 
  

 -59- 

 products containing or comprising Inhibitors of the Target. In the event that Syrrx is acquired by or merged with a Third
Party that has a pre-existing program to discover, develop or commercialize Inhibitors of the Target, then this Section 9.2 shall apply only to those Inhibitors of the Target Controlled by Syrrx prior to the effective date of the merger or
acquisition. 
  
 9.3 Rejected Inhibitors. Notwithstanding
Section 9.2, subject to Section 3.7, Syrrx shall be free to (i) develop each Rejected Inhibitor and any products based thereon for its Permitted Diseases, and (ii) commercialize such Rejected Inhibitor. Such development and commercialization of
Rejected Inhibitors and related products may be performed by Syrrx alone or in conjunction with one or more Third Parties. Subject to Section 3.7, Syrrx may also sell, assign, transfer, license or otherwise grant rights in a particular Rejected
Inhibitor and products based thereon with respect to its Permitted Diseases to one or more Third Parties. The rights set forth in this Section 9.3 shall cease, with respect to a particular Rejected Inhibitor, at such time as it ceases to be a
Rejected Inhibitor. The JOC may subsequently accept a former Rejected Inhibitor as an IND Ready Candidate in accordance with Section 3.6. 
  
 9.4 Negative Covenants of PPD. 
  
 (a) PPD hereby covenants that during the Term of the Agreement it will not: 
  
 (i) Practice the licenses set forth in Section 8.1(a)(i)-(iii) except as necessary or useful for PPD to perform its
responsibilities under a Development Plan and a Commercialization Plan; 
  
 (ii) Grant any sublicenses under the licenses set forth in Section 8.1(a)(i)-(iii) except as approved by the JOC so that such sublicensee can perform, on behalf of PPD, PPD’s responsibilities under a Development
Plan and a Commercialization Plan; or 
  
 (iii) Practice the
license set forth in Section 8.1(a)(iv). 
  
 (b) Prior to the
termination of the Agreement, the negative covenants set forth in Section 9.4(a) shall terminate, on a Target Inhibitor-by-Target Inhibitor (and associated product) basis, at such time as Syrrx fails to perform any of its material obligations under
this Agreement with respect to such Target Inhibitor or its associated product and fails to cure such breach within thirty (30) days after PPD’s notice thereof. 
  
 (c) PPD shall account for all sales of Other Products as if they were Collaboration Products, including without limitation,
providing Syrrx with its share of (i) all Product Profit arising therefrom in accordance with Section 5.16(b) or (ii) all Partnering Profits arising therefrom in accordance with Section 6.2, if PPD enters into a Partnering Agreement with respect to
such Product. 
  
 9.5 Negative Covenants of Syrrx.

  
 (a) Syrrx hereby covenants that during the Term of the
Agreement it will not: 
  
 (i) Practice the licenses set forth
in Section 8.3(a)(i)-(iii) except as necessary or useful for Syrrx to perform its responsibilities under a Development Plan and a Commercialization Plan; 
  

 -60- 

 (ii) Grant any sublicenses under the licenses set forth in Section 8.3(a)(i)-(iii) except as approved by
the JOC so that such sublicensee can perform, on behalf of Syrrx, Syrrx’s responsibilities under a Development Plan and a Commercialization Plan; or 
  
 (iii) Practice the license set forth in Section 8.3(a)(iv). 
  
 (b) Prior to the termination of the Agreement, the negative covenants set forth in Section 9.5(a) shall terminate, on a Target Inhibitor-by-Target
Inhibitor (and associated product) basis, at such time as PPD fails to perform any of its material obligations under this Agreement with respect to such Target Inhibitor or its associated product and fails to cure such breach within thirty (30) days
after Syrrx’s notice thereof. 
  
 (c) Syrrx shall account for
all sales of Other Products as if they were Collaboration Products, including without limitation, providing PPD with its share of (i) all Product Profit arising therefrom in accordance with Section 5.16(b) or (ii) all Partnering Profits arising
therefrom in accordance with Section 6.2, if Syrrx enters into a Partnering Agreement with respect to such Product. 
  
 10. COMPENSATION 
  
 10.1 Milestone Payments. For each Collaboration Product, PPD shall make the noncreditable and nonrefundable milestone payments set forth below to
Syrrx within [*] after the achievement of each of the following events: 
  
 (a) [*] upon [*], for each Collaboration Product containing or comprising a different IND Ready Candidate; 
  
 (b) [*] upon [*], for each Collaboration Product containing or comprising a different IND Ready
Candidate; 
  
 (c) [*] upon [*], for
each Collaboration Product containing or comprising a different IND Ready Candidate; 
  
 (d) [*] upon [*], for each Collaboration Product containing or comprising a different IND Ready Candidate; and 
  
 (e) [*] upon [*], for each Collaboration Product containing or comprising a different IND Ready
Candidate. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -61- 

 [*] 
  

																	
	 	  	 [*]
	  	 	  	 [*]
	  	 	  	 [*]
	  	 	  	 [*]
	  	 
	 [*]
	  	 [*]
	  	 [*]
	  	 [*]
	  	 [*]
	  	 [*]
	  	 [*]
	  	 [*]
	  	 [*]

	 [*]
	  	 [*]
	  	 —  
	  	 —  
	  	 —  1
	  	 [*]
	  	 —  
	  	 —  
	  	 —  

	 [*]
	  	 [*]
	  	 —  
	  	 —  
	  	 —  2
	  	 [*]
	  	 —  
	  	 —  
	  	 —  

	 [*]
	  	 [*]
	  	 —  
	  	 [*]
	  	 —  
	  	 [*]
	  	 —  
	  	 —  
	  	 —  

	 [*]
	  	 [*]
	  	 —  
	  	 [*]
	  	 —  
	  	 [*]
	  	 —  
	  	 —  
	  	 —  

	 [*]
	  	 [*]
	  	 —  
	  	 [*]
	  	 —  
	  	 [*]
	  	 —  
	  	 —  
	  	 —  

  
 [GRAPHIC APPEARS
HERE] 
  
 Time 
  
 10.2 [*]. 
  
 10.3 Payment Method. All milestone payments due under this Agreement
to Syrrx shall be made by bank wire transfer in immediately available funds to an account designated by Syrrx. All payments hereunder shall be made in U.S. dollars. 
  
 10.4 Taxes. Each Party shall pay any and all taxes levied on account of all payments it receives under this
Agreement. If laws or regulations require that taxes be withheld, the other Party will (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, and (c) send evidence of the obligation together with proof
of tax payment to the first Party within 30 days following that tax payment. Any such payments made by the other Party shall be treated as having been made to the first Party under this Article 10. 
  
 10.5 Blocked Currency. In each country where the local currency is
blocked and cannot be removed from the country, Product Profits and Independent Profits arising from sales made in that country shall be paid to the non-selling Party in the country in local currency by deposit in a local bank designated by such
Party, unless the Parties otherwise agree. 
  
 10.6 Foreign
Exchange. Conversion of sales recorded in local currencies to U.S. dollars will be performed in a manner consistent with the Lead Marketing Party’s normal practices used to prepare its audited financial statements for internal and external
reporting purposes, which uses a widely accepted source of published exchange rates. 
 1 [*]. 
 2 [*]. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 
  

 -62- 

 10.7 Records; Inspection. Both Parties shall keep complete, true and accurate books of accounts
and records for the purpose of determining the payments to be made under this Agreement. Such books and records shall be kept for at least five (5) years following the end of the calendar quarter to which they pertain. Such records will be open for
inspection during such five (5) year period by independent accountants, solely for the purpose of verifying payment statements hereunder. Such inspections shall be made no more than once each calendar year, at reasonable time and on reasonable
notice. If any errors in favor of the inspected Party are discovered in the course of such inspection, then within thirty (30) days of its receipt of the inspection report, such inspected Party shall pay the inspecting Party those amounts (plus
interest) that the inspecting Party would have received in the absence of such errors. Inspections conducted under this Section 10.7 shall be at the expense of the inspecting Party, unless a variation or error in favor of the inspected Party
exceeding [*] of the amount stated for the period covered by the inspection is established in the course of such inspection, whereupon all costs relating to the inspection for such period will be paid promptly by the inspected Party.

  
 11. INFORMATION, INVENTIONS
AND INTELLECTUAL PROPERTY 
  
 11.1 Ownership. 
  
 (a)
Inventorship. Inventorship of all DP4 IP, Sole IP and Joint IP will be determined under the patent laws of the United States. 
  
 (b) Pre-Existing Rights. Subject to Sections 1.21, 11.1(c), and 13.2(c), nothing in this Agreement shall be construed as a grant to either Party of
any ownership interest in any copyrights, patents, trademarks, know-how, inventions, trade secrets and registrations and applications for the registration thereof of the other Party created before the Effective Date.  
  
 (c) [*] Ownership. [*] shall own the entire
right, title and interest in and to any and all [*]. [*] hereby transfers and assigns to [*] any and all right, title and interest to all [*]. At the request of [*],
[*]shall execute all documents necessary or desirable to effectuate or record such assignment. [*] may grant licenses outside the Field under the [*]. 
  
 (d) Ownership of Sole IP and Joint IP. Each Party shall own the entire
right, title and interest in and to any and all of its Sole IP. Each Party shall each own an undivided one-half interest in and to any and all Joint IP. Syrrx and PPD as joint owners shall each have the right to exploit and to grant licenses under
such Joint IP (without an accounting or obligation to, or consent required from, the other Party), unless (i) such a grant would be inconsistent with the Development Plan, Commercialization Plan, Partnering Agreements or goals of the Collaboration
or (ii) otherwise specified in this Agreement. 
  
 (e)
Ownership of [*] Information and [*] Information. [*] shall own the entire right, title and interest in and to any and all [*] Information. [*] shall own the entire right, title and interest in
and to any and all [*] Information. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -63- 

 11.2 Disclosure. Each Party shall submit a written report to the JOC (or the JIPC, if formed)
within [*] describing any [*], Sole IP or Joint IP arising during the prior quarter in the course of the Collaboration which it believes may be patentable. The JOC (or the JIPC, if formed) shall decide whether to file a
patent application for a Joint IP, as discussed in Section 11.3(c). 
  
 11.3 Patent Prosecution and Maintenance. 
  
 (a)
Inventions. Each Party shall notify the JOC promptly of each invention that should be included within DP4 IP made by such Party, solely or jointly with the other Party. The JOC shall determine whether to file a patent application in any
country for each such invention, to protect the mutual interests of the Parties. 
  
 (b) DP4 IP. Syrrx shall have the primary responsibility for preparing, filing, prosecuting and maintaining patent rights relating to DP4 IP. Syrrx or its outside patent counsel and PPD or its outside counsel
shall be co-attorneys of record with respect to each Patent within the DP4 IP. Syrrx shall keep PPD reasonably informed with respect to the status of such Patents and their prosecution and shall provide PPD with a reasonable opportunity to review
and comment upon draft patent applications and office action responses for such Patents. Syrrx shall provide to PPD, at least on an annual basis, with a list identifying the status of all DP4 IP rights for which it Controls the preparation, filing,
prosecution, maintenance and defense. 
  
 If Syrrx decides not to file or maintain
any applications or patents on a country-by-country basis or patent family basis any DP4 IP, Syrrx shall give PPD reasonable notice of same and after receipt of such notice, PPD may, at its expense, file or maintain such applications or patents at
its own expense and if it elects to do so shall be made the exclusive attorney of record. PPD shall continue to keep Syrrx reasonably informed with respect to the status of such Patents and their prosecution. 
  
 If PPD decides not to file or maintain any applications or patents on a country-by-country
basis or patent family basis within DP4 IP, PPD shall give Syrrx reasonable notice of same and after receipt of such notice, Syrrx may, at its expense, file or maintain such applications or patents at its own expense and if it elects to do so shall
be made the exclusive attorney of record. Syrrx shall continue to keep PPD reasonably informed with respect to the status of such Patents and their prosecution. 
  

If a license to any DP4 IP that one Party filed or maintained at its own expense is later needed in order to make, use or sell a Collaboration Product, PPD Terminated
Product (solely with respect to DP4 IP filed or maintained by PPD), Syrrx Terminated Product (solely with respect to PD4 IP filed or maintained by Syrrx), or Partnered Product, then the Party that filed or maintained such DP4 IP at its own expense
shall be paid by the other Party [*]. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -64- 

 (c) Sole IP and Joint IP. The Parties shall establish the patent strategy for all Joint IP. Each
Party shall direct the filing, prosecution and maintenance of all Patents covering its Sole IP consistent with such strategy. The JOC (or the JIPC, if formed) shall supervise and direct the filing, prosecution and maintenance of all Patents covering
Joint IP. The Parties shall exchange (i) drafts of any new patent application that covers a Joint IP prior to filing that application, allowing adequate time for review and comment by the other Party if possible; provided, however, the drafting
Party shall not be obligated to delay the filing of any patent application; and (ii) copies of all correspondence from any and all patent offices concerning patent applications covering Joint IP and an opportunity to comment on any proposed
responses, voluntary amendments and submissions of any kind to be made to any and all such patent offices. 
  
 (d) Patent Budget. 
  
 (i) The expenses incurred by the Parties in the course of evaluating and protecting DP4 IP shall be governed by a patent budget (“Patent
Budget”). The Patent Budget shall constitute the maximum expenses to be incurred thereunder in each calendar year, unless such budget is modified by the JOC. 
  
 (ii) Within sixty (60) days of the Effective Date, Syrrx shall provide to the JOC for approval an initial Patent Budget
that sets forth Syrrx’s financial projections for costs associated with evaluating and protecting DP4 IP up until the first anniversary of the Effective Date. 
  
 (iii) The JOC (or the JIPC, if formed) shall prepare and submit to the Parties, by September 1 of each calendar
year, an updated Patent Budget that includes a detailed description of all patent related costs authorized to be incurred during the following calendar year. The Parties shall provide comments on each such updated Patent Budget within thirty (30)
days following its submission to them. Within thirty (30) days following such original submission, the JOC shall either approve the original Patent Budget or a modified version thereof that is consistent with the objectives for protecting DP4 IP.

  
 (e) Expenses. 
  
 (i) Subject to Section 11.3(e)(ii), Syrrx shall be responsible for all
patent costs incurred after the Effective Date in relation to Syrrx Technology, and PPD shall be responsible for patent costs incurred after the Effective Date in relation to PPD Technology. All patent costs incurred for Joint IP shall be
[*] by the Parties. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -65- 

 (ii) Subject to Section 11.3(b), the Parties shall [*] (i) all patent costs approved
pursuant to Section 11.3(d) (including filing fees, maintenance fees, and outside attorney fees) with respect to each Patent within the DP4 IP that covers the composition of matter, manufacture or use of a Target Inhibitor listed on the Target
Inhibitor Catalog, Lead Candidate, IND Ready Candidate, Potential IND Ready Candidate, Reserved IND Ready Candidate, or Collaboration Product, and (2) all costs approved pursuant to Section 11.3(d) (including outside attorney fees) associated with
patentability and freedom to operate assessments with respect to a Target Inhibitor listed on the Target Inhibitor Catalog, Lead Candidate, IND Ready Candidate, Potential IND Ready Candidate, Reserved IND Ready Candidate, or Collaboration Product.

  
 (iii) The Parties shall reconcile all [*]
patent expenses on a quarterly basis until such time as all such expenses are Allowable Expenses that the Parties are sharing as part of their allocation of Product Profit in accordance with Sections 5.16 and 5.17. 
  
 11.4 Enforcement of Patent Rights. 
  
 (a) If a Third Party is apparently infringing a Patent within the DP4 IP,
the Party first obtaining knowledge of such a claim shall immediately provide the other Party notice of such claim and the related facts in reasonable detail. 
  

(b) Syrrx shall have the exclusive right with respect to enforcing any Patent within the DP4 IP against an act of infringement outside the Field and
with respect to settling any action brought relating to such infringement, may grant a license to such Patent outside the Field in conjunction with such settlement. All costs, liabilities and proceeds (each, if any) associated with such enforcement
shall be borne or realized by Syrrx. Syrrx shall not settle any action in a manner that is prejudicial to any of PPD’s interests under this Agreement without PPD’s prior written approval, which approval shall not be unreasonably withheld.

  
 (c) If the suspected infringement of a Patent within the DP4
IP occurs within the Field, the JOC, with advice from the JIPC, if formed, shall determine how to best control the enforcement of such infringement. If either Party brings any such action or proceeding hereunder as decided by the JOC, the other
Party agrees to be joined as a Party plaintiff and to give the first Party reasonable assistance and authority to control, file and prosecute the suit as necessary. All costs, liabilities and proceeds (each, if any) associated with the enforcement
of a given claim with respect to an IND Ready Candidate or Collaboration Product shall be [*] by the Parties. No settlement or consent judgment or other voluntary final disposition of a suit may be entered into without the joint
written consent of Syrrx and PPD. 
  
 (d) For clarity, the Parties
agree that the rights of each Party to enforce claims of infringement with respect to a Collaboration Product may be made subordinate to a subsequent Partnering Agreement if the Collaboration Product is commercialized by Partnered Commercialization.

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -66- 

 11.5 Defense of Third Party Claims. 
  
 (a) If a Third Party asserts that a patent or other right Controlled by it is infringed by the manufacture, import, use,
sale or offer for sale of any IND Ready Candidate or Collaboration Product, the Party first obtaining knowledge of such a claim shall immediately provide the other Party with notice of such claim and the related facts in reasonable detail. The JOC,
with advice from the JIPC, if formed, shall determine how to best control the defense of any such claim. All costs, liabilities and proceeds (each, if any) associated with the defense of a given claim with respect to an IND Ready Candidate or
Collaboration Product shall be [*] by the Parties, provided that neither Party enters into a settlement agreement with such Third Party without the written consent of the other Party, which shall not be unreasonably withheld. 

  
 (b) For clarity, the Parties agree that the rights of each
Party to defend claims of infringement may be made subordinate to a subsequent partnering agreement if the Collaboration Product is commercialized by Partnered Commercialization. 
  
 12. CONFIDENTIALITY 
  
 12.1 Nondisclosure of Confidential Information. All Information disclosed by one Party to the other Party pursuant to this Agreement shall be
“Confidential Information,” provided that it is marked or otherwise identified as “confidential” or “proprietary.” The Parties agree that during the Term, and for a period of [*] years thereafter, a Party receiving
Confidential Information of the other Party will (i) maintain in confidence such Confidential Information to the same extent such Party maintains its own proprietary industrial information of similar kind and value (but at a minimum each Party shall
use commercially reasonable efforts), (ii) not disclose such Confidential Information to any Third Party without prior written consent of the other Party, except for disclosures made in confidence to any Third Party pursuant to arrangements approved
by the JOC or permitted by this Agreement, and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement. 
  
 12.2 Exceptions. The obligations in Section 12.1 shall not apply with respect to any portion of the Confidential Information that the receiving
Party can show by competent written proof: 
  
 (a) Is publicly
disclosed by the disclosing Party, either before or after it is disclosed to the receiving Party hereunder; or 
  
 (b) Was known to the receiving Party, without obligation to keep it confidential, prior to disclosure by the disclosing Party; or 
  
 (c) Is subsequently disclosed to the receiving Party by a Third Party
lawfully in possession thereof and without obligation to keep it confidential; or 
  
 (d) Has been published by a Third Party; or 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -67- 

 (e) Has been independently developed by the receiving Party without the aid, application or use of all or
any part of Confidential Information. 
  
 12.3 Authorized
Disclosure. A Party may disclose the Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
  
 (a) Filing or prosecuting Patents relating to Sole IP, Joint IP or DP4 IP; 
  
 (b) Regulatory Filings and prosecutions of the same; 
  
 (c) Prosecuting or defending litigation; 
  
 (d) Complying with applicable governmental regulations; and 
  
 (e) Disclosure, in connection with the performance of this Agreement, to
sublicensees, research collaborators, employees, consultants, or agents, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 12.

  
 The Parties acknowledge that the terms of this Agreement shall
be treated as Confidential Information of both Parties. Such terms may be disclosed by a Party to investment bankers, investors, and potential investors, provided that they are bound by similar obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this Article 12. In addition, a copy of this Agreement may be filed by either Party with the Securities and Exchange Commission if such filing is required by law or regulation. In connection with any such
filing, such Party shall endeavor to obtain confidential treatment of economic and trade secret information to the extent permitted by the Securities and Exchange Commission. 
  
 In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information except as
permitted hereunder. 
  
 12.4 Publicity. The Parties agree
that the public announcement of the execution of this Agreement shall be substantially in the form of the press release attached as Exhibit C. Any other written publication, news release or other written public announcement relating to this
Agreement or to the performance hereunder, shall first be reviewed and approved by both Parties; provided, however, that any disclosure which is required by law as advised by the disclosing Party’s counsel may be made without the prior consent
of the other Party, although the other Party shall be given prompt notice of any such legally required written disclosure and to the extent practicable shall provide the other Party an opportunity to comment on the proposed written disclosure.

  
 12.5 Publications. Neither Party shall publish or
present the results of studies carried out under this Agreement without the opportunity for prior review and consent by the other Party. Subject to Section 12.3, each Party agrees to provide the other Party the opportunity to review any proposed
abstracts, manuscripts or presentations (including verbal presentations) which relate to any IND Ready Candidate or Collaboration Product at least thirty (30) days prior to its intended submission for publication and agrees, upon request, not to
submit any such 
  

 -68- 

 abstract or manuscript for publication until the other Party is given a reasonable period of time to secure patent
protection for any material in such publication which it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Parties agree to
review and consider delay of publication and filing of patent applications under certain circumstances. The JOC, with advice from the JIPC, if formed, will review such requests and recommend subsequent action. Neither Party shall have the right to
publish or present Confidential Information of the other Party which is subject to Section 12.1. Nothing contained in this Section 12.5 shall prohibit the inclusion of information necessary for a patent application, except for Confidential
Information of the nonfiling Party, provided the nonfiling Party is given a reasonable opportunity to review the information to be included prior to submission of such patent application. Any disputes between the Parties regarding delaying a
publication or presentation or advertising or promotional materials used during commercialization in order to permit the filing of a patent application shall be referred to the JOC. 
  
 13. TERM AND TERMINATION 
  
 13.1 Term of the Agreement. The term during which this Agreement is in effect (the “Term”) shall
commence on the Effective Date and shall continue indefinitely until this Agreement is terminated in accordance with Section 13.2(b) or by written agreement of the Parties. In the event of expiration of this Agreement pursuant to this Section 13.1,
the following provisions of this Agreement shall survive: Sections 8.3(b), 10.7, 11.1, 13.1, and 13.4, and Articles 12, 15, 16 and 17. 
  
 13.2 Early Termination. 
  
 (a) Termination for Material Breach. 
  
 (i) If either Party is in material breach of this Agreement (including without limitation any material breach of a representation or warranty made in
this Agreement), then the other Party may deliver notice of such breach to the breaching Party. In such notice, the non-breaching Party shall identify the actions or conduct that such Party would consider to be an acceptable cure of such breach. The
allegedly breaching Party shall have thirty (30) days to either cure such breach or, if cure cannot be reasonably effected within such thirty (30) day period, to deliver to the other Party a plan for curing such breach which is reasonably sufficient
to effect a cure. Such a plan shall set forth a program for achieving cure as rapidly as practicable. Following delivery of such plan, the breaching Party shall use Diligent Efforts to carry out the plan and cure the breach. 
  
 (ii) If the Party receiving notice of breach fails to cure such breach
within the thirty (30) day period, or the Party providing the notice reasonably determines that the proposed corrective plan or the actions being taken to carry it out is not commercially practicable, the Party originally delivering the notice may,
upon thirty (30) days advance written notice, terminate the breaching Party’s active involvement in this Agreement by converting all Collaboration Products to Terminated Products of the breaching Party. If Syrrx is the breaching Party, then all
Collaboration Products shall become Syrrx Terminated Products as of the effective date of such termination. If PPD is the breaching Party, then all Collaboration Products shall become PPD Terminated Products as of the effective date of such
termination and Syrrx shall have the option set forth in Section 13.3. 
  

 -69- 

 (iii) If a Party gives notice of termination under this Section 13.2(a) and the other Party disputes
whether (a) it was in material breach of this Agreement, (b) it had failed to cure such breach, or (c) the proposed corrective plan or the actions being taken to carry it out is not commercially practical, then the issue of whether this Agreement
has been terminated shall be resolved in accordance with Article 16. If as a result of such dispute resolution process it is determined that the disputing Party had failed to cure a material breach of this Agreement, then such termination shall be
deemed to have been effective thirty (30) days following the date of the notice of termination. If as a result of such dispute resolution process it is determined that the disputing Party had not committed a material breach or had timely cured such
material breach, then no termination shall have occurred and this Agreement shall have remained in effect. If, as a result of such dispute resolution process, it is determined that the disputing Party’s proposed corrective plan or the actions
being taken to carry it out are commercially practical, then the disputing Party shall promptly and diligently implement such plan and shall cure such breach within the time frame set forth in the plan. 
  
 (b) Voluntary Termination for Inactivity. This Agreement may be
terminated by either Party, upon thirty (30) days prior written notice provided no earlier than 
  

	 	(i)	the [*];or 

  

	 	(ii)	the [*]. 

  
 In the event of early termination of this Agreement pursuant to this Section 13.2(b), the following provisions of this Agreement shall survive: Sections 8.3(b), 10.7, 11.1, 13.2(b), and 13.4, and Articles 12, 15, 16
and 17. 
  
 (c) Voluntary Termination of Individual
Collaboration Products. 
  
 (i) Prior to the expiration of
the Term, either Party may terminate its rights and obligations under this Agreement with respect to a particular Collaboration Product in its discretion upon [*] prior written notice to the other Party. Upon the effective date of such
termination, such Product shall cease to be a part of the Collaboration and will become a “PPD Terminated Product” if PPD was the terminating Party and a “Syrrx Terminated Product” if Syrrx was the terminating Party. The
terminating Party shall remain obligated to perform all duties under the Development Plan or Commercialization Plan with respect to such Collaboration Product until the effective date of such termination. 
  
 (ii) If PPD terminates a particular Collaboration Product pursuant to this
Section 13.2(c), then (1) Syrrx shall have the right to exercise the option set forth in Section 13.3 within [*] of receipt of PPD’s written notice of termination with respect to a particular Collaboration Product, (2) PPD shall
assign to Syrrx all of PPD’s right, title and interest in and to the PPD Information, Regulatory Documentation, Regulatory Filings and Regulatory Approvals, for such PPD Terminated Product, (3) PPD shall provide Syrrx with at least two (2)
accurate and 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -70- 

 legible copies (including both paper and electronic copies, where available) of all such PPD Information, (4) upon
Syrrx’s written request, PPD shall assign to Syrrx all PPD Specific Third Party Agreements for such PPD Terminated Product that are specified in such request, and (5) upon Syrrx’s written request, PPD shall grant Syrrx a right, under all
PPD Generic Third Party Agreements for such PPD Terminated Product that are specified in such request, to receive supply of such PPD Terminated Product (including in bulk, finished or any intermediate form) or other products or services related to
such PPD Terminated Product. Syrrx may grant licenses or sublicenses under the DP4 IP, PPD Information and Syrrx Information, with respect to PPD Terminated Products. Syrrx may grant a Third Party rights with respect to any Regulatory Filing or
Regulatory Documentation pertaining to a PPD Terminated Product. 
  
 (iii) If Syrrx terminates a given Collaboration Product pursuant to Section 13.2(c), then (1) Syrrx shall assign to PPD all of Syrrx’s right, title and interest in and to the Syrrx Information for such Syrrx Terminated Product, (2)
Syrrx shall provide PPD with at least two (2) accurate and legible copies (including both paper and electronic copies, where available) of all such Syrrx Information, (3) upon PPD’s written request, Syrrx shall assign to PPD all Syrrx Specific
Third Party Agreements for such Syrrx Terminated Product that are specified in such request, and (4) upon PPD’s written request, Syrrx shall grant PPD a right, under all Syrrx Generic Third Party Agreements for such Syrrx Terminated Product
that are specified in such request, to receive supply of such Syrrx Terminated Product (including in bulk, finished or any intermediate form) or other products or services related to such Syrrx Terminated Product. PPD may grant licenses or
sublicenses under the DP4 IP, PPD Information and Syrrx Information, with respect to Syrrx Terminated Products. PPD may grant a Third Party rights with respect to any Regulatory Filing or Regulatory Documentation pertaining to a Syrrx Terminated
Product. 
  
 13.3 Option for PPD Development and
Commercialization Services. 
  
 (a) PPD hereby grants Syrrx
the option to require PPD to perform all of its obligations, with respect to one or more PPD Terminated Products, each chosen by Syrrx in its discretion, under the Development Plan and Commercialization Plan that were in effect at the time that
Syrrx provided notice of termination pursuant to Section 13.2(a) or PPD provided notice of termination pursuant to Section 13.2(c), as applicable. 
  
 (b) If Syrrx exercises such option, PPD shall perform such obligations for up to [*] after the effective date of such termination, and Syrrx
shall pay PPD the rates described in Section 1.17. The Parties shall enter into a written agreement for PPD to provide such services to Syrrx upon PPD’s standard terms and conditions. In the event that Syrrx and PPD do not enter into such
agreement, PPD shall have no further obligation under such option with respect to such PPD Terminated Product. 
  
 (c) Syrrx may exercise such option by written notification to PPD within [*] of Syrrx’s termination notice pursuant to Section 13.2(a)
or Syrrx’s receipt of notice from PPD under Section 13.2(c). 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -71- 

 13.4 Accrued Rights and Liability The termination of this Agreement or the rights and obligations
with respect to obligations for a particular Collaboration Product, shall not relieve the Parties of any liability which accrued hereunder prior to the effective date of such termination nor preclude either Party from pursuing all rights and
remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. 
  
 14. REPRESENTATIONS AND WARRANTIES 
  
 14.1 Mutual Authority and No Conflict. Syrrx and PPD each represents
and warrants to the other that (i) it has the authority and right to enter into and perform this Agreement and (ii) its execution, delivery and performance of this Agreement will not conflict in any material fashion with the terms of any other
agreement to which it is or becomes a Party or by which it is or becomes bound. 
  
 14.2 Performance by Affiliates. The Parties recognize that each may perform some or all of its obligations under this Agreement through Affiliates, provided, however, that each Party shall remain responsible
and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. In particular, if any Affiliate of a Party participates in research or
development under this Agreement or with respect to Target Inhibitors, (i) the restrictions of this Agreement which apply to the activities of a Party with respect to IND Ready Candidates and Target Inhibitors shall apply equally to the activities
of such Affiliate, (ii) the Party affiliated with such Affiliate shall assure, and hereby guarantees, that any intellectual property developed by such Affiliate shall be governed by the provisions of this Agreement (and subject to the licenses set
forth in Article 8) as if such intellectual property had been developed by the Party, and (iii) the Party affiliated with such Affiliate shall assure, and hereby guarantees, that such Affiliate shall abide by the confidentiality obligations set
forth in Article 12 as if such Affiliate were such Party. 
  
 14.3 Existing Syrrx IP Rights. Syrrx represents and warrants that, as of the Effective Date, it is the owner or licensee, with right to sublicense and grant the rights as provided for herein, of all Syrrx Existing IP that is also DP4
IP. Syrrx further warrants that, as of the Effective Date, it: (a) has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in such Syrrx Existing IP to the extent necessary for conducting the
Collaboration in the Field; (b) is not aware of any ground rendering any of the issued patents that are part of Syrrx Existing IP that is also DP4 IP invalid or unenforceable; (c) is not aware of any material defect regarding the preparation or
prosecution of any pending patents that are part of Syrrx Existing IP that is also DP4 IP that would render a patent issuing therefrom invalid or unenforceable; and (d) has no knowledge of the existence of any patent or other intellectual property
right owned or Controlled by a Third Party not already disclosed to PPD that it believes dominates Syrrx Existing IP that is also DP4 IP or would materially preclude the Parties from conducting the Collaboration. 
  

 -72- 

 14.4 [*]. Syrrx represents and warrants that, as of the Effective Date, (i) it has not
received any notice or other communication [*] with respect to Initial Target Inhibitors, and (ii) that [*] does not possess any rights with respect to Initial Target Inhibitors that would prevent the Parties from
conducting the Collaboration. 
  
 14.5 Initial Target
Inhibitors. Syrrx represents and warrants that, as of the Effective Date, (i) all Target Inhibitors that have been identified as of the Effective Date have been disclosed in writing to PPD by Syrrx, (ii) to Syrrx’s knowledge, the Initial
Target Inhibitors and methods by which Syrrx intends to make or use them do not infringe or misappropriate the intellectual property rights of any Third Party, and (iii) Syrrx has not received any notice or other communication alleging that an
Initial Target Inhibitor infringes or misappropriates the intellectual property rights of a Third Party. 
  
 14.6 Disclosure of Negative Data. Syrrx represents and warrants that, as of the Effective Date, it has provided to PPD all material Initial Target
Inhibitor data relating to efficacy and toxicity in Syrrx’s possession as of November 14, 2003 in form mutually agreed upon by the Parties. 
  
 14.7 Existing PPD Patent Rights. PPD represents and warrants that it or one of its Affiliates is the owner or exclusive licensee, with right to
sublicense and grant the rights as provided for herein, of PPD Existing Patent Rights that is also DP4 IP. PPD further warrants that, as of the Effective Date, neither PPD nor any Affiliate: (a) has previously assigned, transferred, conveyed or
otherwise encumbered its right, title and interest in such PPD Existing Patent Rights to the extent necessary for conducting the Collaboration in the Field; (b) is aware of any ground rendering any of the issued patents that are part of PPD
Technology invalid or unenforceable; (c) is aware of any material defect regarding the preparation or prosecution of any pending patents that are part of PPD Existing IP that is also DP4 IP that would render a patent issuing therefrom invalid or
unenforceable; and (d) has knowledge of the existence of any patent or other intellectual property right owned or Controlled by a Third Party not already disclosed to Syrrx that it believes dominates PPD Existing Patent Rights that is also DP4 IP or
would materially preclude the Parties from conducting the Collaboration. 
  
 14.8 Rates. 
  
 (a) PPD
represents and warrants that, at the time PPD or one of its Affiliates performs activities under a Development Plan, the cost for such activities for which PPD seeks approval from the JOC shall be no more than [*] of the normal and
customary rates PPD or one of its Affiliates charges Third Parties at that time, in arm’s length transactions, for equivalent activities. 
  
 (b) Syrrx represents and warrants that, at the time Syrrx or one of its Affiliates performs activities under a Development Plan, the rates for which Syrrx
seeks approval from the JOC are no more than [*] of the normal and customary rates Syrrx or one of its Affiliates charges Third Parties at the time, in arm’s length transactions, for equivalent activities. 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 -73- 

 15. INDEMNIFICATION AND LIMITATION OF
LIABILITY 
  
 15.1 Indemnification

  
 (a) Subject to Section 15.2, each Party hereby agrees to
defend and hold harmless the other Party and its directors, officers, agents and employees (the “Indemnitees”) from and against any and all damages, liabilities, expenses and/or loss, including reasonable legal expenses and reasonable
attorneys’ fees (“Losses”) resulting from suits, claims, proceedings or causes of action brought by a Third Party against such Indemnitee based on: (i) breach by the indemnifying Party of a representation or warranty contained in this
Agreement; (ii) breach of this Agreement or applicable law by the indemnifying Party; and/or (iii) the negligence or willful misconduct of the indemnifying Party in the performance of this Agreement; except to the extent such Losses result from (1)
breach by the non-indemnifying Party of a representation or warranty contained in this Agreement or Indemnitee; (2) breach of this Agreement or applicable law by the non-indemnifying Party; and/or (3) the negligence or willful misconduct of the
non-indemnifying Party or Indemnitee in the performance of this Agreement. 
  
 (b) In the event that an Indemnitee is seeking indemnification under Section 15.1(a), it shall inform the indemnifying Party of a claim as soon as reasonably practicable after it receives notice of the claim, shall
permit the indemnifying Party to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and shall cooperate as requested by the indemnifying Party (at the expense of the
indemnifying Party) in the defense of the claim. 
  
 15.2
Limitation of Liability. EXCEPT FOR A BREACH OF SECTION 8.2(b), 9.4, 8.4(b), 9.5 OR 12.1 OR AS SPECIFICALLY PROVIDED IN SECTION 15.1, IN NO EVENT SHALL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS BE LIABLE TO THE OTHER PARTY FOR
ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT. For clarification, the
foregoing sentence shall not be interpreted to limit or to expand the express rights specifically granted in the sections of this Agreement. 
  
 16. DISPUTE RESOLUTION. 
  
 16.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the term of this Agreement which relate
to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without
resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 16 if and when a dispute arises under this Agreement. The JOC shall serve as the initial forum for resolving all such disputes.
If the JOC is unable to resolve any dispute within fifteen (15) days, any Party may, by written notice to the other, have such dispute referred to Chief Executive Officers of the Parties (or the most senior member of the Party’s management, if
such Party does not then have a Chief Executive Officer) for attempted resolution by good faith negotiations within fifteen (15) days after such notice is received. In the event the Chief Executive Officers are not able to resolve such dispute
within such fifteen (15) day period, either Party may then invoke the provisions of Section 16.2, 16.14 or 16.15, as applicable. 
  

 -74- 

 16.2 Arbitration. Any dispute, controversy or claim arising out of or relating to the validity,
construction, enforceability or performance of this Agreement that is not resolved pursuant to Section 16.1, except for a dispute, claim or controversy under Section 16.14 or 16.15, may be submitted by either Party for final and binding arbitration
in accordance with the terms of this Agreement by American Arbitration Association (“AAA”) rules. The arbitration will be conducted in a geographically neutral site within the United States that is mutually agreed by the Parties or, in the
absence of such agreement, chosen by the arbitrator. The arbitration will be conducted under the rules then in effect for AAA, except as provided herein, and the Parties consent to the personal jurisdiction of the United States federal courts, for
any cause arising out of or otherwise related to this arbitration, its conduct and its enforcement. Any situation not expressly covered by this Agreement shall be decided in accordance with such rules of AAA. 
  
 16.3 Arbitrator. 
  
 (a) Subject to Section 16.3(b), the arbitrator shall be one (1) neutral,
independent and impartial arbitrator selected from a pool of retired federal judges to be presented to the Parties by AAA. Failing the agreement of the Parties as to the selection of the arbitrator within fifteen (15) days, the arbitrator shall be
appointed by AAA within the subsequent fifteen (15) days. 
  
 (b)
Upon the written request of either Party prior to the commencement of the arbitrator’s duties pursuant to this Article 16, there shall be three (3) arbitrators rather than one (1). If such request is made prior to the selection of an arbitrator
pursuant to Section 16.3(a), then within fifteen (15) days of such request each Party shall select one (1) neutral, independent and impartial arbitrator from the pool of retired federal judges presented to the Parties by AAA and within fifteen (15)
days thereafter those two (2) arbitrators shall select the third (3rd) arbitrator from such pool. If such request is
made after the selection of an arbitrator pursuant to Section 16.3(a), then within fifteen (15) days of such request each Party shall select one (1) additional arbitrator from the pool from which the first arbitrator was selected. 
  
 16.4 Governing Law. Resolution of all disputes arising out of or
related to this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of Delaware, without regard to conflicts
of law rules that would provide for application of the law of a jurisdiction outside Delaware. 
  
 16.5 Rules of Procedure. The Parties shall be entitled to discovery as provided in the Federal Rules of Civil Procedure and the local rules of the Federal District Court in San Francisco, California, provided,
however, that all discovery shall be conducted expeditiously within the time limit set by the arbitrator selected pursuant to Section 16.3. At the hearing, the Parties may present testimony (either by live witness or deposition) and documentary
evidence. Each Party shall have the right to be represented by counsel. 
  

 -75- 

 16.6 Rules of Evidence. The Federal Rules of Evidence shall apply to any and all matters submitted
to final and binding arbitration under this Agreement. 
  
 16.7
Decision. The power of the arbitrator to fashion procedures and remedies within the scope of this Agreement is recognized by the Parties as essential to the success of the arbitration process. The arbitrator shall not have the authority to
fashion remedies which would not be available to a federal judge hearing the same dispute. The arbitrator is encouraged to operate on this premise in an effort to reach a fair and just decision but shall fashion such rules and procedures to best
approximate Federal rules and procedures except with respect to procedural time limits and delays (which shall be set by the arbitrator pursuant to Section 16.5). Reasons for the arbitrator’s decisions should be complete and explicit. A full
transcript and record of the proceedings as well as written decisions including all determinations of law and fact shall be provided for the appellate process. The written reasons should also include the basis for any damages awarded and a statement
of how the damages were calculated. Such a written decision shall be rendered by the arbitrator following a full comprehensive hearing, no later than twelve (12) months following the selection of the arbitrator as provided for in Section 16.3.

  
 16.8 Award. 
  
 (a) The award shall be paid in U.S. dollars free of any tax, deduction or
offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the Party resisting enforcement. 
  
 (b) If as to any issue the arbitrator should determine under the applicable law that the position taken by a Party is
frivolous or otherwise irresponsible or that any wrongdoing they find is in callous disregard of law and equity or the rights of the other Party, the arbitrator shall also award an appropriate allocation of the adversary’s reasonable attorney
fees, costs and expenses to be paid by the offending Party, the precise sums to be determined after a bill of attorney fees, expenses and costs consistent with such award has been presented following the award on the merits. 
  
 (c) Each Party agrees to abide by the award rendered in any arbitration
conducted pursuant to this Article 16, and agrees that a judgment of the Federal District Court in Delaware having jurisdiction may be entered upon the final award and that other courts may award full faith and credit to such judgment in order to
enforce such award. 
  
 (d) The award shall include interest from
the date of any damages incurred for breach of the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator. 
  
 (e) With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s) or any court or any other forum to award
punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for punitive or exemplary damages. The only damages recoverable under this Agreement are compensatory damages (including, without
limitation, consequential damages). 
  
 16.9 Costs. Except
as set forth in Section 16.8, each Party shall bear its own legal fees. The arbitrator shall assess his or her costs, fees and expenses against the Party losing the arbitration unless he or she believes that neither Party is the clear loser, in
which case the arbitrator shall divide his or her fees, costs and expenses according to his or her sole discretion. 
  

 -76- 

 16.10 Injunctive Relief. Provided a Party has made a sufficient showing under the rules and
standards set forth in the Federal Rules of Civil Procedure and applicable case law, the arbitrator shall have the freedom to invoke, and the Parties agree to abide by, injunctive measures after either Party submits in writing for arbitration claims
requiring immediate relief. 
  
 16.11 Confidentiality. The
arbitration proceeding shall be confidential and the arbitrator shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator to make)
any public announcement with respect to the proceedings or decision of the arbitrator without prior written consent of each other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties
and the arbitrator, except as required in connection with the enforcement of such award or as otherwise required by applicable law. 
  
 16.12 Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of the contract for any
reason. 
  
 16.13 Jurisdiction. For the purposes of this
Article 16, the Parties acknowledge their diversity (Syrrx having its principal place of business in California and PPD having its principal place of business in North Carolina) and, with respect to an award in favor of Syrrx, agree to accept the
jurisdiction of the Federal District Court in Delaware, and, with respect to an award in favor of PPD, agree to accept the jurisdiction of the Federal District Court in Delaware in each case for the purposes of enforcing awards entered pursuant to
this Article 16 and for enforcing the agreements reflected in this Article 16. 
  
 16.14 Patents and Trademarks. Any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Patent rights covering the manufacture, use, importation, offer for sale or
sale of any Product or of any trademark rights related to any Product shall be submitted to a court of competent jurisdiction in the country in which such Patent or trademark rights were granted or arose. 
  
 16.15 Neutral Determination. Any dispute, controversy or claim
relating to the adoption of an updated Development Plan, Development Budget, Commercialization Plan or Commercialization Budget that is not resolved pursuant to Section 16.1 may be submitted by either Party to a mutually agreed Third Party with
substantial experience regarding the development and marketing of pharmaceutical products (the “Neutral”). Within ten (10) days of the identification of the Neutral, each Party shall submit to the Neutral in writing its proposal for the
updated Development Plan, Development Budget, Commercialization Plan or Commercialization Budget, as the case may be. The Neutral shall have the authority to determine whether one proposal is more consistent with the typical practices of the
pharmaceutical industry with respect to the development or commercialization (as applicable) of a therapeutic product for such disease than the other proposal. If the Neutral determines that one proposal is more consistent, then such proposal shall
become such updated Development Plan, Development Budget, Commercialization Plan or Commercialization Budget, as the case may be. If the Neutral determines that the two proposals are equally consistent, then the Neutral shall 
  

 -77- 

 craft an updated Development Plan, Development Budget, Commercialization Plan or Commercialization Budget, as the case
may be, that is a reasonable compromise between the terms of the two proposals. The Parties shall equally share the costs associated with the Neutral’s activities under this Section 16.15. The Parties shall direct the Neutral to complete his or
her obligations under this Section 16.15 be completed within thirty (30) days after the Parties’ submissions of their proposals, and each Party shall reasonably cooperate to allow such obligations to be completed within such time period.

  
 17. MISCELLANEOUS 
  
 17.1 Entire Agreement; Amendment. This Agreement sets forth the
complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between
the Parties. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment,
change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 
  
 17.2 Bankruptcy. 
  
 (a) All rights and licenses granted under or pursuant to this Agreement, including amendments hereto, by each Party to the other Party are, for all
purposes of Section 365(n) of Title 11 of the U.S. Code (“Title 11”), licenses of rights to intellectual property as defined in Title 11. Each Party agrees during the term of this Agreement to create and maintain current copies or, if not
amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property. If a case is commenced by or against either Party (the “Bankrupt Party”) under Title 11, then, unless
and until this Agreement is rejected as provided in Title 11, the Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including, without limitation, a Title 11 Trustee) shall, at the election of the
Bankrupt Party made within sixty (60) days after the commencement of the case (or, if no such election is made, immediately upon the request of the non-Bankrupt Party) either (i) perform all of the obligations provided in this Agreement to be
performed by the Bankrupt Party including, where applicable and without limitation, providing to the non-Bankrupt Party portions of such intellectual property (including embodiments thereof) held by the Bankrupt Party and such successors and assigns
or otherwise available to them or (ii) provide to the non-Bankrupt Party all such intellectual property (including all embodiments thereof) held by the Bankrupt Party and such successors and assigns or otherwise available to them. 
  
 (b) If a Title 11 case is commenced by or against the Bankrupt Party and this
Agreement is rejected as provided in Title 11 and the non-Bankrupt Party elects to retain its rights hereunder as provided in Title 11, then the Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns
(including, without limitations, a Title 11 Trustee) shall provide to the non-Bankrupt Party all such intellectual property (including all embodiments thereof) held by the Bankrupt Party and such successors and assigns or otherwise available to them
immediately upon the non-Bankrupt Party’s written request therefor. Whenever the Bankrupt Party or any of its successors or assigns provides to the non-Bankrupt 
  

 -78- 

 Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 17.2(b),
the non-Bankrupt Party shall have the right to perform the obligations of the Bankrupt Party hereunder with respect to such intellectual property, including without limitation, the right to continue to prosecute and maintain Patents, but neither
such provision nor such performance by the non-Bankrupt Party shall release the Bankrupt Party from any such obligation or liability for failing to perform it. For purposes of clarification, all intellectual property provided to the non-Bankrupt
Party pursuant to the provisions of this Section 17.2(b) shall be subject to the licenses set forth elsewhere in this Agreement, but shall not be subject to the negative covenants of the non-Bankrupt Party set forth in Section 9.4 or 9.5, as the
case may be. 
  
 (c) All rights, powers and remedies of the
non-Bankrupt Party provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including, without limitation, Title 11) in the event of the commencement
of a Title 11 case by or against the Bankrupt Party. The non-Bankrupt Party, in addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such
remedies as may now or hereafter exist at law or in equity (including, without limitation, under Title 11) in such event. The Parties agree that they intend the foregoing non-Bankrupt Party rights to extend to the maximum extent permitted by law and
any provisions of applicable contracts with Third Parties, including without limitation for purposes of Title 11, (i) the right of access to any intellectual property (including all embodiments thereof) of the Bankrupt Party or any Third Party with
whom the Bankrupt Party contracts to perform an obligation of the Bankrupt Party under this Agreement, and, in the case of the Third Party, which is necessary for the development, registration and manufacture of licensed products and (ii) the right
to contract directly with any Third Party described in (i) in this sentence to complete the contracted work. Any intellectual property provided pursuant to the provisions of Section 17.2(b) shall be subject to the licenses set forth elsewhere in
this Agreement and the payment obligations of this Agreement, which shall be deemed to be royalties for purposes of Title 11. 
  
 17.3 Force Majeure. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such
performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming
Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, including without limitation, an act of God, voluntary or involuntary compliance with
any regulation, law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of facilities or materials by fire, earthquake, storm or like
catastrophe; provided, however, the payment of invoices due and owing hereunder shall not be delayed by the payer because of a force majeure affecting the payer. 
  
 17.4 Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall
specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes if mailed by first class certified or registered mail, postage 
  

 -79- 

 prepaid, express delivery service or personally delivered. Unless otherwise specified in writing, the mailing addresses
of the Parties shall be as described below. 
  

	 	For Syrrx:	Syrrx, Inc. 

 10410 Science Center Drive 
 San Diego, CA 92121 
 Fax: (858) 550-0526

 Attention: General Counsel 
  

	 	For PPD:	Development Partners, LLC 

 3151 South 17th Street

 Wilmington, NC 28412 
 Fax:
(910) 762-5820 
 Attention: President 
  

	 	With a copy to:	Pharmaceutical Product Development, Inc. 

 3151 South 17th
Street 
 Wilmington, NC 28412 
 Fax: (910) 762-5820 
 Attention: General Counsel 
  
 17.5 Consents Not Unreasonably Withheld or Delayed. Whenever provision is made in this Agreement for either Party to
secure the consent or approval of the other, that consent or approval shall not unreasonably be withheld or delayed, and whenever in this Agreement provisions are made for one Party to object to or disapprove a matter, such objection or disapproval
shall not unreasonably be exercised. 
  
 17.6 Maintenance of
Records. Each Party shall keep and maintain all records required by law or regulation with respect to Products and shall make copies of such records available to the other Party upon reasonable request. 
  
 17.7 United States Dollars. References in this Agreement to
“Dollars” or “$” shall mean the legal tender of the United States of America. 
  
 17.8 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party. 
  
 17.9 Assignment. Except as expressly provided herein, neither Party
may sell, assign, transfer, convey, license, sublicense, pledge, or otherwise dispose (collectively “assignment”) this Agreement, any rights or obligations under this Agreement, DP4 IP, Syrrx Technology, PPD Technology, PPD Information and
Syrrx Information, without the prior written consent of the other, which consent may be withheld in the consenting Party’s discretion; provided, however, (A) that a Party may make such an assignment without the other Party’s consent
to (i) an Affiliate, provided that such Affiliate agrees in writing to be bound by the terms and conditions of this Agreement and that the assigning Party remains liable for the full and complete performance of the obligations hereunder or (ii) in
conjunction with a Change of Control of such Party; and (B) either Party may sell, assign, transfer, convey, license, sublicense, pledge, or 
  

 -80- 

 otherwise dispose to a Third Party without the other Party’s consent any right to milestone payments, Product
Profits, Independent Profits, Licensing Revenues, Partnering Profits or other earned payments that may inure to that Party’s benefit pursuant to the terms of this Agreement, provided, however, that Syrrx may not exercise any right under this
Section 17.9(B) at any time that any Phase III Loan is outstanding unless the outstanding principal, accrued and unpaid interest and other sums due in owing under any outstanding Phase III Loan is repaid to PPD in conjunction with such exercise.
Any assignment or attempted assignment by either Party in violation of the terms of this Section 17.9 shall be null and void and of no legal effect.  
  

17.10 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
  
 17.11 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

  
 17.12 Severability. If any one or more of the
provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any
remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be
realized. 
  
 17.13 Ambiguities. Ambiguities, if any, in
this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 
  
 17.14 Headings. The headings for each article and section in this Agreement have been inserted for convenience of reference only and are not
intended to limit or expand on the meaning of the language contained in the particular article or section. 
  
 17.15 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other matter shall
not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. 
  
 17.16 Tax Treatment and Tax Structure Disclosure. Notwithstanding
anything herein to the contrary, any Party to this Agreement (and any employee, representative, or other agent of any Party to this Agreement) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure
of the transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to it relating to such tax treatment and tax structure; provided however, that such disclosure may
not be made to the extent a lack of disclosure is reasonably necessary to comply with any applicable federal or state securities laws. For the purposes of the foregoing sentence, (a) the “tax treatment” of a transaction means the purported
or claimed federal income tax treatment of the transaction, and (b) the “tax structure” of a transaction means any fact that may be relevant to understanding the purported or claimed federal income tax treatment of the transaction.

  

 -81- 

 17.17 No Use of Name. Except as set forth in Article 12 hereof, neither Party shall use in writing
the name of the other Party without the other Party’s written consent unless such writing simply refers to the existence of this Agreement or other information such concerning this Agreement that has been previously publicly disclosed.

  
 17.18 Performance Guarantee. 
  
 (a) PPD, Inc. hereby fully and unconditionally guarantees to Syrrx (i)
PPD’s performance of each and every one of its obligations under this Agreement, (ii) the performance of PPD Development LP, PPD Discovery, Inc. and each additional Affiliate of PPD that performs work pursuant to this Agreement, and (iii) with
respect to each Affiliate of PPD that receives Confidential Information of Syrrx pursuant to this Agreement, such Affiliates’ performance of Article 12. PPD, Inc. expressly waives any requirement that Syrrx exhaust any right, power or remedy or
proceed against PPD or any Affiliate of PPD for any obligation or performance hereunder. PPD, Inc. agrees to be bound by the provisions of Article 16. With the exception of the rights expressly granted to Syrrx in this Section 17.18(a), nothing
expressed or implied from this Section 17.18(a) is intended to or shall be construed to give to any person or entity other than Syrrx any legal or equitable rights, remedy or claim under or in respect of this Section 17.18(a), and this Section
17.18(a) is intended to be and is for the sole and exclusive benefit of Syrrx. No person or entity, other than Syrrx, is an intended third-party beneficiary of this Section 17.18(a) in any respect whatsoever. For clarity, the foregoing two sentences
shall not be interpreted as limiting the ability of any successor or permitted assign of Syrrx to exercise Syrrx’s rights pursuant to this Section 17.18(a). 
  
 (b) Syrrx hereby fully and unconditionally guarantees to PPD (i) the performance of each of its Affiliates that performs
work pursuant to this Agreement, and (ii) with respect to each Affiliate of Syrrx that receives Confidential Information of PPD pursuant to this Agreement, such Affiliate’s performance of Article 12. Syrrx expressly waives any requirement that
PPD exhaust any right, power or remedy or proceed against any Affiliate of Syrrx for any obligation or performance hereunder. With the exception of the rights expressly granted to PPD in this Section 17.18(b), nothing expressed or implied from this
Section 17.18(b) is intended to or shall be construed to give to any person or entity other than PPD any legal or equitable rights, remedy or claim under or in respect of this Section 17.18(b), and this Section 17.18(b) is intended to be and is for
the sole and exclusive benefit of PPD. No person or entity, other than PPD, is an intended third-party beneficiary of this Section 17.18(b) in any respect whatsoever. For clarity, the foregoing two sentences shall not be interpreted as limiting the
ability of any successor or permitted assign of PPD to exercise Syrrx’s rights pursuant to this Section 17.18(b). 
  
 17.19 Affiliates. 
  
 (a) PPD, Inc. agrees that it will not take, and will prohibit all Affiliates of PPD from taking, any action that PPD is prohibited from taking under this
Agreement as if PPD, Inc. and all Affiliates of PPD were parties to this Agreement. Except as expressly set forth herein, PPD Development LP, PPD Discovery, Inc., and all other Affiliates of PPD that perform one or 
  

 -82- 

 more obligations of PPD under this Agreement, or Control PPD Technology or PPD Existing Patent Rights, shall be governed
and bound by all provisions of this Agreement that employ the terms “PPD”, “Party” or “Parties,” including without limitation Sections 1.4, 1.17, 1.21, 1.52, 1.55, 1.78, 1.80, 1.82, 3.11, 8.2, 8.3, 9.1, 9.4, 10.1, 10.7,
11.1, 11.2, 14.1, 14.2, 14.7, 14.8, 15.1, and 17.2 and Articles 12 and 16. For clarity, the foregoing means that each occurrence of “PPD”, “Party” or “Parties” in this Agreement shall be understood as applying to PPD,
PPD Development LP, PPD Discovery, Inc., and all such other Affiliates of PPD that perform one or more obligations of PPD under this Agreement, or Control PPD Technology or PPD Existing Patent Rights. In addition, all Affiliates of PPD that receive
Confidential Information of Syrrx pursuant to this Agreement shall be governed and bound by all obligations set forth in Article 12. 
  
 (b) Syrrx agrees that it will not take, and will prohibit its Affiliates from taking, any action that Syrrx is prohibited from taking under this Agreement
as if Syrrx’s Affiliates were parties to this Agreement. Except as expressly set forth herein, all Affiliates of Syrrx that perform one or more obligations of Syrrx under this Agreement or Control Syrrx Technology or Syrrx Existing IP shall be
governed and bound by all provisions of this Agreement that employ the terms “Syrrx”, “Party” or “Parties,” including without limitation Sections 1.21, 1.52, 1.55, 1.100, 1.102, 1.104, 8.1, 8.4, 9.2, 9.5, 10.7, 11.1,
11.2, 14.1, 14.2, 14.3, 14.8, 15.1, and 17.2, and Articles 12 and 16. For clarity, the foregoing means that each occurrence of “Syrrx”, “Party” or “Parties” in this Agreement shall be understood as applying to both
Syrrx and such Affiliates of Syrrx. In addition, all Affiliates of Syrrx that receive Confidential Information of Syrrx pursuant to this Agreement shall be governed and bound by all obligations set forth in Article 12. 
  
 (c) PPD and Syrrx shall have the right to subcontract, in accordance with
Section 14.2, with an Affiliate for all or any part of that Party’s performance obligations under this Agreement.  
  
 IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their proper officers as of the date and year first above written.

  

 -83- 

									
	DEVELOPMENT PARTNERS, LLC	 	 	 	SYRRX, INC.
	 By: Applied Bioscience International Inc.,
 its Sole Manager
	 	 	 	 	 	 
					
	 By:
	 	  

	 	 	 	 By:
	 	  

	 Name:
	 	 Fredric N. Eshelman
	 	 	 	 Name:
	 	 Stephen W. Kaldor

	 Title:
	 	 President
	 	 	 	 Title:
	 	 President & CSO

	 Date:
	 	  

	 	 	 	 Date:
	 	  

  
 PPD, INC., by its signature
below, executes and delivers this Agreement to Syrrx for the sole and limited purpose of agreeing to be bound by the provisions of Sections 17.18 and 17.19. 
  

			
	PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
		
	 By:
	 	  

	 Name:
	 	 Fredric N. Eshelman

	 Title:
	 	 Chief Executive Officer

	 Date:
	 	  

  

 -84- 

  
 EXHIBIT A

  
 DETERMINATION OF CERTAIN ACCOUNTING TERMS

  
 “Product Profit” shall be determined in the
manner specified below and in Exhibit B. All amounts shall be determined in accordance with generally accepted accounting principles (“GAAP”), consistently applied. Except where the context requires otherwise, capitalized terms used but
not defined below shall have the meanings assigned to them in the Collaboration Agreement to which this Exhibit A is attached. 
  
 1. COST OF GOODS SOLD 
  
 1.1 “Cost of Goods Sold” means the cost of Collaboration Product shipped in either bulk or final
therapeutic form, as the Parties may then agree. As used herein, “cost” shall mean all direct material, direct labor, overhead attributable to the Collaboration Product. The costs of manufacturing shall be calculated in accordance with
cost accounting methods, consistently applied, of the Party performing the work. 
  
 Direct material costs shall include, but not be limited to, the costs incurred in purchasing raw materials, including sales and excise taxes imposed thereon and customs duty and charges levied by government
authorities, and all costs of packaging components. 
  
 Direct
labor shall include, but not be limited to, the cost of employees engaged in direct manufacturing activities who are directly employed in Collaboration Product manufacturing and packaging. 
  
 Overhead attributable to the Collaboration Product shall include allocations
of indirect labor, administration costs, and facilities costs including electricity, gas, water, sewer, waste disposal, property taxes, insurance, rent, maintenance, and depreciation over the expected life of buildings and machinery. Such
allocations shall be in accordance with cost accounting methods, consistently applied, of the Party performing the work. Overhead shall not include costs associated with capacity not incorporated into standard unit costs. Standard unit costs shall
exclude costs associated with excess capacity not directly related to Collaboration Products. 
  
 To the extent Collaboration Products are manufactured under arrangements with Third Parties, Costs of Goods Sold shall also include manufacturing variances and other attributable costs not in standard (but excluding
capacity not incorporated into standard manufacturing unit costs) such as, but not limited to, excess and obsolescence, inventory reserves, and batches that do not conform to specification to the extent within the limits to be established by the
Parties at the time manufacturing commences. 
  
 The cost of
Collaboration Product manufactured by Third Parties shall equal the Manufacturing Party’s actual costs therefor. 

 1.2 Excluded Costs. Notwithstanding the foregoing, Cost of Goods Sold shall exclude administrative
costs other than indirect manufacturing labor specifically attributable to the Collaboration Product being manufactured. Such excluded administrative costs shall be separately recovered under the category of Allocated Administrative Costs.

  
 2. COMMERCIALIZATION COSTS 
  
 Commercialization Costs shall be the sum of Selling Expenses, Marketing
Management, Market and Consumer Research, Advertising, Trade Promotion, Consumer Promotion, and Education, each of which is specified below, and all other costs which are generally consistent with the Commercialization Plan and attributable to the
sale, promotion or marketing of Collaboration Products. Allocating methodology to be used in accordance with this Section 2 shall be approved by the JOC. 
  
 2.1 “Selling Expenses” shall mean all costs and expenses directly associated with the efforts of field sales
representatives with respect to Collaboration Products, including field sales force (including field sales managers); field sales offices; home offices staffs directly involved in the management of and the performance of the selling functions; and
payments to Third Parties under co-promotion agreements approved by the Steering Committee. Field samples shall normally be charged to Trade Promotion, but if sales management has direct decision making authority for the distribution of field sales
samples, it may be appropriate to charge these costs to Selling Expenses. The costs of detailing sales calls shall be allocated based on field force time at an accounting charge rate consistently applied which is no less favorable to the
Collaboration Products than the internal charge rate used by the Lead Marketing Party for its own internal cost accounting purposes for products other than Collaboration Products (excluding internal profit margins and markups). 
  
 2.2 “Marketing Management” shall include
product management and sales promotion management compensation and departmental expenses, including product related public relations, relationships with opinion leaders and professional societies, health care economics studies, contract pricing and
administration, market information systems, governmental affairs activities for reimbursement, formulary acceptance and other activities directly related to the Collaboration Products, management and administration of managed care and national
accounts and other activities associated with developing overall sales and marketing strategies and planning for Collaboration Products. In addition, payments to Third Parties in connection with trademark selection, filing, prosecution and
enforcement shall be included in this category. Such costs may be allocated on a percent of sales or other basis consistently applied which is no less favorable to the Collaboration Products than the internal allocation for the Lead Marketing
Party’s other products. 
  
 2.3 “Market and
Consumer Research” shall include compensation and departmental expenses for market and consumer research personnel and payments to Third Parties related to conducting and monitoring professional and consumer appraisals of existing, new
or proposed Collaboration Products such as market share services (e.g., IMS data), special research testing and focus groups. Expenditures not directly related to a product may be allocated on a percent of sales or other basis consistently applied
which is no less favorable to the Collaboration Products than the internal allocation for Lead Marketing Party’s other products. 
  

 -2- 

 2.4 “Advertising” shall mean all costs incurred for the advertising and
promotion of Collaboration Products through any means, including, without limitation, (i) television and radio advertisements; (ii) advertisements appearing in journals, newspapers, magazines or other media; (iii) seminars and conventions; (iv)
packaging design; (v) professional education programs; (vi) samples, visual aids and other selling materials; (vii) hospital formulary committee presentations; (viii) presentations to state and other governmental formulary committees, and (ix) all
media costs associated with Collaboration Product advertising as follows: production expense/artwork including set up; design and art work for an advertisement; the cost of securing print space, air time, etc. in newspapers, magazines, trade
journals, television, radio, billboards, etc. 
  
 2.5
“Trade Promotion” shall include the allowances given to retailers, brokers, distributors, hospital buying groups, etc. for purchasing, promoting, and distribution of Collaboration Products. This shall include purchasing,
advertising, new distribution, and display allowances as well as free goods, wholesale allowances and field sales samples. To the extent multiple products are involved and some of such products are not Collaboration Products, then such allowances
shall be allocated on a pro rata basis based upon Net Sales of each respective product during the most recent quarter. 
  
 2.6 “Consumer Promotion” shall include the expenses associated with programs to promote Collaboration Products directly to
the end user. This category shall include expenses associated with promoting products directly to the professional community such as professional samples, professional literature, promotional material costs, patient aids and detailing aids. To the
extent multiple products are involved and some of such products are not Collaboration Products, then such allowances shall be allocated on a pro rata basis based upon Net Sales of each respective product during the most recent quarter.

  
 2.7 “Education” shall include
expenses associated with professional education with respect to Collaboration Products through any means not covered above, including articles appearing in journals, newspapers, magazines or other media; seminars, scientific exhibits, and
conventions; and symposia, advisory boards and opinion leader development activities. 
  
 3. DISTRIBUTION EXPENSES 
  
 Distribution Expenses shall be an amount equal to a percentage of Net Sales to be determined after the characteristics and anticipated price of the Collaboration Products have been determined. Such percentage shall be agreed upon by the
Parties in good faith, and shall be designed to approximate Lead Marketing Party’s cost of distributing such Products. 
  
 4. POST-LAUNCH PRODUCT R&D EXPENSES 
  
 Post-Launch Product R&D Expenses shall include certain research and development costs incurred by a Party in relation to
a Collaboration Product after the first commercial launch of such Collaboration Product and shall exclude administrative expenses and costs that are included within Costs of Goods Sold or Development Expenses. Such post-launch research and
development costs shall include: 
  
 4.1 Phase IIIb
Clinical Trials. 
  

 -3- 

 4.2 Phase IV Clinical Trials. 
  
 4.3 Ongoing product support. 
  

4.4 Ongoing medical affairs. 
  
 4.4 Preclinical research. 
  
 4.5 Contract R&D costs performed by others for a particular project that have no alternative future uses in other R&D projects or
otherwise. 
  
 4.6 Fees and expenses of outside counsel in
respect of regulatory affairs unrelated to obtaining Regulatory Approvals. 
  
 5. ALLOCATED ADMINISTRATION EXPENSES 
  
 The costs eligible for allocation as Allocated Administration Expenses shall include, but not be limited to the following: The direct costs of finance,
management information services, human resources and employees engaged in general management functions (excluding general corporate administration) for the operating units in question, including direct costs of employees performing administration
functions, the costs of supporting such individuals in the performance of their job (e.g., occupancy costs, travel, computers, and telephones), and outside services (e.g., consulting and audit services). Such costs shall be calculated in accordance
with the customary accounting methodology of the Party incurring such expenses, consistently applied throughout such organization. Such costs shall be allocated based on the total efforts of the Party (i.e. allocated to all projects which the
company undertakes including research and development, sales of products, general corporate matters, etc.) and shall exclude any excess capacity due to changes in the Party’s business operations. Cost categories included within Allocated
Administration Expenses shall not be included in any other cost recoverable under this Agreement. 
  
 The Parties shall mutually agree upon a fixed percentage of Net Sales to cover the expected Allocated Administration Expenses. 
  
 6. CURRENCY GAINS OR LOSSES

  
 Currency Gains or Losses shall include the following:

  
 6.1 Unhedged Transactions. Transaction gains or losses
resulting from a change in exchange rates between the functional currency and the currency in which the transaction is denominated. The transaction gain or loss is determined by measuring the increase or decrease 
  

 -4- 

 in the functional currency cash flow due to the changes in the exchange rate from the date of the transaction to the
settlement date. The difference between the functional currency amount calculated using the current exchange rate at the transaction date and the amount calculated using the currency exchange rate at the settlement date is the transaction gain or
loss. Transaction gains or losses on unsettled foreign currency transactions are also reported in this manner. When there is a balance sheet date between the transaction date and settlement date, the gain or loss on the unsettled balance shall be
measured using the current exchange rate at the balance sheet date. 
  
 6.2 Hedged Transactions. For purposes of this collaboration, neither Party shall buy or sell forward, directly or indirectly, foreign currencies in amounts greater than those which can reasonably be expected to be received or paid,
as the case may be, over the relevant time period. If a Party enters into a hedged transaction, the gain or loss realized from the hedge must be included in the underlying transaction. If the currency transaction gain or loss has been included in
Net Sales, inventories, Costs of Goods Sold, etc., it shall not be included in this category. Hedging transactions shall be included in any Commercialization Plan and shall be approved by the JOC. 
  
 7. CALCULATION OF THE COST
OF CAPITAL ALLOWANCE. “Cost of Capital Allowance” means the amount recoverable by either Party under this Agreement for the use of its Utilized Capital allocated to the
Commercialization of the Collaboration Products after the first commercial launch of a Collaboration Product. The JOC shall establish a cost of capital rate to be utilized by both Party’s which shall be designed to reflect a reasonable rate of
return on capital employed for the current market conditions. “Utilized Capital” means the amount of the Parties’ capital specifically Attributable to the support of a particular Collaboration Product following the first
commercial launch of such Collaboration Product, and shall consist of for each Party the then current net book value (i.e., original cost less accumulated depreciation) of facility and equipment utilized specifically in respect of such support
activities. If the facility and equipment of a Party are utilized in connection with the support of a Collaboration Product but such facility and equipment were not built or acquired specifically for such products, then the Party in question shall
be entitled to include as an element of Utilized Capital an amount equal to the book value of such facility and equipment as of the relevant dates after the first commercial launch multiplied by the percentage of total use of such facility,
excluding excess capacity during such quarter for support of the Collaboration Products. The Parties shall attempt to agree upon a fixed percentage of Net Sales to cover the expected Cost of Capital Allowance. 
  
 8. REGULATORY
EXPENSES 
  
 “Regulatory Expenses” shall mean all costs incurred to comply with all Regulatory Approvals and all regulatory agencies, including FDA user and other fees, reporting, and other regulatory
affairs activities. 
  

 -5- 

 9. ALLOCATION OF COSTS. The following guidelines shall
be used to allocate costs to the Collaboration Products: 
  
 (a) If the expense
is specifically and exclusively used for the Commercialization of a Collaboration Product, 100% of such expense shall be an Allowable Expense. 
  
 (b) If the expense is not specifically and exclusively used for the Commercialization of a Collaboration Product (i.e., for other products of Lead Marketing Party), it
shall be allocated based on objective means (such as man-hours or amounts consumed) as determined by the JOC. 
  
 (c) No item of cost shall be duplicated in any of the categories comprising Allowance Expenses. 
  

 -6- 

 EXHIBIT B 
  
 FINANCIAL STATEMENT FORMAT 
  

					
	 	  	 Total
 DP-4
 Product
 Line
 P(L)

	  	 % Net
 Sales

	 Gross Sales
	  	 	  	 
			
	 Less:
	  	 	  	 
	 Transportation Charges
	  	 	  	 
	 Credits & Allowances
	  	 	  	 
	 Taxes & Duties
	  	 	  	 
			
	 Net Sales
	  	 	  	 
			
	 Cost of Goods Sold:
	  	 	  	 
	 Standard Material Cost
	  	 	  	 
	 Standard Direct Labor Costs
	  	 	  	 
	 Standard Overhead Costs
	  	 	  	 
	 Manufacturing Variances (with detail)
	  	 	  	 
	 Total Cost of Goods Sold
	  	 	  	 
			
	 Gross Profit
	  	 	  	 
			
	 Commercialization Costs:
	  	 	  	 
	 Selling Expenses (including provisions for uncollectible accounts)
	  	 	  	 
	 Marketing Management
	  	 	  	 
	 Market & Consumer Research
	  	 	  	 
	 Advertising
	  	 	  	 
	 Trade Promotion
	  	 	  	 
	 Consumer Promotion
	  	 	  	 
	 Education
	  	 	  	 
	 Other
	  	 	  	 
	 Total Commercialization Costs
	  	 	  	 
			
	 Total Distribution Expenses
	  	 	  	 
			
	 Post-Launch Product R&D Expenses:
	  	 	  	 
	 Phase IV Clinical Trials
	  	 	  	 
	 Product Support
	  	 	  	 
	 Medical Affairs
	  	 	  	 
	 Preclinical Research
	  	 	  	 
	 Other Contract R&D
	  	 	  	 
	 Total Post-Launch Product R&D Expenses
	  	 	  	 
			
	 Allocated Administration Expenses:
	  	 	  	 
			
	 Patent Expenses
	  	 	  	 

					
	 Currency Gains (Losses):
	  	 	  	 
	 Unhedged Transactions
	  	 	  	 
	 Hedged Transactions
	  	 	  	 
	 Total Currency Gains (Losses)
	  	 	  	 
			
	 Cost of Capital Allowance:
	  	 	  	 
	 Utilized Capital:
	  	 	  	 
	 Book Value of Capital Expenditures
	  	 	  	 
			
	 Cost of Capital (%) (A)
	  	 	  	 
			
	 Total Cost of Capital Allowance
	  	 	  	 
			
	 Net Sublicense Revenues
	  	 	  	 
			
	 Product Profits (Losses)
	  	 	  	 
			
	 Equalization Receipt (Payment)
	  	 	  	 
			
	 Balance After Equalization
	  	 	  	 

  

 -2-UNIT SUBSCRIPTION AGREEMENT

 Exhibit 10.1 
  
 LIGHTPATH TECHNOLOGIES, INC. 
  

UNIT SUBSCRIPTION AGREEMENT 
 COMMON STOCK 
 AND WARRANTS 
  
 UNIT SUBSCRIPTION AGREEMENT (the “Agreement”) dated as of February 20, 2004 among LIGHTPATH TECHNOLOGIES, INC., a Delaware corporation
(the “Company”), and the persons who execute this agreement as investors (the “Investors”). 
  
 Background: The Company desires to sell to the Investors, and the Investors desire to purchase, for an aggregate price of $1,952,500, an aggregate of 550,000
shares (the “Shares”) of Common Stock in Units with 5-year warrants, in substantially the form attached hereto as Exhibit 1, exercisable to purchase an aggregate of 110,000 shares of Common Stock at $4.30 per share (the
“Warrants”). The proceeds are necessary for the development and continuance of the business of the Company and each of its Subsidiaries. 
  
 Certain Definitions: 
  
 “Common Stock” shall mean stock of the Company of any class (however designated) whether now or hereafter authorized, which generally has
the right to participate in the voting and in the distribution of earnings and assets of the Company without limit as to amount or percentage, including the Company’s Class A Common Stock, $.01 par value per share. 
  
 “Company” includes the Company and any corporation or other
entity which shall succeed to or assume, directly or indirectly, the obligations of the Company hereunder. The term “corporation” shall include an association, joint stock company, business trust, limited liability company or other
similar organization. 
  
 “Company Disclosure
Letter” means the disclosure letter delivered to the Investors prior to the execution of this Agreement, which letter is incorporated in this Agreement. 
  
 “Material Adverse Change” shall mean a material adverse change in the business, financial condition,
results of operation, prospects, properties or operations of the Company and its Subsidiaries taken as a whole. 
  
 “Own” means own beneficially, as that term is defined in the rules and regulations of the SEC. 
  
 “Person” means any individual, sole proprietorship,
partnership, corporation, limited liability company, business trust, unincorporated association, joint stock corporation, trust, joint venture or other entity, any university or similar institution, or any government or any agency or instrumentality
or political subdivision thereof. 

 “SEC” means the Securities and Exchange Commission. 
  
 “Subsidiary” shall mean any corporation of which stock or
other interest having ordinary power to elect a majority of the Board of Directors (or other governing body) of such entity (regardless of whether or not at the time stock or interests of any other class or classes of such corporation shall have or
may have voting power by reason of the happening of any contingency) is at the time directly or indirectly owned by the Company or by one or more Subsidiaries. 
  

“Underlying Shares” shall mean the shares of Common Stock issued or from time to time issuable upon exercise of the Warrants.

  
 “Unit” shall mean (i) 10,000 Shares and (ii)
Warrants to purchase 2,000 shares of Common Stock. 
  
 In
consideration of the mutual covenants contained herein, the parties agree as follows: 
  
 1. Purchase and Sale of Stock. 
  
 1.1. Sale and Issuance of Securities. (a) The Company shall sell to the Investors and the Investors shall purchase from the Company, 55 units (the “Units”) at a price per Unit equal to
$35,500.00, or a total of (x) 550,000 Shares (the “Purchased Shares”) and (y) Warrants to purchase an aggregate of 110,000 shares of Common Stock (the “Purchased Warrants” and collectively with the Purchased Shares,
the “Securities”), for an aggregate purchase price of $1,952,500.00. 
  
 (b) The number of Purchased Shares and Purchased Warrants to be purchased by each Investor from the Company is set forth on Schedule
1.1(b) hereto, subject to acceptance, in whole or in part, by the Company. 
  
 1.2. Closing. The closing (the ”Closing”) of the purchase and sale of the Securities hereunder shall take place within three business days of the date of this Agreement or such other date
within ten business days of this Agreement as agreed to by the Company and Investors who subscribe for at least 33 Units (the “Closing Date”). The Closing shall take place at the offices of Hahn & Hessen LLP, the Investors’
counsel, in New York, New York, or at such other location as is mutually acceptable to the Investors and the Company, subject to fulfillment of the conditions of closing set forth in the Agreement. At the Closing: 
  
 (a) each Investor purchasing Securities at the Closing shall
deliver to the Company or its designees by wire transfer or such other method of payment as the Company shall approve, an amount equal to the purchase price of the Securities purchased by such Investor hereunder, as set forth opposite such
Investor’s name on the signature pages hereof. 

 (b) the Company shall authorize its transfer agent (the “Transfer Agent”) to
arrange delivery to each Investor of one or more stock certificates registered in the name of the Investor, or in such nominee name(s) as designated by the Investor in writing, representing the number of Shares equal to 10,000 multiplied by the
number of Units purchased by the Investor. 
  
 (c) the Company shall issue and deliver to each Investor purchasing Securities at the Closing Warrants equal to 2,000 multiplied by the number of Units purchased. 
  
 (d) The Company shall wire the Legal Fee to Hahn & Hessen LLP in accordance with instructions provided
by Hahn & Hessen LLP. 
  
 1.3. Conditions
of Closing. The obligation of the Investors to complete the purchase of the Securities at the Closing is subject to fulfillment of the following conditions: 
  
 (a) the Company and the Investors shall execute and deliver an Investor Rights Agreement, dated the Closing
Date, in the form attached as Exhibit 2 with respect to the Purchased Shares and the Underlying Shares (the “Investor Rights Agreement” and with the Agreement and the Warrants, the “Transaction Documents”);

  
 (b) the Company shall deliver to the
Investors an Opinion of Counsel, dated the Closing Date and reasonably satisfactory to counsel for the Investors, with respect to the matters set forth on Exhibit 4; 
  
 (c) the representation and warranties of the Company set forth in this Agreement shall be true and correct
as of the date of this Agreement and (except to the extent such representations and warranties speak as of an earlier date) as of the Closing Date as though made on and as of the Closing Date, and the Company shall have performed in all material
respects all covenants and other obligations required to be performed by it under this Agreement at or prior to the Closing Date, and the Investors shall have received a certificate signed on behalf of the Company by the President and Secretary of
the Company, in such capacities, to such effect (the “Closing Certificate”); 
  
 (d) the Company shall have executed and delivered all other documents reasonably requested by counsel for the Investors that are necessary
to complete the contemplated transactions; 
  
 (e) All Securities delivered at the Closing shall have all necessary stock transfer tax stamps (purchased at the expense of the Company) affixed; and 
  

(f) the Company shall pay the Legal Fee as set forth in Section 6.9 hereof. 

 (g) the Company shall deliver to Investors a certified copy of its Certificate of
Incorporation and by-laws and a Certificate of Good Standing from the Secretary of State of the State of Delaware. 
  
 2. Representations and Warranties of the Company. The Company hereby represents and warrants to each of the Investors as follows: 
  
 2.1. Corporate Organization; Authority; Due
Authorization. 
  
 (a) The Company (i) is a
corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, (ii) has the corporate power and authority to own or lease its properties as and in the places where such business is now
conducted and to carry on its business as now conducted and (iii) is duly qualified as a foreign corporation authorized to do business in every jurisdiction where the failure to so qualify, individually or in the aggregate, would have a material
adverse effect on the operations, prospects, assets, liabilities, financial condition or business of the Company (a “Material Adverse Effect”). Set forth in the Company Disclosure Letter is a complete and correct list of all
Subsidiaries. Each Subsidiary is duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation and is qualified to do business as a foreign corporation in each jurisdiction in which qualification is
required, except where failure to so qualify would not have a Material Adverse Effect. 
  
 (b) The Company (i) has the requisite corporate power and authority to execute, deliver and perform this Agreement and the other
Transaction Documents to which it is a party and to incur the obligations herein and therein and (ii) has been authorized by all necessary corporate action to execute, deliver and perform this Agreement and the other Transaction Documents to which
it is a party and to consummate the transactions contemplated hereby and thereby (the “Contemplated Transactions”). Each of this Agreement and the other Transaction Documents is a valid and binding obligation of the Company
enforceable in accordance with its terms except as limited by applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting the enforcement of creditors’ rights and the availability of equitable remedies (regardless of
whether such enforceability is considered in a proceeding at law or equity). 
  
 2.2. Capitalization. As of February 20, 2004, the authorized capital stock of the Company consisted of (i) 40,000,000 shares of Common Stock, $.01 par value, all of which are designated as Class A Common Stock,
and of which 2,817,284 shares are outstanding and (ii) 5,000,000 shares of Preferred Stock, $.01 par value, of which 100,000 shares are designated as Series D Participating Preferred Stock, and of which no shares are outstanding. All outstanding
shares were issued in compliance with all applicable Federal and state securities laws, and the issuance of such shares was duly authorized. Except as contemplated by this Agreement or as set forth in the Company Disclosure Letter, there are

 (i) no outstanding subscriptions, warrants, options, conversion privileges or other rights or agreements
obligating the Company to purchase or otherwise acquire or issue any shares of capital stock of the Company (or shares reserved for such purpose), (ii) no preemptive rights contained in the Company’s Certificate of Incorporation, as amended
(the “Certificate of Incorporation”), By-Laws of the Company or contracts to which the Company is a party or rights of first refusal with respect to the issuance of additional shares of capital stock of the Company (other than as
set forth in the Investor Rights Agreement), including without limitation the Securities and the Underlying Shares, and (iii) no commitments or understandings (oral or written) of the Company to issue any shares, warrants, options or other rights.
Except as set forth in the Company Disclosure Letter, none of the shares of Common Stock are subject to any stockholders’ agreement, voting trust agreement or similar arrangement or understanding. Except as set forth in the Company Disclosure
Letter, the Company has no outstanding bonds, debentures, notes or other obligations the holders of which have the right to vote (or which are convertible into or exercisable for securities having the right to vote) with the stockholders of the
Company on any matter. With respect to each Subsidiary, (i) all the issued and outstanding shares of the Subsidiary’s capital stock have been duly authorized and validly issued, are fully paid and nonassessable, have been issued in compliance
with applicable federal and state securities laws, were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities, and (ii) except as disclosed in the Company Disclosure Letter, there are
no outstanding options to purchase, or any preemptive rights or other rights to subscribe for or to purchase, any securities or obligations convertible into, or any contracts or commitments to issue or sell, shares of the Subsidiary’s capital
stock or any such options, rights, convertible securities or obligations. Except as disclosed in the Company Disclosure Letter, the Company owns 100% of the outstanding equity of each Subsidiary. 
  
 2.3. Validity of Securities. The issuance of the
Securities has been duly authorized by all necessary corporate action on the part of the Company and, when issued to, delivered to, and paid for by the Investors in accordance with this Agreement, the Purchased Shares will be validly issued, fully
paid and non-assessable. 
  
 2.4. Underlying
Shares. The issuance of the Underlying Shares upon exercise of the Purchased Warrants has been duly authorized, and the Underlying Shares have been, and at all times prior to such exercise will have been, duly reserved for issuance upon such
exercise and, when so issued, will be validly issued, fully paid and non-assessable. 
  
 2.5. Private Offering. Neither the Company nor anyone acting on its behalf has within the last 12 months issued, sold or offered
any security of the Company (including, without limitation, any Common Stock or warrants of similar tenor to the Purchased Warrants) to any Person under circumstances that would cause the issuance and sale of the Securities, as contemplated by this
Agreement, to be subject to the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company agrees that neither the Company nor anyone acting on its behalf will offer the Securities or any
part thereof or any similar securities for issuance or sale to, or solicit any offer to acquire any of the same from, anyone so as to make the issuance and sale of the Securities subject to the registration requirements of Section 5 of the
Securities Act. 

 2.6. Brokers and Finders. The Company has not retained any investment banker,
broker or finder in connection with the Contemplated Transactions. 
  
 2.7. No Conflict; Required Filings and Consents. 
  
 (a) The execution, delivery and performance of this Agreement and the other Transaction Documents by the Company do not, and the
consummation by the Company of the Contemplated Transactions will not, (i) conflict with or violate the Certificate of Incorporation or By-Laws of the Company or such Subsidiaries, (ii) conflict with or violate any law, rule, regulation, order,
judgment or decree applicable to the Company or its Subsidiaries or by which any property or asset of the Company or its Subsidiaries is bound or affected, or (iii) result in any breach of or constitute a default (or an event which with notice or
lapse of time or both would become a default) under, result in the loss of a material benefit under, or give to others any right of purchase or sale, or any right of termination, amendment, acceleration, increased payments or cancellation of, or
result in the creation of a lien or other encumbrance on any property or asset of the Company or of any of its Subsidiaries pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument
or obligation to which the Company or any of its Subsidiaries is a party or by which the Company or of any of its Subsidiaries or any property or asset of the Company or of any of its Subsidiaries is bound or affected; except, in the case of clauses
(ii) and (iii) above, for any such conflicts, violations, breaches, defaults or other occurrences which would not prevent or delay consummation of any of the Contemplated Transactions in any material respect or otherwise prevent the Company from
performing its obligations under this Agreement or any of the other Transaction Documents in any material respect, and would not, individually or in the aggregate, have a Material Adverse Effect. 
  
 (b) The execution and delivery of this Agreement and the
other Transaction Documents by the Company do not, and the performance of this Agreement and the other Transaction Documents and the consummation by the Company of the Contemplated Transactions will not, require any consent, approval, authorization
or permit of, or filing with or notification to, any Governmental Body (as hereinafter defined) except for the filing of a Form D with the Securities and Exchange Commission and applicable requirements, if any, of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) or any state securities or “blue sky” laws (“Blue Sky Laws”), and any approval required by applicable rules of the markets in which the Company’s securities are
traded. For purposes of this Agreement, “Governmental Body” shall mean any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local,
municipal, foreign or other government; or (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, instrumentality, official, organization, unit, body or entity and any
court or other tribunal). Without limitation on the foregoing, the consummation of the Contemplated Transactions does not require the approval of The Nasdaq Stock Market (or any related regulatory body) or the stockholders of the Company.

 2.8. Compliance. Except as set forth in the Company Disclosure Letter, neither the
Company nor any Subsidiary is in conflict with, or in default or violation of (i) any law, rule, regulation, order, judgment or decree applicable to the Company or such subsidiary or by which any property or asset of the Company or such subsidiary
is bound or affected (“Legal Requirement”), or (ii) any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation to which the Company or such subsidiary is a party or
by which the Company or such subsidiary or any property or asset of the Company or such subsidiary is bound or affected (the “Material Agreements”), in each case except for any such conflicts, defaults or violations that would not,
individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor any Subsidiary has received any written notice or other communication from any Governmental Body regarding any actual or possible violation of, or failure to
comply with, any Legal Requirement. 
  
 2.9.
SEC Documents; Financial Statements. 
  
 (a) The information contained in the following documents, did not, as of the date of the applicable document, include any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances in which they were made, not misleading, as of their respective filing dates or, if amended, as so amended (the following documents, collectively, the “SEC Documents”),
provided that the representation in this sentence shall not apply to any misstatement or omission in any SEC Document filed prior to the date of this Agreement which was superseded by a subsequent SEC Document filed prior to the date of this
Agreement: 
  
 (i) the Company’s Annual
Report on Form 10-K for the year ended June 30, 2003; 
  
 (ii) the Company’s definitive Proxy Statement with respect to its 2003 Special Meeting of Stockholders, filed with the Commission on October 10, 2003; 
  
 (iii) the Company’s Quarterly Reports on Form 10-Q for the quarters ended September 30, 2003 and
December 31, 2003; and 
  
 (iv) the
Company’s Current Reports on Form 8-K, filed with the Commission on October 2, 2003, November 17, 2003, January 7, 2004, January 9, 2004, January 22, 2004 and February 18, 2004. 
  
 (b) In addition, as of the date of this Agreement, the Company Disclosure Letter, when read together with
the information, qualifications and exceptions contained in this Agreement, does not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances in
which they were made, not misleading. 

 (c) To its knowledge, the Company has filed all forms, reports and documents required to
be filed by it with the SEC since June 30, 2001, including without limitation the SEC Documents, except where the failure to so file could not reasonably be expected to result in a Material Adverse Effect. As of their respective dates, the SEC
Documents filed prior to the date hereof complied as to form in all material respects with the applicable requirements of the Securities Act, the Exchange Act, and the rules and regulations thereunder. 
  
 (d) The Company’s Annual Report on Form 10-K for the
year ended June 30, 2003, includes consolidated balance sheets as of June 30, 2002 and 2003 and consolidated statements of income for the one year periods then ended (collectively, the “Form 10-K Financial Statements”). 

 
 (e) The Company’s Quarterly Report on Form 10-Q for
the quarter ended December 31, 2003, includes consolidated balance sheets as of June 30, 2003 and December 31, 2003 and consolidated statements of income for the quarters ended December 31, 2002 and 2003 (the “December 31 Form 10-Q Financial
Statements”, and together with the “Form 10-K Financial Statements,” the “Financial Statements”). 
  
 (f) The Financial Statements (including the related notes and schedules thereto and all other financial information included in the SEC
Documents) fairly present in all material respects the consolidated financial position, the results of operations, retained earnings or cash flows, as the case may be, of the Company for the periods set forth therein (subject, in the case of
unaudited statements, to normal year-end audit adjustments that would not be material in amount or effect), in each case in accordance with generally accepted accounting principles consistently applied during the periods involved, except as may be
noted therein. 
  
 2.10. Litigation.
Except as set forth in the SEC Documents or the Company Disclosure Letter, there are no claims, actions, suits, investigations, inquiries or proceedings (each, an “Action”) pending against the Company or any of its Subsidiaries or,
to the knowledge of the Company, threatened against the Company or any of its Subsidiaries, at law or in equity, or before or by any court, tribunal, arbitrator, mediator or any federal or state commission, board, bureau, agency or instrumentality,
that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party to or subject to the provisions of any order, writ, injunction, judgment or decree of
any court or government agency or instrumentality. 
  
 2.11. Absence of Certain Changes. Except as specifically contemplated by this Agreement or set forth in the Company Disclosure Letter, the SEC Documents, or the Financial Statements, since December 31, 2003, there has not been (i)
any Material Adverse 

 Change; (ii) any return of any capital or other distribution of assets to stockholders of Company (except
to Company); (iii) any acquisition (by merger, consolidation, acquisition of stock and/or assets or otherwise) of any Person; or (iv) any transactions, other than in the ordinary course of business, consistent with past practices and reasonable
business operations (“Ordinary Course of Business”), with any of its officers, directors, principal stockholders or employees or any Person affiliated with any of such persons. 
  
 2.12. Proprietary Assets. 
  
 (a) For purposes of this Agreement, “Proprietary
Assets” shall mean all right, title and interest of the Company and the Subsidiaries in and to the following items or types of property: (i) every patent, patent application, trademark (whether registered or unregistered), trademark
application, trade name, fictitious business name, service mark (whether registered or unregistered), service mark application, copyright (whether registered or unregistered), copyright application, maskwork, maskwork application, trade secret,
know-how, customer list, franchise, system, computer software, computer program, invention, design, blueprint, engineering drawing, proprietary product, technology, proprietary right or other intellectual property right or intangible asset; and (ii)
all licenses and other rights to use or exploit any of the foregoing. 
  
 (b) The Company Disclosure Letter sets forth, with respect to each Proprietary Asset of the Company and the Subsidiaries registered with any Governmental Body in the U.S., or for which an application has been filed
with any Governmental Body in the U.S., (i) a brief description of such Proprietary Asset and (ii) the names of the jurisdictions covered by the applicable registration or application. The Company Disclosure Letter identifies and provides a brief
description of all other material Proprietary Assets owned by the Company and its Subsidiaries, and identifies and provides a brief description of each material Proprietary Asset, or source code version of any software licensed to the Company or any
Subsidiary by any Person (except for any Proprietary Asset that is licensed to the Company or any Subsidiary under any third party software license generally available to the public at a cost of less than $10,000), and identifies such license
agreement under which such Proprietary Asset is being licensed to the Company or any Subsidiary. Except as set forth in the Company Disclosure Letter, the Company or its Subsidiaries have good, valid and marketable title to each of the Proprietary
Assets identified in the Company Disclosure Letter as owned by it, free and clear of all liens and other encumbrances); has a valid right to use all Proprietary Assets of third parties identified in the Company Disclosure Letter; and is not
obligated to make any payment to any Person for the use of any Proprietary Asset except as set forth in the applicable license agreement. Except as set forth in the Company Disclosure Letter, neither the Company nor any of its Subsidiaries has
developed jointly with any other Person any material Proprietary Asset with respect to which such other Person has any rights. 

 (c) Each of the Company and its Subsidiaries has taken commercially reasonable and
customary measures and precautions to protect and maintain the confidentiality and secrecy of all Proprietary Assets of the Company and its Subsidiaries (except Proprietary Assets whose value would be unimpaired by public disclosure) and otherwise
to maintain and protect the value of all Proprietary Assets of the Company and its Subsidiaries. Except as set forth in the Company Disclosure Letter, neither the Company nor any of its Subsidiaries has (other than pursuant to license agreements
identified in the Company Disclosure Letter) disclosed or delivered to any Person, or permitted the disclosure or delivery to any Person of, (i) the source code, or any portion or aspect of the source code, of any Proprietary Asset, (ii) the object
code, or any portion or aspect of the object code, of any Proprietary Asset of the Company and its Subsidiaries, except in the ordinary course of its business or (iii) any patent applications (except as required by law). 
  
 (d) To the knowledge of the Company, (i) none of the
Proprietary Assets of the Company and its Subsidiaries infringes or conflicts with any Proprietary Asset owned or used by any other Person; (ii) neither the Company nor any Subsidiary is infringing, misappropriating or making any unlawful use of any
Proprietary Asset owned or used by any other Person; and (iii) no other Person is infringing, misappropriating or making any unlawful use of, and no Proprietary Asset owned or used by any other Person infringes or conflicts with, any Proprietary
Asset of the Company or any of its Subsidiaries. 
  
 (e) Except as set forth in the Company Disclosure Letter, excluding warranty claims received by Company or any of its Subsidiaries in the ordinary course of business, there has not been any claim by any customer or other Person alleging
that any Proprietary Asset of the Company or any of its Subsidiaries (including each version thereof that has ever been licensed or otherwise made available by the Company to any Person) does not conform in all material respects with any
specification, documentation, performance standard, representation or statement made or provided by or on behalf of the Company. 
  
 (f) To the knowledge of the Company, the Proprietary Assets of the Company and its Subsidiaries constitute all the Proprietary Assets
necessary to enable the Company and its Subsidiaries to conduct their respective businesses in the manner in which such businesses have been and are being conducted. Except as set forth in the Company Disclosure Letter (i) neither the Company nor
any Subsidiary has licensed any of its Proprietary Assets to any Person on an exclusive, semi-exclusive or royalty-free basis, and (ii) neither the Company nor any Subsidiary has entered into any covenant not to compete or contract limiting such
entity’s ability to exploit fully any of such entity’s material Proprietary Assets or to transact business in any material market or geographical area or with any Person. 
  
 (g) Except as set forth in the Company Disclosure Letter,
neither the Company nor any of its Subsidiaries has at any time received any notice or other communication (in writing or otherwise) of any actual, alleged, possible or potential infringement, misappropriation or unlawful use of, any Proprietary
Asset owned or used by any other Person. 

 2.13. No Adverse Actions. Except as set forth in the Company Disclosure Letter,
there is no existing, pending or, to the knowledge of the Company, threatened termination, cancellation, limitation, modification or change in the business relationship of the Company or any of its Subsidiaries, with any supplier, customer or other
Person except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 
  
 2.14. Registration Rights. Except as set forth in the Investor Rights Agreement, the SEC Documents, or in the Company Disclosure
Letter, the Company is not under any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities nor is the Company
obligated to register or qualify any such securities under any state securities or blue sky laws. 
  
 2.15. Corporate Documents. The Company’s Certificate of Incorporation and Bylaws, each as amended to date, which have been
requested and previously provided to the Investors are true, correct and complete and contain all amendments thereto. 
  
 2.16. Disclosure. No representation or warranty of the Company herein, no exhibit or schedule hereto, and no information contained
or referenced in the SEC Documents, when read together, contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact necessary in order to make the statements contained herein or therein, in light
of the circumstances under which they were made, not misleading. On or before 9:00 a.m., New York City Time, on the third business day after the Closing, the Company shall file a Current Report on Form 8-K describing the material terms of the
transactions contemplated by this Agreement, and disclosing such portions of the Transaction Documents as contain material nonpublic information with respect to the Company that has not previously been publicly disclosed by the Company, and
attaching as an exhibit to such Form 8-K a form of this Agreement. Except for information that may be provided to the Investors pursuant to this Agreement, the Company shall not, and shall use commercially reasonable efforts to cause each of its
officers, directors, employees and agents not to, provide any Investor with any material nonpublic information regarding the Company from and after the filing of such Form 8-K without the express written consent of such Investor. 
  
 2.17. Use of Proceeds. The net proceeds received by
the Company from the sale of the Securities shall be used by the Company for working capital and general corporate purposes, including without limitation to support the operations of each of the Subsidiaries. 

 3. Representations and Warranties of the Investors. Each Investor represents and warrants to the
Company as follows: 
  
 3.1.
Authorization. Such Investor (i) has full power and authority to execute, deliver and perform this Agreement and the other Transaction Documents to which it is a party and to incur the obligations herein and therein and (ii) if applicable has
been authorized by all necessary corporate or equivalent action to execute, deliver and perform this Agreement and the other Transaction Documents and to consummate the Contemplated Transactions. Each of this Agreement and the other Transaction
Documents is a valid and binding obligation of such Investor enforceable in accordance with its terms, except as limited by applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting the enforcement of creditors’
rights and the availability of equitable remedies (regardless of whether such enforceability is considered in a proceeding at law or equity). 
  
 3.2. Brokers and Finders. Such Investor has not retained any investment banker, broker or finder in connection with the
Contemplated Transactions. 
  
 4. Securities Laws.

  
 4.1. Securities Laws Representations and
Covenants of Investors. 
  
 (a) This
Agreement is made with each Investor in reliance upon such Investor’s representation to the Company, which by such Investor’s execution of this Agreement such Investor hereby confirms, that the Securities to be received by such Investor
will be acquired for investment for such Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof such that such Investors would constitute an “underwriter” under the
Securities Act; provided that this representation and warranty shall not limit the Investor’s right to sell the Underlying Shares pursuant to the Investor Rights Agreement or in compliance with an exemption from registration under the
Securities Act or the Investor’s right to indemnification under this Agreement or the Investor Rights Agreement. 
  
 (b) Each Investor understands and acknowledges that the offering of the Securities pursuant to this Agreement will not be registered under
the Securities Act or qualified under any Blue Sky Laws on the grounds that the offering and sale of the Securities are exempt from registration and qualification, respectively, under the Securities Act and the Blue Sky Laws. 
  
 (c) Each Investor covenants that, unless the Purchased
Shares, the Purchased Warrants, the Underlying Shares or any other shares of capital stock of the Company received in respect of the foregoing have been registered pursuant to the Investor Rights Agreement being entered into among the Company and
the Investors, such Investor will not dispose of such securities unless and until such Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with an opinion of counsel reasonably satisfactory in
form and substance to the Company to the effect that (x) such disposition will not require registration under the Securities Act and (y) appropriate action necessary for 

 compliance with the Securities Act and any applicable state, local or foreign law has been taken;
provided, however, that an Investor may dispose of such securities without providing the opinion referred to above if the Company has been provided with adequate assurance that such disposition has been made in compliance with Rule 144
under the Securities Act (or any similar rule). 
  
 (d) Each Investor represents that (i) such Investor is able to fend for itself in the Contemplated Transactions; (ii) such Investor has such knowledge and experience in financial and business matters as to be capable of evaluating the
merits and risks of such Investor’s prospective investment in the Securities; (iii) such Investor has the ability to bear the economic risks of such Investor’s prospective investment and can afford the complete loss of such investment;
(iv) such Investor has been furnished with and has had access to such information as is in the Company Disclosure Letter together with the opportunity to obtain such additional information as it requested to verify the accuracy of the information
supplied; and (v) such Investor has had access to officers of the Company and an opportunity to ask questions of and receive answers from such officers and has had all questions that have been asked by such Investor satisfactorily answered by the
Company. 
  
 (e) Each Investor further represents
by execution of this Agreement that such Investor qualifies as an “accredited investor” as such term is defined under Rule 501 promulgated under the Securities Act. Any Investor that is a corporation, a partnership, a limited liability
company, a trust or other business entity further represents by execution of this Agreement that it has not been organized for the purpose of purchasing the Securities. 
  
 (f) By acceptance hereof, each Investor agrees that the Purchased Shares, the Purchased Warrants, the
Underlying Shares and any shares of capital stock of the Company received in respect of the foregoing held by it may not be sold by such Investor without registration under the Securities Act or an exemption therefrom, and therefore such Investor
may be required to hold such securities for an indeterminate period. 
  
 4.2. Legends. All certificates for the Purchased Shares, Purchased Warrants and the Underlying Shares, and each certificate representing any shares of capital stock of the Company received in respect of the
foregoing, whether by reason of a stock split or share reclassification thereof, a stock dividend thereon or otherwise and each certificate for any such securities issued to subsequent transferees of any such certificate (unless otherwise permitted
herein) shall bear a legend in substantially the following form, as well as any legends required by applicable Blue Sky Laws: 
  
 “THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT.” 

 5. Additional Covenants of the Company. 
  
 5.1. Reports, Information, Shares. 
  
 (a) The Company shall cooperate with each Investor in
supplying such information as may be reasonably requested by such Investor to complete and file any information reporting forms presently or hereafter required by the SEC as a condition to the availability of an exemption, presently existing or
hereafter adopted, from the Securities Act for the sale of any of the Purchased Shares, the Purchased Warrants, the Underlying Shares and shares of capital stock of the Company received in respect of the foregoing. 
  
 (b) For so long as an Investor (or the successor or assign
of such Investor) holds either Securities or Underlying Shares, the Company shall deliver to such Investor (or the successor or assign of such Investor), contemporaneously with delivery to other holders of Common Stock, a copy of each report of the
Company delivered to holders of Common Stock. 
  
 (c) The Company shall keep reserved for issuance a sufficient number of authorized but unissued shares of Common Stock (or other securities into which the Purchased Warrants are then exercisable) so that the Purchased Warrants may be
converted or exercised to purchase Common Stock (or such other securities) at any time. 
  
 5.2. Expenses; Indemnification. 
  
 (a) The Company agrees to pay on the Closing Date and save the Investors harmless against liability for the payment of any stamp or
similar taxes (including interest and penalties, if any) that may be determined to be payable in respect of the execution and delivery of this Agreement, the issue and sale of any Securities and the Underlying Shares, the expense of preparing and
issuing the Securities and the Underlying Shares, the cost of delivering the Securities and the Underlying Shares of each Investor to such Investor’s address, insured in accordance with customary practice, and the costs and expenses incurred in
the preparation of all certificates and letters on behalf of the Company and of the Company’s performance and compliance with all agreements and conditions contained herein on its part to be performed or complied with. Each Investor shall be
responsible for its out-of-pocket expenses arising in connection with the Contemplated Transactions, except that, at the Closing, the Company shall pay the Legal Fee as set forth in Section 6.9. 
  
 (b) The Company hereby agrees and acknowledges that the
Investors have been induced to enter into this Agreement and to purchase the Securities hereunder, in part, based upon the representations, warranties and covenants of the 

 Company contained herein. The Company hereby agrees to pay, indemnify and hold harmless the Investors and
any director, officer, partner, member, employee or other affiliate of any Investor against all claims, losses and damages resulting from any and all legal or administrative proceedings, including without limitation, reasonable attorneys’ fees
and expenses incurred in connection therewith (collectively, “Loss”), resulting from a breach by the Company of any representation or warranty of the Company contained herein or the failure of the Company to perform any covenant
made herein; provided that the Company’s liability under this Section 5.2(b) shall be limited to the aggregate purchase price of the Securities. 
  
 (c) The Investors hereby agree and acknowledge that the Company has been induced to enter into this Agreement and to sell the Securities
hereunder, in part, based upon the representations, warranties and covenants of the Investors contained herein. The Investors hereby agree, jointly and severally, to pay, indemnify and hold harmless the Company and any director, officer, partner,
member, employee or other affiliate of the Company against any Loss resulting from a breach by an Investor of any representation or warranty of the Investors contained herein or the failure of an Investor to perform any covenant made herein;
provided that the Investors’ liability under this Section 5.2(c) shall be limited to the aggregate purchase price of the Securities. 
  
 (d) Promptly after receipt by an indemnified party under this Section 5.2 of notice of the commencement of any action, such indemnified
party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 5.2, notify the indemnifying party in writing of the commencement thereof and the indemnifying party shall have the right to participate in
and, to the extent the indemnifying party desires, jointly with any other indemnifying party similarly noticed, to assume at its expense the defense thereof with counsel mutually satisfactory to the indemnifying parties with the consent of the
indemnified party which consent will not be unreasonably withheld, conditioned or delayed. In the event that the indemnifying party assumes any such defense, the indemnified party may participate in such defense with its own counsel and at its own
expense, provided, however, that the counsel for the indemnifying party shall act as lead counsel in all matters pertaining to such defense or settlement of such claim and the indemnifying party shall only pay for such indemnified
party’s reasonable legal fees and expenses for the period prior to the date of its participation in such defense, and provided further, however, that the indemnified party (together with all indemnified parties which may be
represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if the representation of the indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between the indemnified party and any other party represented by such counsel in such proceeding. Notwithstanding the foregoing, the indemnifying party shall
not be obligated to pay the fees of more than one separate counsel. The failure to notify an indemnifying party of the commencement of any such action will not relieve such indemnifying party of any liability to the indemnified party under

 this Section 5.2 (except to the extent that such failure materially and adversely affects the
indemnifying party’s ability to defend such action), nor shall the omission so to notify an indemnifying party relieve such indemnifying party of any liability which it may have to any indemnified party otherwise other than under this Section
5.2. No indemnifying party shall, without the consent of the indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
indemnified party of a release from all liability in respect to such claim or litigation and otherwise in form and substance reasonably satisfactory to the indemnified party. 
  
 (d) The Company shall maintain the effectiveness of the Registration Statement (as defined in the Investor
Rights Agreement) under the Securities Act for as long as is required under the Investor Rights Agreement. 
  
 6. Miscellaneous. 
  
 6.1. Entire Agreement; Successors and Assigns. This Agreement and the other Transaction Documents constitute the entire contract
between the parties relative to the subject matter hereof and thereof, and no party shall be liable or bound to the other in any manner by any warranties, representations or covenants except as specifically set forth herein or therein. This
Agreement and the other Transaction Documents supersede any previous agreement among the parties with respect to the Securities. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective executors,
administrators, heirs, successors and assigns of the parties. Except as expressly provided herein, nothing in this Agreement, expressed or implied, is intended to confer upon any party, other than the parties hereto, any rights, remedies,
obligations or liabilities under or by reason of this Agreement. 
  
 6.2. Survival of Representations and Warranties. Notwithstanding any right of the Investors fully to investigate the affairs of the Company and notwithstanding any knowledge of facts determined or determinable
by any Investor pursuant to such right of investigation, each Investor has the right to rely fully upon the representations, warranties, covenants and agreements of the Company contained in this Agreement or in any documents delivered pursuant to
this Agreement. All such representations and warranties of the Company shall survive the execution and delivery of this Agreement and the Closing hereunder and shall continue in full force and effect until registration statements covering all
Registrable Securities as defined in the Investor Rights Agreement have become effective. The covenants of the Company set forth in Section 5 shall remain in effect as set forth therein. 
  
 6.3. Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York without regard to principles of conflicts of law. Each party hereby irrevocably consents and submits to the jurisdiction of any New York State or United States Federal Court sitting in the State of New York,
County of New York, over any action or proceeding arising out of or relating to 

 this Agreement and irrevocably consents to the service of any and all process in any such action or
proceeding by registered mail addressed to such party at its address specified in Section 6.6 (or as otherwise noticed to the other party). Each party further waives any objection to venue in New York and any objection to an action or proceeding in
such state and county on the basis of forum non conveniens. Each party also waives any right to trial by jury. 
  
 6.4. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
  
 6.5. Headings. The headings of the sections of this Agreement are for convenience and shall not by themselves determine the interpretation of this Agreement. 
  
 6.6. Notices. Any notice required or permitted
hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, delivery by fax (with answer back confirmed), addressed to a party at its address or sent to the fax number or e-mail address shown below or at such
other address or fax number as such party may designate by three days advance notice to the other party. 
  
 Any notice to the Investors shall be sent to the addresses set forth on the signature pages hereof, with a copy to: 
  
 Hahn & Hessen LLP 
 488 Madison Avenue 
 New York, New York 10022

 Attention: James Kardon 
 Fax
Number: (212) 478-7400 
  
 Any notice to the Company shall be sent
to: 
  
 LightPath Technologies, Inc. 
 2603 Challenger Tech Ct., Suite 100 
 Orlando,
Florida 32826 
 Attention: Chief Executive Officer 
 Fax Number: (407) 823-9176 
  
 with a copy to: 
  
 Baker &
Hostetler LLP 
 SunTrust Center, Suite 2300 
 200 South Orange Avenue 
 Orlando, Florida 32801-3432 
 Attention: Jeff Decker 
 Fax Number: (407)
841-0168 

 6.7. Rights of Transferees. Any and all rights and obligations of each of the
Investors herein incident to the ownership of Securities or the Underlying Shares shall pass successively to all subsequent transferees of such securities until extinguished pursuant to the terms hereof. 
  
 6.8. Severability. Whenever possible, each provision
of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be deemed prohibited or invalid under such applicable law, such provision shall be ineffective to
the extent of such prohibition or invalidity, and such prohibition or invalidity shall not invalidate the remainder of such provision or any other provision of this Agreement. 
  
 6.9. Expenses. Irrespective of whether any Closing is effected, the Company shall pay all costs and
expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement. Each Investor shall be responsible for all costs incurred by such Investor in connection with the negotiation, execution, delivery and
performance of this Agreement and the other Transaction Documents and otherwise related to this Offering including, but not limited to, legal fees and expenses, except that the Company shall pay at the Closing $25,000 for the legal fees and expenses
of Hahn & Hessen LLP (the “Legal Fee”), as counsel to the Investors. 
  
 6.10. Amendments and Waivers. Unless a particular provision or section of this Agreement requires otherwise explicitly in a
particular instance, any provision of this Agreement may be amended and the observance of any provision of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written
consent of the Company and the holders of 50% of the Purchased Shares (not including for this purpose any Purchased Shares which have been sold to the public pursuant to a registration statement under the Securities Act or an exemption therefrom).
Any amendment or waiver effected in accordance with this Section 6.10 shall be binding upon each holder of any Securities at the time outstanding (including securities into which such Securities are convertible), each future holder of all such
Securities, and the Company. 
  
 [REMAINDER OF PAGE INTENTIONALLY
BLANK] 

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is an INDIVIDUAL, please complete the following: 
  
 IN WITNESS WHEREOF, the undersigned has executed this Agreement this 20th
day of February, 2004. 
  

			
	 Amount of Subscription:
 $1,354,325.00
	 	 ORIN HIRSCHMAN

 Print Name

		
	 Number of Units to be Purchased:
 38.15, including
 381,500 Purchased
Shares and related Purchased Warrants, subject to reduction pursuant to the proviso in Section 1.1(b) hereof
	 	 /s/ Orin Hirschman

 Signature of Investor

		
	 	 	 XXX XX XXXX

 Social Security Number

		
	 	 	 XXXXXXXXXXXXXXXXXXX

 Address and Fax Number

		
	 	 	 XXXXXXXXXXXXXXXXXXX

 E-mail Address

  

	
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

	
	 By: /s/ Kenneth Brizel

	
	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is an INDIVIDUAL, please complete the following: 
  
 IN WITNESS WHEREOF, the undersigned has executed this Agreement this 20th
day of February, 2004. 
  

			
	 Amount of Subscription:
 $50,055
	 	 Paul Packer

 Print Name

		
	 Number of Units to be Purchased:
 1.41, including
 14,100 Purchased Shares and related Purchased Warrants, subject to reduction pursuant to the proviso in
Section 1.1(b) hereof
	 	 /s/ Paul Packer

 Signature of Investor

		
	 	 	 XXX XX XXXX

 Social Security Number

		
	 	 	 XXXXXXXXXXXXXXXXXXX

 Address and Fax Number

		
	 	 	 XXXXXXXXXXXXXXXXXXX

 E-mail Address

  

	
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

	
	 By: /s/ Kenneth Brizel

	
	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY, TRUST or OTHER ENTITY, please complete the
following: 
  
 IN WITNESS WHEREOF, the undersigned has executed
this Agreement this 20th day of February, 2004. 
  
 Amount $100,110 
 Number of Units to be Purchased: 
 2.82, including 
 28,200 Purchased Shares and related Purchased Warrants 
  

			
	 	 	 GLOBIS CAPITAL PARTNERS L.P.
 Print Full Legal Name of Partnership, Company, Limited Liability Company, Trust or Other Entity

		
	 	 	 By: /s/ Paul Packer

                     (Authorized Signatory)

	 	 	 Name: Paul Packer

	 	 	 Title: Managing Member

	 	 	Address and Fax Number: XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXX
		
	 	 	 Taxpayer Identification Number: XX XXX XXXX

	
	 Date and State of Incorporation or Organization: _________________________

	
	 Date on which Taxable Year Ends: Dec. 31

		
	 	 	 E-mail Address: ______________________________

  

			
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Kenneth Brizel

	 Name: Kenneth Brizel

	 Title: President & CEO

	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is an INDIVIDUAL, please complete the following: 
  
 IN WITNESS WHEREOF, the undersigned has executed this Agreement this 20th
day of February, 2004. 
  

			
	 Amount of Subscription:
 $50,055
	  	 Richard Grossman

 Print Name

		
	 Number of Units to be Purchased:
 1.41, including
 14,100 Purchased
Shares and related Purchased Warrants, subject to reduction pursuant to the proviso in Section 1.1(b) hereof
	  	 /s/ Richard Grossman

 Signature of Investor

		
	 	  	 XXX XX XXXX

 Social Security Number

		
	 	  	 XXXXXXXXXXXXXXXXXXX

 Address and Fax Number

		
	 	  	 XXXXXXXXXXXXXXXXXXX

 E-mail Address

  

			
	
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Kenneth Brizel

	
	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is an INDIVIDUAL, please complete the following: 
  
 IN WITNESS WHEREOF, the undersigned has executed this Agreement this 20th
day of February, 2004. 
  

			
	 Amount of Subscription:
 $30,175.00
	 	 JOSHUA A. HIRSCH

 Print Name

		
	 Number of Units to be Purchased:
 0.85, including
 8,500 Purchased
Shares and related Purchased Warrants, subject to reduction pursuant to the proviso in Section 1.1(b) hereof
	 	 /s/ Joshua A. Hirsch

 Signature of Investor

		
	 	 	 XXX XX XXXX

 Social Security Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXXX

 Address and Fax Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXXX

 E-mail Address

  

			
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Kenneth Brizel

	
	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is an INDIVIDUAL, please complete the following: 
  
 IN WITNESS WHEREOF, the undersigned has executed this Agreement this 20th
day of February, 2004. 
  

			
	 Amount of Subscription:
 $15,625.00
	 	 James Kardon

 Print Name

		
	 Number of Units to be Purchased:
 0.43, including
 4,300 Purchased
Shares and related Purchased Warrants, subject to reduction pursuant to the proviso in Section 1.1(b) hereof
	 	 /s/ James Kardon

 Signature of Investor

		
	 	 	 XXX XX XXXX

 Social Security Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXX

 Address and Fax Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXX

 E-mail Address

  

			
	
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Kenneth Brizel

	
	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is an INDIVIDUAL, please complete the following: 
  
 IN WITNESS WHEREOF, the undersigned has executed this Agreement this 20th
day of February, 2004. 
  

			
	 Amount of Subscription:
 $297,490.00
	 	 HERSHEL P. BERKOWITZ

 Print Name

		
	 Number of Units to be Purchased:
 8.38, including
 83,800 Purchased
Shares and related Purchased Warrants, subject to reduction pursuant to the proviso in Section 1.1(b) hereof
	 	 /s/ Hershel P. Berkowitz

 Signature of Investor

		
	 	 	 XXX XX XXXX

 Social Security Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXX

 Address and Fax Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXX

 E-mail Address

  

			
	
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Kenneth Brizel

	
	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February 20, 2004 
  
 IF the PURCHASER is an INDIVIDUAL, please complete the following: 
  
 IN WITNESS WHEREOF, the undersigned has executed this Agreement this 20th
day of February, 2004. 
  

			
	 Amount of Subscription:
 $4,970.00
	 	 Anthony Altamura

 Print Name

		
	 Number of Units to be Purchased:
 .14, including
 1,400 Purchased
Shares and related Purchased Warrants, subject to reduction pursuant to the proviso in Section 1.1(b) hereof
	 	 /s/ Anthony Altamura

 Signature of Investor

		
	 	 	 XXX XX XXXX

 Social Security Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXX

 Address and Fax Number

		
	 	 	 XXXXXXXXXXXXXXXXXXXX

 E-mail Address

  

			
	
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Kenneth Brizel

	
	 Dated: 2/20/04

 SIGNATURE PAGE 
 TO 
 LIGHTPATH TECHNOLOGIES, INC. 
 SUBSCRIPTION AGREEMENT 
 Dated February     , 2004 
  
 IF the PURCHASER is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY,
TRUST or OTHER ENTITY, please complete the following: 
  
 IN
WITNESS WHEREOF, the undersigned has executed this Agreement this 20th day of February, 2004. 
  
 $50,055 
 Number of Units to be Purchased: 
 1.41, including 
 14,100 Purchased Shares and related Purchased Warrants 
  

			
	 	 	 HEWLETT FUND
 Print Full Legal Name of Partnership, Company, Limited Liability Company, Trust or Other Entity

		
	 	 	 By: /s/ Jay Spinner

                     (Authorized Signatory)

	 	 	 Name: Jay Spinner

	 	 	 Title: Director

	 	 	 Address and Fax Number: XXXXXXXXXX
 XXXXXXXXXXXXXXXXXXXXXXXXX

		
	 	 	 Taxpayer Identification Number: XX XXX XXXX

	
	 Date and State of Incorporation or Organization: ___________________________

	
	 Date on which Taxable Year Ends: ______________________________________

		
	 	 	 E-mail Address: ________________________________

  

			
	 ACCEPTED AND AGREED:

	
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Kenneth Brizel

	 Name: Kenneth Brizel

	 Title: President & CEO

	 Dated: 2/20/04

 Schedule 1.1(b) 
  
 INVESTORS 
  
 Orin Z. Hirschman 
 Paul Packer 
 Globis Capital Partners L.P. 
 Richard Grossman

 Joshua Hirsch 
 James Kardon

 Hershel Berkowitz 
 Anthony
Altamura 
 Hewlett Fund 

 EXHIBITS AND SCHEDULES TO THE UNIT SUBSCRIPTION AGREEMENT 
  

			
	Schedule 1.1(b)	  	 Investors

	Exhibit 1:	  	 Form of Warrants

	Exhibit 2:	  	 Form of Investor Rights Agreement

	Exhibit 3:	  	 Legal Opinion

	Exhibit 4:	  	 Company Disclosure Letter

 EXHIBIT 1— FORM OF WARRANTS 
  

			
	 Void after February 23, 2009
	 	Warrant No. 2004 – H    

  
 This Warrant and any shares acquired upon the exercise of this Warrant have not been registered under the Securities Act of 1933. This Warrant and such shares may not be sold or transferred in the absence of such registration or an
exemption therefrom under said Act. This Warrant and such shares may not be transferred except upon the conditions specified in this Warrant, and no transfer of this Warrant or such shares shall be valid or effective unless and until such conditions
shall have been complied with. 
  
 LIGHTPATH TECHNOLOGIES, INC.

  
 COMMON STOCK PURCHASE WARRANT 
  
 LightPath Technologies, Inc. (the “Company”), having its principal
office at 2603 Challenger Tech Ct., Suite 100, Orlando, Florida 32826 hereby certifies that, for value received,
                                , or assigns, is entitled, subject to the terms
set forth below, to purchase from the Company at any time on or from time to time after November 22, 2004 (the “Initial Exercisable Date”) and before 5:00 P.M., New York City time, on February 23, 2009, or as extended in accordance with
the terms hereof (the “Expiration Date”),
                                
(            ) fully paid and non-assessable shares of Common Stock of the Company, at the initial Purchase Price per share (as defined below) of $4.30. The number and character of
such shares of Common Stock and the Purchase Price per share are subject to adjustment as provided herein. 
  
 Background. The Company agreed to issue warrants to purchase an aggregate of 110,000 shares of Common Stock (subject to adjustment as provided
herein) in connection with the Company’s private placement of 55 units (“Units”) each Unit consisting of (i) 10,000 shares of Common Stock and (ii) 2,000 5-year warrants to purchase Common Stock at $4.30 per share (the
“Warrants”), each Warrant entitling the Holder thereof to purchase one share of Common Stock. 
  
 As used herein the following terms, unless the context otherwise requires, have the following respective meanings: 
  
 The term “Company” includes the Company and any corporation which
shall succeed to or assume the obligations of the Company hereunder. The term “corporation” shall include an association, joint stock company, business trust, limited liability company or other similar organization. 
  

 1 

 The term “Common Stock” includes all stock of any class or classes (however designated) of the
Company, authorized upon the Original Issue Date or thereafter, the Holders of which shall have the right, without limitation as to amount, either to all or to a share of the balance of current dividends and liquidating dividends after the payment
of dividends and distributions on any shares entitled to preference, and the Holders of which shall ordinarily, in the absence of contingencies, be entitled to vote for the election of a majority of directors of the Company (even though the right so
to vote has been suspended by the happening of such a contingency). 
  
 The term “Convertible Securities” means (i) options to purchase or rights to subscribe for Common Stock, (ii) securities by their terms convertible into or exchangeable for Common Stock or (iii) options to purchase or rights to
subscribe for such convertible or exchangeable securities. 
  
 The
term “Exchange Act” means the Securities Exchange Act of 1934 as the same shall be in effect at the time. 
  
 The term “Excluded Stock” shall mean shares of Common Stock issued or issuable by the Corporation (i) to employees, directors or consultants
pursuant to any equity compensation plan approved by the Company’s stockholders, including all existing equity plans for the benefit of employees, (ii) to bona fide leasing companies, strategic partners, or major lenders, (iii) as the purchase
price in a bona fide acquisition or merger (including reasonable fees paid in connection therewith) or (iv) upon issuance upon conversion or exercise of the Warrants or other Convertible Securities outstanding on the date hereof. 
  
 The term “Fair Market Value” shall mean the fair market value of
assets or securities as reasonably determined by the Board of Directors of the Corporation in good faith in accordance with generally accepted accounting principles. 
  
 The term “Holder” means any record owner of Warrants or Underlying Securities. 
  
 The term “Nasdaq” means the Nasdaq SmallCap Market or Nasdaq Stock
Market. 
  
 The “Original Issue Date” means February 23,
2004. 
  
 The term “Other Securities” refers to any
stock (other than Common Stock) and other securities of the Company or any other person (corporate or otherwise) which the Holders of the Warrants at any time shall be entitled to receive, or shall have received, upon the exercise of the Warrants,
in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Common Stock or Other Securities pursuant to Section 6 or otherwise. 
  
 The term “Purchase Price per share” means $4.30 per share, as
adjusted from time to time in accordance with the terms hereof. 
  
 The terms “registered” and “registration” refer to a registration effected by filing a registration statement in compliance with the Securities Act, to permit the disposition of Common Stock (or Other Securities) issued
or issuable upon the exercise of Warrants, and any post-effective amendments and supplements filed or required to be filed to permit any such disposition. 
  

 2 

 The term “Securities Act” means the Securities Act of 1933 as the same shall be in effect at
the time. 
  
 The term “Underlying Securities” means any
Common Stock or Other Securities issued or issuable upon exercise of Warrants. 
  
 The term “Warrant” means, as applicable, this Warrant or each right as set forth in this Warrant to purchase one share of Common Stock, as adjusted. 
  
 1. Registration, etc. The Holder shall have the rights to registration
of Underlying Securities issuable upon exercise of the Warrants that are set forth in the Investor Rights Agreement, dated the Original Issue Date, between the Company and the Holder (the “Investor Rights Agreement”). 
  
 2. Sale or Exercise Without Registration. If, at the time of any
exercise, transfer or surrender for exchange of a Warrant or of Underlying Securities previously issued upon the exercise of Warrants, such Warrant or Underlying Securities shall not be registered under the Securities Act, the Company may require,
as a condition of allowing such exercise, transfer or exchange, that the Holder or transferee of such Warrant or Underlying Securities, as the case may be, furnish to the Company from counsel reasonably satisfactory to the Company an opinion in form
and substance reasonably satisfactory to the Company, to the effect that such exercise, transfer or exchange may be made without registration under the Securities Act, provided that the disposition thereof shall at all times be within the control of
such Holder or transferee, as the case may be, and provided further that nothing contained in this Section 2 shall relieve the Company from complying with any request for registration pursuant to the Investor Rights Agreement. 
  
 3. Exercise of Warrant. 
  
 3.1. Exercise in Full. Subject to the provisions
hereof, this Warrant may be exercised in full by the Holder hereof by surrender of this Warrant, with the form of subscription at the end hereof duly executed by such Holder, to the Company at its principal office accompanied by payment, in cash or
by certified or official bank check payable to the order of the Company, in the amount obtained by multiplying the number of shares of Common Stock issuable upon exercise of this Warrant by the Purchase Price per share, after giving effect to all
adjustments through the date of exercise. 
  
 3.2. Partial Exercise. Subject to the provisions hereof, this Warrant may be exercised in part by surrender of this Warrant in the manner and at the place provided in Section 3.1 except that the amount payable by the Holder upon any
partial exercise shall be the amount obtained by multiplying (a) the number of shares of Common Stock (without giving effect to any adjustment therein) designated by the Holder in the subscription at the end hereof by (b) the Purchase Price per
share. Upon any such partial exercise, the 

  

 3 

 
Company at its expense will forthwith issue and deliver to or upon the order of the Holder hereof a new Warrant or Warrants of like tenor, in the name of the
Holder hereof or as such Holder (upon payment by such Holder of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock equal (without giving effect to any adjustment
therein) to the number of such shares called for on the face of this Warrant minus the number of such shares designated by the Holder in the subscription at the end hereof. 
  
 3.3. Exercise by Surrender of Warrant or Shares of Common Stock. Except during any period when (i) a
Registration Statement under the Investor Rights Agreement (as defined therein) is effective covering all Underlying Securities or (ii) during any Suspension (as defined in the Investor Rights Agreement), in addition to the method of payment set
forth in Sections 3.1 and 3.2 and in lieu of any cash payment required thereunder, the Holder(s) of the Warrants shall have the right at any time and from time to time to exercise the Warrants in full or in part by surrendering shares of Common
Stock, this Warrant or other securities issued by the Company in the manner and at the place specified in Section 3.1 as payment of the aggregate Purchase Price per share for the Warrants to be exercised. The number of Warrants or shares of Common
Stock to be surrendered in payment of the aggregate Purchase Price for the Warrants to be exercised shall be determined by multiplying the number of Warrants to be exercised by the Purchase Price per share, and then dividing the product thereof by
an amount equal to the Market Price (as defined below) . The number of shares of Common Stock or such other securities to be surrendered in payment of the aggregate Purchase Price for the Warrants to be exercised shall be determined in accordance
with the preceding sentence as if the other securities had been converted into Common Stock immediately prior to exercise or, in the case the Company has issued other securities which are not convertible into Common Stock, at the Market Price
thereof. 
  
 3.3. Definition of Market
Price. As used herein, the phrase “Market Price” at any date shall be deemed to be (i) if the principal trading market for such securities is an exchange, the average of the high reported sale prices per share for the last ten (10)
previous trading days in which a sale was reported, as officially reported on any consolidated tape, (ii) if the principal market for such securities is the over-the-counter market, the average of the high reported sale prices per share on such
trading days as set forth by Nasdaq or, (iii) if the security is not quoted on Nasdaq, the average of the high sale prices per share on such trading days as set forth in the National Quotation Bureau sheet listing such securities for such days.
Notwithstanding the foregoing, if there is no reported high sale price, as the case may be, reported on any of the ten trading days preceding the event requiring a determination of Market Price hereunder, then the Market Price shall be the average
of the high bid and asked prices for such days; and if there is no reported high bid and asked prices, as the case may be, reported on any of the ten trading days preceding the event requiring a determination of Market Price hereunder, then the
Market Price shall be determined in good faith by resolution of the Board of Directors of the Company, based on the best information available to it. 
  

 4 

 3.5. Company to Reaffirm Obligations. The Company will, at the time of any
exercise of this Warrant, upon the request of the Holder hereof, acknowledge in writing its continuing obligation to afford to such Holder any rights (including, without limitation, any right to registration of the Underlying Securities) to which
such Holder shall continue to be entitled after such exercise in accordance with the provisions of this Warrant, provided that if the Holder of this Warrant shall fail to make any such request, such failure shall not affect the continuing
obligation of the Company to afford such Holder any such rights. 
  
 3.6. Certain Exercises. If an exercise of a Warrant or Warrants is to be made in connection with a registered public offering or sale of the Company, such exercise may, at the election of the Holder, be
conditioned on the consummation of the public offering or sale of the Company, in which case such exercise shall not be deemed effective until the consummation of such transaction. 
  
 3.7 Representations of Holder. Holder will, at the time of any exercise of this Warrant and as a
condition to such exercise, affirm in writing to the Company that Holder is acquiring the Underlying Shares issuable upon the exercise of this Warrant for investment for Holder’s own account, not as a nominee or agent, and not with a view to
the resale or distribution of any part thereof such that Holder would constitute an “underwriter” under the Securities Act, other than pursuant to an effective registration statement under the Securities Act. Holder acknowledges that the
Underlying Securities may not be sold by Holder without registration under the Securities Act or an exemption therefrom. 
  
 4. Delivery of Stock Certificates, etc., on Exercise. As soon as practicable after the exercise of this Warrant in full or in part, and in any
event within three business days thereafter, the Company at its own expense (including the payment by it of any applicable issue taxes) will cause to be issued in the name of and delivered to the Holder hereof, or as such Holder (upon payment by
such Holder of any applicable transfer taxes) may direct, a certificate or certificates for the number of fully paid and non-assessable shares of Common Stock or Other Securities to which such Holder shall be entitled upon such exercise, plus, in
lieu of any fractional share to which such Holder would otherwise be entitled, cash equal to such fraction multiplied by the then current Market Price of one full share, together with any other stock or other securities and property (including cash,
where applicable) to which such Holder is entitled upon such exercise pursuant to Section 5 or otherwise. 
  
 5. Adjustment for Dividends in Other Stock, Property, etc.; Reclassification, etc. In case at any time or from time to time after the Original
Issue Date the holders of Common Stock (or, if applicable, Other Securities) shall have received, or (on or after the record date fixed for the determination of stockholders eligible to receive) shall have become entitled to receive, without payment
therefor 
  
 (i) other or additional stock or
other securities or property (other than cash) by way of dividend, or 
  
 (ii) any cash paid or payable (including, without limitation, by way of dividend), or 
  

 5 

 (iii) other or additional stock or other securities or property (including cash) by way
of spin-off, split-up, reclassification, recapitalization, combination of shares or similar corporate rearrangement, 
  
 then, and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 3, shall be entitled to receive the amount of stock and other
securities and property (including cash in the cases referred to in subdivisions (ii) and (iii) of this Section 5(a)) which such Holder would hold on the date of such exercise if on the Original Issue Date such Holder had been the Holder of record
of the number of shares of Common Stock called for on the face of this Warrant and had thereafter, during the period from the Original Issue Date to and including the date of such exercise, retained such shares and all such other or additional stock
and other securities and property (including cash in the cases referred to in subdivisions (ii) and (iii) of this Section 5(a)) receivable by such Holder as aforesaid during such period, giving effect to all adjustments called for during such period
by Sections 6 and 7 hereof. If the number of shares of Common Stock outstanding at any time after the date hereof is decreased by a combination or reverse stock split of the outstanding shares of Common Stock, the Purchase Price per share shall be
increased, and the number of shares of Common Stock purchasable under this Warrant shall be decreased in proportion to such decrease in outstanding shares of Common Stock. 
  
 6. Reorganization, Consolidation, Merger, etc. In case the Company after the Original Issue Date shall (a) effect a
reorganization, (b) consolidate with or merge into any other person, or (c) transfer all or substantially all of its properties or assets to any other person under any plan or arrangement contemplating the dissolution of the Company, then, in each
such case, the Holder of this Warrant, upon the exercise hereof as provided in Section 3 at any time after the consummation of such reorganization, consolidation or merger or the effective date of such dissolution, as the case may be, shall be
entitled to receive (and the Company shall be entitled to deliver), in lieu of the Underlying Securities issuable upon such exercise prior to such consummation or such effective date, the stock and other securities and property (including cash) to
which such Holder would have been entitled upon such consummation or in connection with such dissolution, as the case may be, if such Holder had so exercised this Warrant immediately prior thereto, all subject to further adjustment thereafter as
provided in Sections 5 and 7 hereof. The Company shall not effect any such reorganization, consolidation, merger or sale, unless prior to or simultaneously with the consummation thereof, the successor corporation resulting from such consolidation or
merger or the corporation purchasing such assets or the appropriate corporation or entity shall assume, by written instrument, the obligation to deliver to each Holder the shares of stock, cash, other securities or assets to which, in accordance
with the foregoing provisions, each Holder may be entitled to and all other obligations of the Company under this Warrant. In any such case, if necessary, the provisions set forth in this Section 6 with respect to the rights thereafter of the
Holders shall be appropriately adjusted so as to be applicable, as nearly as may reasonably be, to any Other Securities or assets thereafter deliverable on the exercise of the Warrants. 
  
 7. Intentionally omitted. 
  
 8. Further Assurances. The Company will take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and non-assessable shares of stock upon the exercise of all Warrants from time to time outstanding. 
  

 6 

 9. Accountants’ Certificate as to Adjustments. In each case of any adjustment or readjustment
in the shares of Common Stock (or Other Securities) issuable upon the exercise of the Warrants, the Company at its expense will promptly cause the Company’s regularly retained auditor to compute such adjustment or readjustment in accordance
with the terms of the Warrants and review a letter from the Company to the Holders setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, and the number of shares of Common
Stock outstanding or deemed to be outstanding, in accordance with procedures agreed upon by the Company and the Holders as provided for under AICPA Professional Standards Section AT-20. The Company will forthwith mail a copy of each such letter to
each Holder. 
  
 10. Notices of Record Date, etc. In the
event of 
  
 (a) any taking by the Company of a
record of its stockholders for the purpose of determining the stockholders thereof who are entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any
other securities or property, or to receive any other right, or for the purpose of determining stockholders who are entitled to vote in connection with any proposed capital reorganization of the Company, any reclassification or recapitalization of
the capital stock of the Company or any transfer of all or substantially all the assets of the Company to or consolidation or merger of the Company with or into any other person, or 
  
 (b) any voluntary or involuntary dissolution, liquidation or winding-up of the Company, or 
  
 (c) any proposed issue or grant by the Company of any Common
Stock, Convertible Securities or any other securities, or any right or option to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities (other than the issue of Common Stock on the exercise of the
Warrants), 
  
 then and in each such event the Company will mail or cause to be
mailed to each Holder of a Warrant a notice specifying (i) the date on which any such record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, (ii)
the date on which any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up is to take place, and the time, if any, as of which the Holders of record of Underlying Securities
shall be entitled to exchange their shares of Underlying Securities for securities or other property deliverable upon such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up,
and (iii) the amount and character of any stock or other securities, or rights or options with respect thereto, proposed to be issued or granted, the date of such proposed issue or grant and the persons or class of persons to whom such proposed
issue or grant and the persons or class of persons to whom such proposed issue or grant is to be offered or made. Such notice shall be mailed at least 20 days prior to the date therein specified. 
  

 7 

 11. Reservation of Stock, etc., Issuable on Exercise of Warrants. The Company will at all times
reserve and keep available, solely for issuance and delivery upon the exercise of the Warrants, all shares of Common Stock (or Other Securities) from time to time issuable upon the exercise of the Warrants. 
  
 12. Listing on Securities Exchanges; Registration; Issuance of Certain
Securities. 
  
 12.1. In furtherance and not in limitation
of any other provision of this Warrant, if the Company at any time shall list any Common Stock on any national securities exchange or Nasdaq, the Company will, at its expense, simultaneously list on such exchange or Nasdaq, upon official notice of
issuance upon the exercise of the Warrants, and maintain such listing of all shares of Common Stock from time to time issuable upon the exercise of the Warrants; and the Company will so list on any national securities exchange or Nasdaq, will so
register and will maintain such listing of, any Other Securities if and at the time that any securities of like class or similar type shall be listed on such national securities exchange or Nasdaq by the Company. 
  
 12.2. The Company shall not issue any (a) Convertible Securities or similar
securities that contain a provision that provides for any change or determination of the applicable conversion price, conversion rate, or exercise price (or a similar provision which might have a similar effect) based on the Market Price or any
other determination of the market price or value of the Company’s securities or any other market based or contingent standard; provided that the Company shall not be barred from agreeing to customary weighted average anti-dilution provisions,
or (b) any preferred stock, debt instruments or similar securities or investment instruments providing for (i) preferences or other payments substantially in excess of the original investment by purchasers thereof or (ii) dividends, interest or
similar payments other than dividends, interest or similar payments computed on an annual basis and not in excess, directly or indirectly, of the lesser of a rate equal to (A) twice the interest rate on 10 year US Treasury Notes and (B) 20%.

  
 13. Exchange of Warrants. Subject to the provisions of
Section 2 hereof, upon surrender for exchange of any Warrant, properly endorsed, to the Company, as soon as practicable (and in any event within three business days) the Company at its own expense will issue and deliver to or upon the order of the
Holder thereof a new Warrant or Warrants of like tenor, in the name of such Holder or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces thereof for the number of
shares of Common Stock called for on the face or faces of the Warrant or Warrants so surrendered. 
  
 14. Redemption. 
  
 14.1. Commencing on the Initial Exercise Date, the Company may, on ten (10) business days’ prior written notice, redeem all the
Warrants at five cents ($.05) per Warrant, provided however, that before any such call for redemption of Warrants can take place the closing sale price of the Common Stock as quoted on Nasdaq or, if such shares are not quoted on Nasdaq, on the
principal market on which such shares shall then be trading, shall have, for each of the ten (10) consecutive trading days ending on the third (3rd) day prior to the date on which the notice contemplated by (b) and (c) below is given, equaled or
exceeded $6.45 per share (subject to adjustment in the event of any stock splits or other similar events as provided in Section 5 hereof); provided that the Company shall not have 
  

 8 

 the right to give notice of redemption or to redeem the Warrants unless a Registration Statement under
the Investor Rights Agreement covering all the Underlying Securities shall be effective at the time of the notice and the Redemption Date, as defined below. 
  
 14.2. The notice of redemption shall specify (i) the redemption price, (ii) the date fixed for redemption, which shall in no event be less
than ten (10) business days after the date of mailing of such notice, (iii) the place where the Warrant shall be delivered and the redemption price shall be paid, and (iv) that the right to exercise the Warrant shall terminate at 5:00 p.m. (New York
time) on the business day immediately preceding the date fixed for redemption. The date fixed for the redemption of the Warrants shall be the Redemption Date. No failure to mail such notice nor any defect therein or in the mailing thereof shall
affect the validity of the proceedings for such redemption except as to a holder (a) to whom notice was not mailed or (b) whose notice was defective. An affidavit of the Warrant Agent or the Secretary or Assistant Secretary of the Company that
notice of redemption has been mailed shall, in the absence of fraud, be prima facie evidence of the facts stated therein. 
  
 14.3. Any right to exercise a Warrant shall terminate at 5:00 p.m. (New York time) on the business day immediately preceding the
Redemption Date. The redemption price payable to the Holders shall be mailed to such persons at their addresses of record. 
  
 15. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of any
Warrant and, in the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, upon surrender and cancellation of such
Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
  
 16. Warrant Agent. The Company may, by written notice to each Holder of a Warrant, appoint an agent having an office in New York, New York, for the
purpose of issuing Common Stock (or Other Securities) upon the exercise of the Warrants pursuant to Section 3, exchanging Warrants pursuant to Section 13, redeeming warrants pursuant to Section 14, and replacing Warrants pursuant to Section 15, or
any of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office by such agent. 
  
 17. Remedies. The Company stipulates that the remedies at law of the Holder of this Warrant in the event of any default or threatened default by
the Company in the performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and that such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or by
an injunction against a violation of any of the terms hereof or otherwise. 
  
 18. Negotiability, etc. Subject to Section 2 above, this Warrant is issued upon the following terms, to all of which each Holder or owner hereof by the taking hereof consents and agrees: 
  
 (a) subject to the provisions hereof, title to this Warrant
may be transferred by endorsement (by the Holder hereof executing the form of assignment at the end hereof) and delivery in the same manner as in the case of a negotiable instrument transferable by endorsement and delivery; 
  

 9 

 (b) subject to the foregoing, any person in possession of this Warrant properly endorsed
is authorized to represent himself as absolute owner hereof and is empowered to transfer absolute title hereto by endorsement and delivery hereof to a bona fide purchaser hereof for value; each prior taker or owner waives and renounces all of his
equities or rights in this Warrant in favor of each such bona fide purchaser and each such bona fide purchaser shall acquire absolute title hereto and to all rights represented hereby; and 
  
 (c) until this Warrant is transferred on the books of the
Company, the Company may treat the registered Holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 
  
 19. Notices, etc. All notices and other communications from the Company to the Holder of this Warrant shall be mailed by first class registered or
certified mail, postage prepaid, at such address as may have been furnished to the Company in writing by such Holder, or, until an address is so furnished, to and at the address of the last Holder of this Warrant who has so furnished an address to
the Company. 
  
 20. Miscellaneous. This Warrant and any
term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant is being delivered in the State of
New York and shall be construed and enforced in accordance with and governed by the laws of such State. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. 
  
 21. Assignability. Subject to Section 2 hereof, this Warrant is fully
assignable at any time. 
  
 Dated: February 23,
2004 
  

			
	 LIGHTPATH TECHNOLOGIES, INC.

		
	 By:
	 	  

	 Name:
	 	 
	 Title:
	 	 

  
 Attest:                                     
            
  

 10 

 FORM OF SUBSCRIPTION 
  
 (To be signed only upon exercise of Warrant) 
  
 To: LIGHTPATH TECHNOLOGIES, INC. 
  
 The undersigned, the Holder of the within Warrant, hereby irrevocably elects to exercise the purchase right represented by
such Warrant for, and to purchase thereunder, shares of Common Stock of LightPath Technologies, Inc. (the “Exercise Shares”), and herewith makes payment therefor: 
  
 (i) of $        *        or

  
 (ii) by surrender of the number of Warrants included in
the within Warrant required for full exercise pursuant to Section 3.3 of the Warrant, 
  
 and requests that the certificates for the Exercise Shares be issued in the name of, and delivered to,                     , whose
address is                     . The undersigned is acquiring the Exercise Shares issuable upon the exercise of this Warrant for investment
for Holder’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof such that the undersigned would constitute an “underwriter” under the Securities Act, other than pursuant to an
effective registration statement under the Securities Act. The undersigned acknowledges that the Exercise Shares may not be sold by the undersigned without registration under the Securities Act or an exemption therefrom. 
  
 Dated: 
  

	
	  

	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
	
	  

	           (Address)

	*	Insert here the number of shares called for on the face of the Warrant (or, in the case of a partial exercise, the portion thereof as to which the Warrant is being exercised), in
either case without making any adjustment for additional Common Stock or any other stock or other securities or property or cash which, pursuant to the adjustment provisions of the Warrant, may be deliverable upon exercise. 

 

 11 

 FORM OF ASSIGNMENT 
  
 (To be signed only upon transfer of Warrant) 
  
 For value received, the undersigned hereby sells, assigns and transfers unto
                     the right represented by the within Warrant to purchase
                     of Common Stock of LightPath Technologies, Inc. to which the within Warrant relates, and appoints
                             Attorney to transfer such right on the books of LightPath Technologies,
Inc. with full power of substitution in the premises. The Warrant being transferred hereby is one of the Warrants issued by LightPath Technologies, Inc. as of
                    , 2004 to purchase an aggregate of 110,000 shares of Common Stock. 
  
 Dated:
                     
  

	
	  

	(Signature must conform in all respects to name of
Holder as specified on the face of the Warrant)
	
	  

	 (Address)

  

	
	  

	Signature guaranteed by a Bank or Trust Company having its principal office in New York City or by a Member Firm of the New York or American Stock Exchange

  

 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]